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ABSTRACT 
 Cardiovascular disease (CVD) is the leading cause of death globally. There will be an 
estimated 23.6 million deaths by 2030 due to some form of CVD. Moreover, CVD costs more 
than any other diagnostic group: coronary heart disease alone costs the US $108.9 billion 
each year. Finally, the most vulnerable populations to suffer CVD are the populations with 
diabetes and other metabolic disorders. At least 65% of diabetics die from some form of 
CVD. 
 The classic cardiovascular risk factors include age, smoking, diabetes, blood 
pressure and dyslipidemia. Some forms of dyslipidemia include elevated total or low-density 
lipoprotein (LDL) cholesterol levels, low levels of high-density lipoprotein (HDL) cholesterol, 
and high levels of triglycerides. Although the use of statins is well established into the 
clinical guidelines for primary prevention of CVD, its use is controversial. Indeed, 50% of 
people who have a cardiovascular event have normal cholesterol levels. Thus, we are 
currently experiencing a paradigm shift in cardiovascular risk assessment based on the 
blood lipid profile. 
 This lack of benefit on the use of statins to reduce cardiovascular events might be 
explained partly due to the fact that two individuals with the same LDL cholesterol 
concentration can show different distributions of LDL particles. The individual with a 
preponderance of smaller-denser LDL particles will be at increasing risk, because smaller-
denser LDL particles are more susceptible to oxidation and to enter the intima media of 
arterial walls leading to atherosclerosis. This preponderance of smaller and denser LDL 
particles is the result of an increase in triglycerides concentration, which also leads to a 
decrease in HDL cholesterol. This triad of lipid and lipoprotein abnormalities is known as 
atherogenic dyslipidemia and it is characteristic of diabetic patients, being also known as 
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diabetic dyslipidemia. 
 For this reason, they have appeared recently different analytical approaches to 
characterize lipoproteins aimed at providing complementary information on these 
macromolecular complexes beyond its lipid charge. In particular, the size and particle 
number of the different classes and subclasses of lipoprotein particles may improve 
cardiovascular risk assessment and management in those individuals at high risk of CVD, 
such as patients with diabetes and other metabolic disorders. 
 One of the analytical techniques that is emerging to the clinical arena is nuclear 
magnetic resonance (NMR). NMR is a highly reproducible, quantitative and versatile tool for 
the study of physical, chemical and biological properties of matter. Moreover, NMR can be 
used as a high-throughput analytical technique because sample manipulation is minimal. 
For these reasons, NMR has found a myriad number of applications in several areas of 
science and now is being introduced into the clinical practice thanks to the development 
and commercialization by Liposcience Inc. of The LipoProfile Test, an advanced lipoprotein 
test which measures the concentration of LDL particles among other lipoprotein 
parameters. 
 The doctoral thesis presented in this document is the result of the research 
conducted in the Department of Electronic, Electrical and Automation Engineering at the 
Rovira i Virgili University (URV). Other research institutions have been involved in this 
research, such as the Metabolomics Platform of the same university, the Research Unit of 
Lipids and Atherosclerosis (URLA) of Sant Joan University Hospital from Reus (HUSJR) and 
the CIBER of Diabetes and Metabolic Diseases (CIBERDEM). All these groups are part of the 
Institut d'Investigació Sanitària Pere Virgili (IISPV). 
 Thanks to this collaboration it has been possible to develop the LipoScale test, an 
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advanced lipoprotein test based on NMR spectroscopy. This test is aimed at obtaining a 
better characterization of plasma lipoproteins, i.e. lipid content, size and particle number, in 
order to improve cardiovascular risk prediction. The main difference between our approach 
and the commercial test is that they use standard 1D NMR methods, while our test is based 
on the use of magnetic gradients, which generates 2D spectra with direct and objective 
information on lipoprotein particle sizes. 
 This thesis has generated different scientific publications which will be detailed 
through the next sections, as well as a patent that has been filled to the European Patent 
Office (EPO) and a spin-off company which will commercialize the LipoScale test. 
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RESUM 
 Les malalties cardiovasculars (MCV) són la principal causa de mort a tot el món. 
S'estima que hi hauran 23.6 milions de defuncions el 2030 degudes a les MCV. A més, les 
MCV costen més que qualsevol altre grup diagnòstic: només les malalties coronàries costen 
als EEUU 108.9 bilions de dòlars cada any. Finalment, les poblacions més vulnerables a les 
MCV són les poblacions amb diabetis i altres desordres metabòlics. Almenys el 65% dels 
diabètics moren d'alguna forma de MCV. 
 Els factors de risc clàssics són l'edat, el tabaquisme, la diabetis, la pressió arterial i 
les dislipidèmies. Algunes formes de dislipidèmia inclouen concentracions altes de 
colesterol total o de les lipoproteïnes de baixa densitat (LDL), concentracions altes de 
triglicèrides, o concentracions baixes de les lipoproteïnes d'alta densitat (HDL). Encara que 
l'ús d'estatines està ben establert a les guies clíniques per a la prevenció primària de les 
MCV, el seu ús és controvertit. Verdaderament, el 50% de les persones que pateixen un 
event cardiovascular tenen nivells normals de colesterol. Per això, actualment estem vivint 
un canvi de paradigma pel que fa a l'avaluació del risk cardiovascular basada en un perfil 
bàsic de les concentracions de lípids en sang. 
 Aquesta falta de benefici en l'ús de les estatines per reduir el nombre d'events 
cardiovasculars pot ser explicada en part pel fet que dos individus amb la mateix 
concentració de colesterol LDL poden mostrar distribucions diferents d'aquestes partícules. 
L'individu amb més partícules LDL petites tindrà associat un risc cardiovascular més alt, ja 
que les partícules LDL petites són més susceptibles d'oxidar-se i d'entrar a les artèries, 
començant el procés conegut com arteriosclerosi. Aquests nivells més elevats de partícules 
LDL petites són deguts a un increment de les concentracions de triglicèrids, que també 
provoquen una baixada de les concentracions de colesterol HDL. Aquesta triada 
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d'anormalitats lipídiques i lipoproteiques és coneguda com dislipidèmia aterògena i és 
característica de pacients diabètics, essent coneguda també com dislipidèmia diabètica. 
 Per aquesta raó, han aparegut durant els últims anys diferents aproximacions 
analítiques per caracteritzar les lipoproteïnes de manera que es pugui determinar 
informació complementària d'aquests complexes moleculars, més enllà de la seva càrrega 
lipídica. Concretament, la mida i el nombre de partícules de les diferents classes i subclasses 
de lipoproteïnes milloren l'avaluació del risc cardiovascular en aquells individus d'alt risc de 
patir MCV, com pacients amb diabetis o desordres metabòlics. 
 Una de les tècniques analítiques que està emergent a l'escena clínica és la 
ressonància magnètica nuclear (RMN). La RMN és una eina altament reproduïble, 
quantitativa i versàtil per a l'estudi de les propietats físiques, químiques i biològiques de la 
matèria. A més a més, la RMN pot ser utilitzada com una tècnica analítica d'alt rendiment ja 
que la manipulació de les mostres és mínima. Per totes aquestes raons, la RMN ha trobat 
infinitat d'aplicacions en moltes àrees de la ciència i ara està essent introduïda a la pràctica 
clínica gràcies al desenvolupament i la comercialització per part de Liposcience Inc. del 
LipoPorfile Test, un test avançat de lipoproteïnes que determina el nombre de partícules 
LDL entre d'altres paràmetres. 
 La tesi doctoral presentada en aquest document sorgeix com a resultat de la 
investigació realitzada en el Departament d'Enginyeria Electrònica, Elèctrica i Automàtica de 
la Universitat Rovira i Virgili (URV). En la investigació han col·laborat altres institucions, com 
la Plataforma Metabolòmica de la mateixa universitat, la Unitat de Recerca en Lípids i 
Arteriosclerosi (URLA) de l'Hospital Universitari Sant Joan de Reus (HUSJR) i el CIBER de 
Diabetis i Malalties Metabòliques (CIBERDEM). Tots els grups formen part de l'Institut 
d'Investigació Sanitària Pere Virgili (IISPV). 
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 Gràcies a aquesta col·laboració s'ha pogut desenvolupar The LipoScale Test, un test 
avançat de lipoproteïnes basat en RMN. Amb aquest test es pretén obtenir una millor 
caracterització de les lipoproteïnes plasmàtiques, tant el seu contingut lipídic com la seva 
mida i nombre de partícules, de manera que amb ell s'aconsegueixi una millor predicció del 
risc cardiovascular. La principal característica entre la nostra aproximació i la del test 
comercial és que Liposcience Inc. utilitza mètodes de RMN 1D estàndards, mentre que el 
nostre test està basat en l'ús de gradients de camps magnètic, els quals generen espectres 
2D amb els que es pot obtenir informació directa i objectiva de la mida de les partícules 
lipoproteiques. 
 Aquesta tesi a generat diferents publicacions científiques que seran detallades al 
llarg del text, així com també s'ha fet la sol·licitud d'una patent europea i s'ha creat una 
spin-off per comercialitzar el test. 
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ALT  advanced lipoprotein tests 
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DM  diabetic metabolism 
DOSY  diffusion ordered NMR spectroscopy 
DSS  4,4-dimethyl-4-silapentane-1-sulfonic acid 
DSTE  double stimulated echo 
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IDL-C  IDL cholesterol 
IISPV  Institut d’Investigació Sanitària Pere Virgili 
IM  ion mobility 
KNN  Kohonen neural networks 
LDL  low density lipoprotein 
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1.1. Background 
1.1.1. Cardiovascular disease 
 According to the World Heath Organization (WHO), cardiovascular disease (CVD) is 
the leading cause of death globally. Indeed, an estimated 17.3 million of people died from 
CVD in 2008, representing 30% of all global deaths. An estimated 7.3 million, out of these 
deaths, were due to coronary heart disease and 6.2 million of them were due to stroke. 
There will be an estimated 23.6 million deaths by 2030 due to some form of CVD, mainly 
from heart disease and stroke. Moreover, CVD costs more than any other diagnostic group: 
coronary heart disease alone costs the US $108.9 billion each year. Also importantly, CVD is 
one of the most misdiagnosed and mistreated conditions in medicine. 
 CVD risk is most frequently the result of multiple interacting risk factors [1]. The 
classic cardiovascular risk factors include age, smoking, diabetes, blood pressure and 
dyslipidemia. Among the above-mentionned risk factors, this text is focused on 
dyslipidemias (i.e., abnormal levels of lipids in the blood) and lipoproteins (spherical 
macromolecular complexes that transport lipids). Briefly, lipoproteins have been historically 
classified according to their size and density, arising five main lipoprotein classes: 
Chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), 
low density lipoproteins (LDL), and high density lipoproteins (HDL). These macromolecular 
complexes transport lipid molecules from the liver or intestines to peripheral tissues 
through the blood stream for structural and energy functions, among others. Thus, 
cholesterol should not be taken as “good” or “bad”, but it should be thought as a vital 
molecule for life. 
 The role of lipoproteins in the metabolism of triglycerides and cholesterol in relation 
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to cardiovascular disease is highly complex. The cholesterol molecules transported by LDL 
lipoproteins are susceptible to be deposited within the intima media of arterial walls, 
triggering the development of atherosclerosis and subsequent cardiovascular events. In 
fact, there are a number of epidemiological studies that show that high concentrations of 
LDL cholesterol (LDL-C) are associated with increased severity of cardiovascular disease. 
Therefore, LDL-C is the primary target for the therapeutic treatment of adults with high 
cholesterol in the blood. On the other hand, HDL lipoproteins play the role of reverse 
cholesterol transport: they remove the cholesterol from the arterial walls to transport them 
back to the liver for excretion purposes [2, 3]. Thus, low concentrations of HDL cholesterol 
(HDL-C) are associated with an increased risk of atherosclerosis. However, HDL-C levels do 
not always predict cardiovascular risk. For example, high HDL-C levels caused by some 
genetic disorders may not protect against cardiovascular disease and low HDL-C levels 
caused by some genetic disorders may not increase the risk of cardiovascular disorders. 
Although HDL levels predict cardiovascular risk in the general population, the increased risk 
may be due to other factors such as accompanying lipid and metabolic abnormalities, rather 
than the HDL-C level itself. High levels of triglycerides (TG) are also a risk factor for 
cardiovascular disease because there is evidence suggesting that TGs are a marker of high 
atherogenic lipoprotein remnants. 
 Altogether, dyslipidemia can be defined as the presence of elevated plasma 
cholesterol, triglycerides, or both, or a low level of high-density lipoprotein that contributes 
to the development of atherosclerosis. The causes of these abnormal lipid levels may be 
primary (genetic) or secondary (lifestyle and other). Dyslipidemia is diagnosed by measuring 
serum lipids. Routine measurements (lipid profile) include total cholesterol (TC), TG, HDL-C 
and LDL-C. TC, TG and HDL-C are measured directly. The values TC and TG reflect the 
cholesterol and TG in all circulating lipoproteins, including chylomicrons, VLDL, intermediate 
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density lipoprotein (IDL), LDL and HDL. The values of LDL-C are calculated usually as the 
amount of cholesterol not contained in HDL and VLDL [4]. VLDL is estimated by TG/5 
because the concentration of cholesterol in VLDL particles is generally one-fifth of the total 
lipid particle. Therefore, 
LDL-C= TC - HDL-C - TG/5 
 This calculation is valid only when TGs are < 400 mg/dL and patients are fasting, 
because eating increases TGs. The calculated LDL-C value incorporates measures of all non-
HDL, nonchylomicron cholesterol, including that in IDL and lipoprotein (a) [Lp(a)]. LDL-C can 
also be measured directly using plasma ultracentrifugation, which separates chylomicrons 
and VLDL fractions from HDL and LDL, and by an immunoassay method. Direct 
measurement may be useful in some patients with elevated TGs, but these direct 
measurements are not routinely necessary [5]. 
 The treatment of dyslipidemia includes changes in diet, exercise, and lipid-lowering 
drugs. Treatment is indicated for all patients with cardiovascular disease (secondary 
prevention) and for some without (primary prevention). The National Institutes of Health's 
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) guidelines 
are the most common reference for deciding which adults should be treated [6]. The 
guidelines focus primarily on reducing elevated LDL-C levels and secondarily on treating 
high TGs, low HDL-C, and metabolic syndrome. 
 Although the use of statins is well established into the clinical guidelines for primary 
prevention of CVD, its use is controversial. Indeed, 50% of people who have a cardiovascular 
event have normal cholesterol levels. One explanation for this undesired clinical outcomes 
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may be as follows. Both LDL and HDL lipoprotein classes comprise a continuum distribution 
of lipoprotein particles in terms of their size, density, and composition. Due to the 
limitations of the current characterization techniques, main LDL and HDL lipoprotein 
fractions can be divided into small and large lipoprotein subclasses as a simplification, 
though some analytical techniques can provide even seven and five lipoprotein subclasses 
for the LDL and HDL main fractions, respectively. In terms of their association to 
cardiovascular risk, the smaller-denser LDL subclass is more susceptible to enter the intima 
media than the larger one and thus individuals with a preponderance of this subclass have 
been associated with an increase of cardiovascular risk. On the other hand, the presence of 
a larger HDL subclass is indicative of an efficient reverse cholesterol transport process, so 
individuals with a preponderance of larger HDL particles have been associated with a 
decrease of cardiovascular risk. 
 
1.1.2. Advanced lipoprotein testing 
 The scenario presented above opened the door for shifting the cardiovascular risk 
prediction protocols based on lipid levels to a new paradigm of cardiovascular risk 
prediction based on the size and particle number of lipoprotein particles [7, 8]. A particular 
case in which this new paradigm can overcome the limitation of current protocols for 
cardiovascular risk prediction is in patients with a constellation of lipid and lipoprotein 
abnormalities known as atherogenic dyslipidemia: increased triglyceride levels, decreased 
HDL levels, and a preponderance of small LDL particles [9]. The atherogenic dyslipidemia is 
characteristic of diabetic patients, and thus it is also known as diabetic dyslipidemia. The 
atherogenic dyslipidemia may be a consequence of obesity, poorly controlled diabetes, or 
both, which can increase circulating free fatty acids (FFA), which leads to increased hepatic 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
1. Introduction 
 
45 
 
VLDL production. TG-rich VLDL then transfers TG and cholesterol to LDL and HDL, promoting 
the formation of TG-rich, small and dense LDL and clearance of TG-rich HDL. Atherogenic 
dyslipidemia is often exacerbated by increased caloric intake and sedentary lifestyles that 
characterizes some patients with type 2 diabetes. Patients with other metabolic disorders 
such as patients with obesity or metabolic syndrome can also present this kind of 
dyslipidemia. All these populations are one of the most vulnerable populations to suffer 
CVD since at least 65% of diabetics die from some form of CVD and women with diabetes 
may be especially at risk of heart disease of this form. 
 The rationale for characterising such a dyslipidemia is the fact that it usually shows 
normal LDL cholesterol levels. However, cardiovascular risk is still high due to the presence 
of higher concentrations of small LDL particles. The reason for this is that two subjects with 
the same levels of LDL cholesterol can have different distributions of LDL particles in terms 
of their size [10]. Thus, a subject with smaller particles will need more particles in order to 
transport the same amount of cholesterol. As stated before, smaller LDL particles have an 
inherent increased risk for atherosclerosis, but determining only the concentration of LDL 
cholesterol will not uncover such risk. This is known as Residual Cardiovascular Risk. 
 This is why recent studies have stressed the importance of adding other parameters 
when analysing lipoproteins such ApoB concentration or the number of lipoprotein particles 
and their size [11, 12]. The role of apo B testing is under study because values reflect all 
non-HDL cholesterol (in VLDL, VLDL remnants, IDL, and LDL) and may be more predictive of 
CAD risk than LDL cholesterol [13, 14]. In addition, non-HDL cholesterol (TC - HDL 
cholesterol) may also be more predictive of CAD risk than LDL cholesterol. In this regard, the 
National Lipid Association Expert Panel has recently advised testing on LDL-P to assess and 
manage cardiovascular risk. Although ApoB and LDL-P are highly correlated, the latter 
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parameter is more accurate for the estimation of CVD risk because it does not include the 
particle numbers of VLDL and IDL fractions, less atherogenic than LDL fractions [15]. As has 
been mentioned before, diabetic individuals characterized by a dense LDL fraction (the so 
called Pattern B phenotype) as well as high level of triglycerides and a low level of HDL-C are 
a target group well-suited for an LDL-P measurement. 
 The set of analytical techniques that provide more detailed information on 
lipoprotein particles are known as advanced lipoprotein tests (ALT). Some limitations of ALT 
are the lack of standardization and the disagreement between different ALT approaches. 
Unfortunately, the number and nomenclature of lipoprotein subfractions are not uniform 
across the different techniques and have not been standardized, making it difficult to 
compare results from various tests. Moreover, some of these tests can only be performed at 
the company that markets the test, limiting the ability to obtain independent information 
on test performance. Thus, although it is unclear if these methods are ready for clinical use, 
it is necessary to perform more exhaustive and detailed analysis of (i) the utility of 
progressive changes in lipoproteins as therapeutic targets and (ii) whether certain 
subgroups of individuals may benefit from these analyses. Moreover, these methods may 
be important for advancing research and understanding the pathophysiology of CVD. 
 
1.1.3. Nuclear magnetic resonance spectroscopy 
 Nuclear magnetic resonance (NMR) spectroscopy is a tool highly reproducible, 
quantitative and versatile for the study of the physical, chemical and biological properties of 
matter. Its physical principle relies on the fact that spins within a sample are excited by 
means of a magnetic field followed by a radio frequency pulse which aligns the spins in a 
manner that they can be measured. Once the radio frequency pulse is switched off, spins 
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recover their initial state at a rate that depends on their molecular weight. This recovering 
step is known as relaxation and the signal obtained between the alignment and the total 
recovery of the spins is called finite impulse decay (FID). The FID shows a decaying sinusoid 
containing all the signals from all the molecules within the sample. Fourier transformation 
of the FID yields the NMR spectrum of a given sample and it provides information of both 
the environment of the molecule moieties (structure elucidation) and the abundance of a 
given molecule (quantification). 
 NMR can be used as an analytical technique of high performance because sample 
handling is minimal [16]. For this reason, NMR has found a myriad of applications in many 
different areas of science. In particular, NMR has been shown to be a robust and 
reproducible tool to analyse lipoproteins for cardiovascular risk prediction [17]. The NMR 
spectrum of lipoproteins shows signals across a wide range of NMR frequencies [18]. The 
most studied signal is the signal coming from the methyl moiety of the lipids contained in a 
particular lipoprotein [19-21]. Because the methyl NMR signals of lipoproteins are broad 
and highly overlap, different strategies can be used to characterize the different classes and 
subclasses. However, current methods for lipoprotein characterization using NMR 
spectroscopy are indirect, so information regarding lipoprotein particles are based either on 
calibration using NMR spectra of lipoprotein fractions which have been calibrated with 
other techniques such as transmission electron microscope or gradient gel electrophoresis, 
or using regression methods such as partial least squares (PLS) which relate the information 
contained in the NMR envelope of arbitrary regions containing the NMR signals arising from 
the different lipid moieties to lipid and lipoprotein values [17, 22]. Another limiting aspect 
for translating NMR methods to clinical practice is the lack of standardization [10]. Current 
NMR methods for lipoprotein analysis do not match in terms of the number and type of 
parameters being provided. To overcome this, diffusion-ordered NMR spectroscopy (DOSY) 
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provide a direct measure of lipoprotein particle sizes, neither without prior calibration with 
other techniques nor using a library of defined lipoprotein fractions previously 
characterized using NMR [23]. 
1.2 Motivation 
 Our aim was to develop a new methodology based on NMR to determine other 
parameters of lipoprotein particles beyond of their lipid content, such as size and particle 
number of several subclasses, thought to be better predictors of cardiovascular risk in these 
individuals whose classical risk factors do not unmask their real cardiovascular risk. These 
individuals include subjects with metabolic disorders, such as patients with obesity, 
diabetes and/or metabolic syndrome, among others. 
 In order to let the reader to get the sufficient knowledge for the critical judgement 
of this thesis and the scientific articles within it, Chapter 2 includes a description of the 
different theoretical aspects involving this very multi-disciplinar thesis, including theory on 
lipid and lipoprotein metabolism, nuclear magnetic resonance spectroscopy and 
mathematical tools for the treatment of NMR data (See Scheme 1). 
 The doctoral thesis presented in this document is the result of the research 
conducted in the Department of Electronic, Electrical and Automation Engineering at the 
Rovira i Virgili University (URV). Other research institutions have been involved in this 
research, such as the Metabolomics Platform owned by the same university and the CIBER 
of Diabetes and Metabolic Diseases (CIBERDEM), the Research Unit of Lipids and 
Atherosclerosis (URLA) of Sant Joan University Hospital from Reus (HUSJR). All these groups 
are part of the Institut d'Investigació Sanitària Pere Virgili (IISPV). 
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Scheme 1. Building blocks of the theoretical knowledge included within the framework of 
this thesis. 
 
 Thanks to this collaboration it has been possible to develop The LipoScale Test, an 
advanced lipoprotein test based on difussion NMR spectroscopy. This test is aimed at 
obtaining a better characterization of plasma lipoproteins, i.e. lipid content, size and particle 
number, in order to improve cardiovascular risk prediction. The main difference between 
our approach and the commercial test is that they use standard 1D NMR methods, while 
our test is based on the use of magnetic gradients, which generates 2D spectra with direct 
and objective information on lipoprotein particle sizes. 
 This thesis has generated different scientific publications which will be detailed 
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through the next sections, as well as a patent that has been filled to the European Patent 
Office (EPO) and a spin-off which will commercialize the test. 
 Future challenges that advanced lipoprotein tests must overcome will be the quest 
for the target population who will benefit such advanced tests, standardization of the 
different analytical techniques and the translation of these tests into clinical practice. 
 
1.3. Objectives 
 The aim of this thesis has been to develop and evaluate a novel advanced 
lipoprotein test, the Liposcale test, based on 2D diffusion-ordered 1H NMR spectroscopy 
to measure the size and particle number of lipoproteins. This new test has been developed 
either for measuring human plasma/serum samples as well as isolated lipoprotein fractions. 
Therefore, the goals related to this purpose are the following: 
 Optimization of the measurement conditions of human plasma/serum samples by 
2D diffusion-ordered 1H NMR spectroscopy. 
 Set up of the Lipsocale test, a deconvolution algorithm to obtain the size and 
particle number of several lipoprotein subclasses lipoprotein-related information 
from 2D diffusion- ordered 1H NMR spectra. 
 Application of the Lipsocale test to the study of dyslipidemias (e.g. atherogenic 
dyslipidemia). 
 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
1. Introduction 
 
51 
 
1.4. Organization of the text 
 This chapter has provided a general overview of the background and motivation for 
the realization of this thesis. As has been highlighted previously, the need for better 
predictors of cardiovascular disease is increasing due to the pandemic levels that metabolic 
disorders are achieving. One of the main areas where new biomarkers can be looked for is 
in the area of lipids and lipoproteins. For this purpose, NMR spectroscopy appears to be a 
suitable analytical technique to develop new methods which will aid in the assessment and 
management of cardiovascular events. 
 Chapter 2 presents an state of the art of the current applications of lipoprotein 
analysis methods by NMR spectroscopy and their applications to study diabetes and related 
disorders. The contents of this chapter have been published recently as a review article in 
the journal Progress in Nuclear Magnetic Resonance Spectroscopy. The first part of the 
review describes the main concepts on lipid metabolism and one of the most important 
lipid abnormalities: the diabetic dyslipidemia. It is in this sort of dyslipidemia where the 
advanced lipoprotein tests can take an advantage over other common lipid tests due to the 
fact that this dyslipidemia is characterized, among others, by showing normal LDL 
cholesterol levels but a preponderance of small LDL particles, resulting in an increase in 
total LDL particle concentrations. The second part of the review focuses on the practical 
aspects of human plasma/serum analysis by NMR, covering issues such as sample handling 
and conservation, common NMR measurements of plasma/serum samples and diffusion 
NMR measurements to obtain optimum information on lipoprotein particles. 
 Chapter 3 contains three scientific articles published during the realization of this 
thesis. These scientific articles deal with the different phases involved in the development 
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and evaluation of a novel NMR-based advanced lipoprotein test either in plasma/serum or 
lipoprotein fractions. Our first results show the development of a new methodology to 
measure the size of lipoprotein fractions previously isolated using ultracentrifugation. We 
evaluated this methodology with the results obtained from the transmission electron 
microscope (TEM). These results have been published in the journal Analytical and 
Bioanalytical Chemistry. 
 The second scientific article presented in Chapter 3 describes our first attempt to 
analyze a number of human plasma samples using 2D diffusion-edited 1H NMR 
spectroscopy. We also wrote the necessary MATLAB code to optimize the different 
lorentzian parameters to characterize an arbitrary number of lipoprotein subclasses. The 
NMR areas obtained through this optimization process were used to classify the different 
samples according their associated dyslipidemias using the unsupervised Principal 
Component Analysis (PCA). These results were published in the journal METABOLOMICS. 
The above-described methodology was the origin for a further improvement both in the 
NMR experiments and the NMR data processing, leading to the development of the final 
advanced lipoprotein test. Overall, our advanced lipoprotein tests provides the lipid 
concentration (cholesterol and triglycerides) and size for the main lipoprotein fractions and 
the particle concentration of the main lipoprotein fractions as well as nine subclasses. To 
mention, partial least squares (PLS) regression models were built to obtain the lipid 
concentrations. The development and evaluation of this NMR-based advanced lipoprotein 
test have been submitted to the Journal of Lipid Research. 
 The advantage of this novel advanced lipoprotein test is based on the use of 
diffusion measurements, which yields the size of the main lipopotein particles directly, 
without the need for external libraries or calibrations with a reference technique. This novel 
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advanced lipoprotein test was evaluated through the validation of the LDL particle number 
parameter, the most important risk factor for cardiovascular disease in patients with 
diabetic dyslipidemia. Moreover, the LDL particle number is being a matter of debate in the 
scientific community in order to incorporate it to the clinical guidelines for screening and 
managing of dyslipidemias and their associated cardiovascular risk. Thus, the accurate 
validation of this parameter is of most value in order to translate its use into clinical 
practice. In this regard, we obtained high accuracy and precision values of this parameter 
compared with standard measures of LDL apolipoprotein B, which is a surrogate of the 
number of LDL particles. 
 The Annexes contains three scientific studies showing the usefulness of the NMR-
based lipoprotein analysis. The first one deals with the monitorization of a pharmacological 
intervention on women with polycystic ovary syndrome. The second one studies the effect 
of a nutritional intervention on the lipoprotein profile. And the latter studies the effect of 
different protocols to extract information on lipoprotein particles usign DOSY. 
 
1.5 References 
1. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V: Assessment of 
cardiovascular risk by use of multiple-risk-factor assessment equations - A 
statement for healthcare professionals from the American Heart Association and 
the American College of Cardiology. Circulation 1999, 100(13):1481-1492. 
2. Rader DJ, Tall AR: The not-so-simple HDL story: Is it time to revise the HDL 
cholesterol hypothesis? Nature medicine 2012, 18(9):1344-1346. 
3. Heinecke JW: The not-so-simple HDL story: A new era for quantifying HDL and 
cardiovascular risk? Nature medicine 2012, 18(9):1346-1347. 
4. Friedewa.Wt, Fredrick.Ds, Levy RI: Estimation of concentration of low-density 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
1. Introduction 
54 
 
lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. 
Clinical Chemistry 1972, 18(6):499-&. 
5. Mora S, Rifai N, Buring JE, Ridker PM: Comparison of LDL cholesterol concentrations 
by Friedewald calculation and direct measurement in relation to cardiovascular 
events in 27,331 women. Clin Chem 2009, 55(5):888-894. 
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421. 
7. Brook RD, Kansal M, Bard RL, Eagle K, Rubenfire M: Usefulness of low-density 
lipoprotein particle size measurement in cardiovascular disease prevention. Clinical 
Cardiology 2005, 28(11):534-537. 
8. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, 
D'Agostino RB: LDL particle number and risk of future cardiovascular disease in the 
Framingham Offspring Study-Implications for LDL management. Journal of Clinical 
Lipidology 2007, 1(6):583-592. 
9. Chahil TJ, Ginsberg HN: Diabetic dyslipidemia. Endocrinol Metab Clin North Am 
2006, 35(3):491-510, vii-viii. 
10. Mora S: Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for 
Routine Clinical Use. Circulation 2009, 119(17):2396-2404. 
11. Superko HR: Advanced Lipoprotein Testing and Subfractionation Are Clinically 
Useful. Circulation 2009, 119(17):2383-2395. 
12. Robinson JG: What Is the Role of Advanced Lipoprotein Analysis in Practice? Journal 
of the American College of Cardiology 2012, 60(25):2607-2615. 
13. Sniderman A, Kwiterovich PO: Update on the detection and treatment of 
atherogenic low-density lipoproteins. Current opinion in endocrinology, diabetes, 
and obesity 2013, 20(2):140-147. 
14. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR: 
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC 
Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
1. Introduction 
 
55 
 
Chem 2009, 55(3):407-419. 
15. Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, Hoefner DM, 
Mallory T, Sethi AA, Warnick GR: Association of Apolipoprotein B and Nuclear 
Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 
25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases 
Division Working Group on Best Practices. Clin Chem 2013, 58(5):752-770. 
16. Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, Järvelin MR, 
Kähönen M, Lehtimäki T, Viikari J et al: High-throughput serum NMR metabonomics 
for cost-effective holistic studies on systemic metabolism. Analyst 2009, 
134(9):1781-1785. 
17. Jeyarajah EJ, Cromwell WC, Otvos JD: Lipoprotein particle analysis by nuclear 
magnetic resonance spectroscopy. Clinics in Laboratory Medicine 2006, 26(4):847-+. 
18. Mallol R, Rodriguez MA, Brezmes J, Masana L, Correig X: Human serum/plasma 
lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog 
Nucl Magn Reson Spectrosc 2013, 70:1-24. 
19. Ala-Korpela M, Korhonen A, Keisala J, Horkko S, Korpi P, Ingman LP, Jokisaari J, 
Savolainen MJ, Kesaniemi YA: 1H NMR-based absolute quantitation of human 
lipoproteins and their lipid contents directly from plasma. Journal of Lipid Research 
1994, 35(12):2292-2304. 
20. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM: Development of a proton nuclear 
magnetic resonance spectroscopic method for determining plasma lipoprotein 
concentrations and subspecies distributions from a single, rapid measurement. Clin 
Chem 1992, 38(9):1632-1638. 
21. Mallol R, Rodríguez MA, Heras M, Vinaixa M, Cañellas N, Brezmes J, Plana N, 
Masana L, Correig X: Surface fitting of 2D diffusion-edited 1H NMR spectroscopy 
data for the characterisation of human plasma lipoproteins. Metabolomics 2011, 
7(4):572-582. 
22. Mihaleva VV, van Schalkwijk DB, de Graaf AA, van Duynhoven J, van Dorsten FA, 
Vervoort J, Smilde A, Westerhuis JA, Jacobs DM: A systematic approach to obtain 
validated partial least square models for predicting lipoprotein subclasses from 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
1. Introduction 
56 
 
serum NMR spectra. Analytical chemistry 2014, 86(1):543-550. 
23. Mallol R, Rodríguez M, Heras M, Vinaixa M, Plana N, Masana L, Morris G, Correig X: 
Particle size measurement of lipoprotein fractions using diffusion-ordered NMR 
spectroscopy. Analytical and Bioanalytical Chemistry 2012, 402(7):2407-2415. 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
  
57 
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ANALYSIS BY NMR: APPLICATION TO 
THE STUDY OF DIABETIC 
DYSLIPIDEMIA" 
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2.1. Introduction 
 NMR spectroscopy is an analytical technique used in the profiling of blood. 
Depending on the sample preparation method, it is used to examine either serum or 
plasma. With this technique it is possible to obtain the spectra of the most abundant 
chemical components such as lipoproteins, aminoacids, organic acids, carbohydrates and 
albumin with minimum sample preparation [1,2]. NMR has proven to be a straightforward 
and useful technique for the qualitative and quantitative measurement of lipoproteins, 
giving the cholesterol and triglyceride concentration [3,4], as well as the number of 
subfraction particles and their size [5]. This is a great achievement because even though the 
behavior of the different lipoprotein subfractions is modulated by their size, the overlap 
between them in the spectra is severe, and sophisticated deconvolution algorithms are 
required for data analysis [6]. 
 The importance of NMR spectroscopy as an analytical tool for metabolomic studies 
with biological fluids, especially for serum and plasma samples, can be clearly assessed by 
considering the relevant literature during the past few years. Since the year 2000, the ISI 
Web of Science lists more than 500 papers on the subject (and more than 130 in 2011). 
These papers deal with NMR spectroscopy, metabolomics and serum/plasma. Human 
serum/plasma NMR measurements have been applied, for example, to monitor changes in 
the organization of lipids within particle density subclasses [7], to assess diabetes studies 
[8–10], to study the effects of exercise on lipoprotein profiles [11], to monitor changes in 
lipids induced by diet therapies [12,13], to assess cholesterol-lowering drugs [14,15] and to 
investigate dyslipidemias associated with HIV/AIDS therapy [16–18], among others. The 
serum/plasma NMR measurement is also a highly valued tool in scientific experiments on 
animal models (rats, mice, etc.) that aim to assess the effects of drug/diet intervention 
[12,13]. However, in most of these publications, the information extracted from spectra 
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about lipoproteins is rather qualitative [1]. 
 The Adult Treatment Panel Guidelines of the National Cholesterol Education 
Program and, more recently, the European Societies of Cardiology and Atherosclerosis have 
established lowdensity lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-
high-density lipoprotein (HDL-C) treatment goals for people with hypertriglyceridemia, but 
these risk factors are unable to predict cardiovascular events in individuals with 
‘‘apparently’’ normal lipid levels. These events are frequently found in individuals with such 
metabolic disorders as obesity and diabetes mellitus [19]. This means that lipoprotein 
characterization needs to be more sophisticated, and justifies the advent of the advanced 
lipoprotein tests (ALT), a set of techniques that enable the lipoprotein to be 
subfractionated and the lipids from the different subfractions to be measured. In this 
context, Liposcience Inc. has recently received 510(k) clearance from the U.S. Food and 
Drug Administration to market the Vantera(R) Clinical Analyzer. It is the first NMR-based 
diagnostic platform that is commercially available for in vitro diagnostic use, consisting in 
the determination of the low density lipoprotein particle number (LDL-P). If cleared, it 
would become the first 121 NMR-based diagnostic platform to be commercially available 
for in vitro diagnostic use. If this trend continues, NMR spectrometry will become the 
reference technique for the determination of such cardiovascular risk factors associated 
with lipids as low-density lipoprotein particle numbers (in particular LDL-P). There is still 
some controversy about the clinical utility of the ALT (i.e. LDL and HDL subfractionation) 
[20,21], one of the greatest impediments being the lack of standardization in the 
characterization techniques. Ala-Korpela’s group, very active in the area since the mid 90s, 
reported in 2009 an NMR-based highthroughput analytical method for serum profiling, 
which can quantify up to 130 metabolites, lipids and 14 subfraction lipoproteins [2]. This 
analytical platform has turned out to be very useful in epidemiological cohort studies [22–
24], and has found associations in wide-genome studies. 
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 Recently, some articles have been published and patents filed that directly relate to 
the use of diffusion NMR spectroscopy for the characterization of lipoproteins [25,26]. The 
application of magnetic gradients in the z-direction attenuates the diffusion of the smaller 
lipoproteins more strongly. Therefore, for low gradients all the lipoprotein response is 
present, but for high gradients only those of the larger lipoproteins are observed. Using this 
technique, the lipoprotein diffusion coefficients can be determined experimentally and, 
according to the Einstein–Stokes law, these values can give a direct estimation of the 
lipoprotein radii. However, at the moment the approach has not been perfected and 
cannot give reliable and meaningful results for clinical applications. 
 The aim of this review is to help researchers interested in serum/plasma-based 
NMR analysis of lipoproteins for clinical diagnostics, metabolomic studies, etc. We provide 
comprehensive information about all the steps needed to characterize lipoproteins by NMR 
spectroscopy. In Section 2.2.1 there is an introduction to lipoproteins and their role in 
metabolism and the clinical importance of lipoprotein characterization for assessing risk 
factors important for cardiovascular diseases (CVD). Because diabetic patients are one of 
the target groups for ALT, Section 2.2.2 gives an explanation about diabetic dyslipidemia. 
Section 2.2.3 discusses the clinical utility of the ‘‘new biomarkers’’ measured by ALT. The 
state of the art of these techniques is reviewed in the same section. Section 2.3 describes 
all the NMR measurement procedures used for serum/plasma, giving information about 
blood collection and conservation procedures and also about the pulses used. Diffusion-
edited NMR pulses will be reviewed in detail because they enhance the NMR signal from 
lipoproteins and eliminate the signal from small metabolites. The reader will find a detailed 
discussion of the advantages and disadvantages of the various pulses used in diffusion 
NMR. As has been mentioned above, extracting the information about the lipoproteins 
from the lipid peaks in NMR spectra (i.e. methyl or methylene) is not straightforward, so we 
will make a detailed review of the various signal processing strategies. We group them in 
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three main approaches: (a) curve fitting methods, which are based on a mathematical 
deconvolution of the peak to extract new features from the lipid peak(s) that will then be 
used as inputs for multivariate analysis; (b) correlation statistical methods, where the 
points of the original lipid peak envelop are considered to be input features for further 
processing algorithms since these methods do not deconvolute the peak; and (c) diffusion 
NMR methods. In this subsection, we will consider all the studies made of 2D diffusion 
NMR, regardless of whether there has been a deconvolution process or only a statistical 
correlation used in the analysis. Finally, in Section 2.5, the application of NMR lipoprotein 
analysis in diabetes will be reviewed in detail and Section 2.6 will draw the final conclusions 
and discuss the future outlook. 
 
2.2. Clinical interest of lipoprotein analysis 
2.2.1. Lipoproteins and the lipoprotein metabolism 
 Lipids are key molecules for life [27]. For instance, triacylglycerols provide energy 
for metabolic processes, and fatty acids, cholesterol and phospholipids are part of cell 
membranes that, as well as having a role as precursors of hormone molecules are also 
constituents of the central nervous system and genetic signal modulators. However, their 
hydrophobic chemical structure makes them incompatible with an aqueous medium like 
blood. In order for lipids to circulate throughout the blood stream and reach peripheral 
tissues, they are packaged into macromolecular complexes together with protein 
molecules. This gives rise to lipoproteins. The general structure of lipoprotein molecules is 
spherical and they are synthesized within the liver and intestines. Non-polar lipids 
(triacylglycerols and cholesterol esters) are found within the core, while polar lipids 
(phospholipids and free cholesterol) are distributed through a surface monolayer (Figure 1). 
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Figure 1. An schematic diagram of a typical lipoprotein, with its lipid content (taken from 
[136]). 
 
 The protein components of lipoproteins are called apolipoproteins (or apoproteins), 
a group of proteins of immense structural diversity, which are located on the surface 
together with polar lipids. They define the structure, metabolism and functionality of a 
given lipoprotein class, as well as how it interacts with receptor molecules or different 
enzymes in the liver and peripheral tissues. Lipoproteins have historically been defined 
according to their density and are divided into five main classes [28,29]: chylomicrons; very 
low density lipoproteins (VLDL); intermediate density lipoproteins (IDL); low density 
lipoproteins (LDL), and high density lipoproteins (HDL) [29]. Each of these lipoprotein 
classes can be further divided into several subclasses, but the number and nomenclature is 
method-dependent (see Section 2.2.3.2), since the density of lipoproteins is really a 
continuum, not discrete values corresponding to a finite number of classes. 
 Chylomicrons transport triglycerides and esterified cholesterol formed by dietary 
lipids (such as free fatty acids, monoglycerides and free cholesterol) being processed. In 
addition to cholesterol absorbed from the diet, they may also receive new cholesterol 
synthesized in the gut and cholesterol transferred from other lipoproteins. Chylomicrons 
are rich in triglycerides. However, while tissues take up fatty acids and glycerol from 
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released and hydrolyzed core triglycerides, as the circulating chylomicrons become 
progressively smaller, their triglyceride content decreases and they become relatively richer 
in cholesterol and protein. They become what is known as a chylomicron remnant. 
 VLDLs are secreted by the liver to supply triglycerides to tissues in the fasting or 
postprandial state. VLDL particles are somewhat smaller than chylomicrons and they 
undergo exactly the same lipid release process described for chylomicrons. The loss of 
triglycerides converts some VLDL into IDL and LDL, which are very rich in cholesterol. 
 HDL are the most diverse lipoproteins. They are synthesized in the liver and small 
intestine as protein-rich, disc-shaped particles containing ApoA1 and phospholipids. These 
particles mature by the acquisition of cholesterol from peripheral tissues and the action of 
several sterifying enzymes (LCAT) [30]. The HDL particles make it possible for the 
cholesterol to flow out of the cells, esterify in plasma, transfer to other lipoproteins and 
return to the liver for excretion. The HDL mediation of the transfer of lipids and 
apolipoproteins between lipoprotein classes also plays an important role in the overall 
lipoprotein metabolism. 
 
2.2.2. Diabetic dyslipidemias and CVD risk 
 Diabetic dyslipidemia is defined as a characteristic set of lipid and lipoprotein 
abnormalities with a high prevalence in diabetic subjects [31]. In these subjects there is a 
low HDL concentration, a high triglyceride concentration and a clear preponderance of 
small, dense (SD) LDLs [32–34]. Disturbances in the production and clearance of plasma 
lipoproteins are characteristic of the metabolic abnormalities of diabetic patients. Therein 
brief, these abnormalities are the slower clearance of chylomicrons, increased production 
of VLDL, and the incomplete conversion of VLDL to LDL [35,36]. 
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 On the other hand, this overproduction of VLDL increases the exchange of 
triglycerides from VLDL to the cholesteryl esters in HDL and LDL and thus decreases the 
concentration of cholesterol in LDL and HDL particles, leading to small and denser LDL and 
HDL. Small HDL particles are rapidly catabolized, which contributes to the low HDL 
cholesterol levels observed in this situation [37]. Moreover, small dense LDL is found in 
most hypertriglyceri- demia states, including diabetes. The potential role of this phenotype 
in atherosclerosis is based on the physicochemical properties of these particles. For 
instance, sdLDL can be oxidized more easily, the particles do not interact well with LDL 
receptors, and they may associate more readily with proteoglycans on the surface of cells 
or in the matrix. Thus, it is thought that SD LDLs have an important role in diabetic 
dyslipidemia along with reduced HDLs and increased triglyceride levels [38]. 
 Several studies support the view that each of these abnormalities increases the risk 
of suffering cardiovascular heart disease (CHD) [39,40]. CHD is the main cause of death of 
diabetic patients [41]. Diabetic subjects are two-to-four times more likely to suffer a 
cardiovascular event [42]. Moreover, development of dyslipidemia may be a precursor of 
diabetes. To assess cardiovascular risk, clinicians use a standard lipid panel, which includes 
the concentration of plasma triglycerides (TG), total cholesterol (TC), LDL cholesterol (LDL-
C) and HDL cholesterol (HDL-C). All these parameters are experimentally measured except 
for the LDL-C, which is estimated using the Friedewald formula in clinical settings even 
though it can be measured directly [43]. A critical limitation of this formula is that it cannot 
be used when the concentration of plasma triglycerides exceeds 400 mg/dL, which is 
common in diabetic dyslipidemia. In addition, the resulting LDL-C value may include the 
concentration of cholesterol from IDL (IDL-C), making the use of this parameter for the 
clinical interpretation of a pathological state even more inaccurate. 
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2.2.3. Advanced lipoprotein tests 
2.2.3.1. New biomarkers for cardiovascular risk assessment 
 New insights into the relationship between lipoproteins and atherosclerosis have 
highlighted the limitations of reporting the total amount of cholesterol in each major 
lipoprotein fraction. For instance, individuals receiving statin therapy to reduce LDL-C may 
still be at significant risk of developing CHD. This residual risk is higher in patients with 
metabolic syndrome, diabetes mellitus and/or obesity disorder, which are experiencing a 
significant increase in prevalence in recent decades. LDL-C, then, has less predictive power 
in these populations. An explanation for the abovementioned paradox regarding LDL-C and 
cardiovascular risk is that two individuals can possess the same total LDL-C, but if the 
amount of cholesterol that LDL particles carry is not constant, for the same amount of LDL-
C, different subjects will have different LDL particle (LDL-P) numbers [19]. Nevertheless, 
smaller LDL particles have less cholesterol [44] than bigger ones, so denser LDL lipoproteins 
will be indicative of higher LDL-P and, thus, a higher risk of CVD. This is why recent studies 
have stressed the importance of adding other parameters when analyzing lipoproteins such 
as the Apo B concentration or the number of lipoprotein particles and their size. In this 
regard, the National Lipid Association Expert Panel has recently advised testing of LDL-P to 
assess and manage cardiovascular risk [45]. Although Apo B and LDL-P are highly 
correlated, the latter parameter is more accurate for estimating CVD risk because it does 
not include the particle numbers of VLDL and IDL fractions, which are less atherogenic than 
LDL fractions [45]. As has been mentioned above, diabetic individuals characterized by a 
dense LDL fraction (the so called Pattern B phenotype [46]) and a high level of triglycerides 
and a low level of HDL-C are a target group that is well-suited for an LDL-P measurement. 
 NMR is the most common technique used (see Sections 2.2.3.2 and 2.4.1) for 
measuring LDL-P [6]. Liposcience, Inc. has performed more than 6.5 million tests using its 
NMR LipoProfile® test. At the same time, there is some controversy about whether the LDL 
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and HDL subfraction parameters improve cardiovascular risk prediction in comparison with 
the standard lipid panel guidelines. It has been reported that the relationship between LDL 
particle size and cardiovascular risk is not inherent to this parameter but related to the fact 
that smaller particles lead to an increase in the particle number of this type of LDL [45]. 
 The set of analytical techniques that provides the most detailed information on 
lipoprotein particles is known as advanced lipoprotein testing (ALT) [20]. 
 In summary, although advanced lipoprotein testing and fractionation is not yet 
ready for routine clinical use, there is a need to account for a complete lipoprotein subclass 
composition, size and functionality analysis. This will be useful for developing and 
monitoring novel diet and drug therapies and getting insight into the pathophysiology of 
atherosclerosis. 
 Because of their high cost, advanced lipoprotein tests cannot be applied to the 
general population, but in the context of personalized medicine, they could be used in 
selected groups of patients who have been identified as having some risk factors (i.e. 
patients with diabetic dyslipidemia). 
 Some of the limitations of ALT are the lack of standardization and the varying 
approaches. Unfortunately, the number of lipoprotein subfractions and their nomenclature 
are not uniform across the techniques, which makes it difficult to compare results from 
different tests (Table 1) [47]. Moreover, some of the tests can only be performed by the 
company that markets the test, so the possibility of obtaining independent information on 
test performance is severely limited [21]. 
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Table 1. Comparison of reported analytical techniques for advanced lipoprotein tests. 
Advanced lipoprotein testing (ALT) Subfractions Cholesterol Triglycerides Particle Number Size References 
Vertical Auto Profile (VAP) II 3 VLDL, 1 IDL, 5 LDL, 5 HDL √ − − − [51] 
Gradient Gel Electrophoresis (GGE) 7 LDL, 5 HDL − − − √ [52] 
Dynamic Light Scattering (DLS) CM+VLDL+IDL, 2 LDL, HDL* − − − √ [53] 
High Performance Liquid Chromatography (HPLC) 2 CM, 5 VLDL, 6 LDL, 7 HDL √ √ − √ [54] 
Ion Mobility Analysis (IM) 3 VLDL, 2 IDL, 4 LDL, 2 HDL − − √ √ [55] 
Diffusion-Ordered NMR Spectroscopy of lipoprotein fractions any fractiona - - - √ [56] 
aSubfractions previously isolated by density gradient ultracentrifugation 
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 A recent study was aimed at evaluating the degree of heterogeneity among four 
ALT methods that assess LDL particle size. Complete agreement among these methods was 
only 8% [48]. Another review brought together all the results of studies comparing different 
ALT methods [49] and found that the agreement between methods for LDL subfraction 
determination varied widely (7–94%). 
 Although it is unclear if these methods are ready for clinical use, more exhaustive 
and detailed analyses need to be made to determine whether (i) progressive changes in 
lipoproteins are useful as therapeutic targets and (ii) certain subgroups of individuals can 
benefit from these analyses. These methods may also be important for advancing research 
and understanding the pathophysiology of CVD [50]. Moreover, many of these tests are of 
limited accessibility and it sometimes is difficult to identify the groups that might benefit 
from them. 
 
2.2.3.2. Reported analytical techniques 
 As stated above, there are a variety of ALT techniques. The techniques based on 
serum/plasma NMR spectroscopy will be reviewed in Section 2.4. Here, we briefly describe 
and discuss the most important methods. 
 – Density Gradient Ultracentrifugation: The Vertical Auto Profile (VAP) II test is a 
rapid and sensitive ultracentrifugation method which measures the relative cholesterol 
distribution for different lipoprotein subfractions [51]. With this technique it is possible to 
obtain 3 VLDL fractions, 1 IDL fraction, 5 LDL fractions, and 5 HDL fractions. However, it 
does not provide either the concentration of triglycerides, or the numbers and sizes of the 
lipoprotein particles. 
 – Gradient Gel Electrophoresis: Gradient gel electrophoresis can fractionate LDL and 
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HDL subfractions directly from plasma according to their size. With this method, the size 
and relative (%) distribution of 7 LDL and 5 HDL subfractions can be determined [52]. It 
often requires custom-made gels and strict attention to laboratory quality control because 
small variations in gel quality and laboratory conditions may affect accuracy. The GGE 
method (available from Berkeley Heart Lab, Inc.) delivers the distribution of LDL size 
phenotype and refers to a preponderance of larger particles as Pattern A and a 
preponderance of smaller particles as Pattern B [46]. 
 – Dynamic Light Scattering: Dynamic Light Scattering (DLS) can assess lipoprotein 
particle sizes by measuring the intensity of scattered light [53]. This technique has been 
used to determine the mean particle size of CM + VLDL + IDL, large LDL, smalldense LDL, 
and HDL fractions previously fractionated using sequential ultracentrifugation. 
 – High Performance Liquid Chromatography: A simple and fully automated HPLC 
method commercialized by LipoSearch® can measure the cholesterol and triglyceride 
content as well as the size of the major lipoproteins and their subclasses (2 CM, 5 VLDL, 6 
LDL and 7 HDL) [54]. 
 – Ion Mobility Analysis: This method relies on differences in electrophoretic 
mobility of gas-phased lipoprotein particles [55]. After an ultracentrifugation step to 
remove albumin, it can measure the size and concentration of 3 VLDL, 2 IDL, 5 LDL, and 2 
HDL. 
 – Diffusion-Ordered NMR Spectroscopy of lipoprotein fractions. This technique uses 
the methyl peak of isolated lipoproteins to calculate the diffusion coefficient of the 
lipoproteins and, from this value, to estimate their size [56]. 
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2.3. Serum/plasma lipoprotein analysis by 1H Nuclear Magnetic 
Resonance (NMR) spectroscopy 
2.3.1. Main characteristics of serum/plasma NMR analysis 
 As has been shown in the sections above, measuring lipids in plasma and serum is 
of great interest since it enables abnormal metabolic levels, and unusual cholesterol and 
triglyceride transport mechanisms to be highlighted, and it provides valuable clues for 
clinical diagnosis. Detailed information about the lipids in biological fluids can be obtained 
by rapid total lipid 1H NMR profiling without the need to apply complicated sample 
preparation procedures. However, the results will be rendered worthless if samples are not 
collected, stored, and prepared correctly. For this reason, protocols for handling biofluids, 
such as plasma and serum, have recently been proposed [57]. 
 When the analytical measurement is made, the operational NMR equipment must 
remain stable and any analytical drift must be identified, quantified and compensated for in 
order to reduce systematic differences over time. Bias should also be minimized so that 
measurements between different labs are comparable (this is one of the key advantages of 
the NMR approach). Fortunately, the coefficient of variation associated with inter- and 
intra-laboratory spectroscopic NMR experimentation is typically very low and, generally 
speaking, biological differences between individuals are far greater than the variations 
induced by experimental factors. Moreover, Lenz and co-workers have demonstrated high 
variability between subjects but low variability within subjects and study days in 1H NMR 
measurements in plasma [58]. 
 Whenever possible, the analyst should be involved throughout the design and 
decision-taking-process of all protocols, from the experimental design and sample 
collection to final data results. This involvement is becoming more and more important in 
serum and plasma analysis, since it can lead to good inter-laboratory reproducibility. 
Complex biofluid matrices can be easily affected by contamination and external factors, 
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which are visible in the NMR spectra, so samples should be prepared and measured 
carefully if the results are to be of any biological import. 
 
2.3.2. Serum/plasma handling and conservation 
2.3.2.1. Introduction 
 Blood plasma and serum are considered to be the most representative biofluids of 
the homeostatic state of the body. Because most of the tissues and organs in the body are 
profusely irrigated, the serum/plasma composition reflects even minimal changes in the 
whole body metabolism. This is why the collection of blood plasma or serum is the first step 
in most clinical, metabolic and nutritional studies. Nevertheless, untreated blood is not a 
suitable biofluid for lipoprotein NMR measurements. Although some studies with raw 
blood have been performed with NMR [59–61], lipoproteins are not present in erythrocytes 
and, even for the measurement of low molecular weight metabolites, the presence of cells 
and their sedimentation gives rise to problems of lack of homogeneity in the magnetic field 
and line broadening. 
 Plasma and serum contain high levels of proteins and many endogenous 
metabolites, some of which have yet to be identified. They also contain significant amounts 
of active enzymes and exogenous microorganisms that will change the concentration of the 
metabolites or generate new ones after a short period at physiological temperature. 
Therefore, improper storage and handling of plasma or serum samples may significantly 
influence accuracy and final results compared to the analysis of fresh samples. In addition, 
there are specific protocols for different analytes and sparse information about specific 
storage conditions and handling protocols. 
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2.3.2.2. Collection procedures 
 In order to obtain serum or plasma, blood should be collected in clean tubes and 
allowed to clot or be centrifuged. Collection of plasma requires an appropriate 
anticoagulant to prevent clotting before the cellular components are removed by 
centrifugation. Some commonly used anticoagulants include heparin, ethylene diamine 
tetraacetic acid (EDTA), citrate, and oxalate salts of sodium, potassium, or lithium. EDTA, 
oxalate, and citrate prevent clotting by complexing divalent calcium (Ca2+), which is 
required for coagulation. Heparin interferes with the formation of fibrin [62]. 
 For the NMR analysis of plasma, Li-heparin is preferred because other 
anticoagulants such as EDTA, sodium citrate or oxalate generate intrusive signals in the 
NMR spectrum [63]. Moreover, citrate and oxalate tubes contain an aqueous solution that 
dilutes the collected sample. Also, in order to prevent clotting, the high concentration of 
these anticoagulants changes the osmolarity of plasma, induces a shift of water from 
erythrocytes and adds an additional factor of dilution to lipoproteins by 10% or more. EDTA 
(especially K3-EDTA) can cause less severe, but still noticeable (3–5%), dilution. Tubes with 
protease inhibitor cocktails, routinely used in proteomic studies, should also be avoided for 
the same reason. 
 
2.3.2.3. Serum vs. plasma 
 For some NMR applications serum may be preferred to plasma. Anticoagulant 
problems such as fibrinogen precipitation on freezing and thawing are avoided if serum is 
used. Serum is prepared by allowing the blood sample to coagulate. This can be done by 
collecting the blood in a clean glass tube and allowing it to stand at room temperature until 
it clots. Serum contains all of the original blood components except the cellular elements 
and protein components that constitute the clot. This approach makes the analysis of 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
74 
 
lipoproteins easier than the analysis of plasma. However, the delay introduced by clot 
formation allows some biological processes to take place in the blood at room temperature. 
Therefore, the binding of lipoproteins to the clot must be taken into account. Our 
experience tells us that clotting at low temperature (4 ºC) yields more serum and clot 
variability than clotting after half an hour at room temperature. 
 Thus, it is recommended that the clot be formed at room temperature and the 
supernatant serum collected in another suitable storage container. A separator gel in the 
tubes could be used to facilitate collection, but some gels are not suitable for NMR 
measurements because they can introduce interfering compounds that are NMR-visible. 
Clot sedimentation for obtaining serum could produce hemolysis of the blood sample, a 
reaction that has an interfering effect in most of the classic clinical assays. However, the 
lipoprotein profile by NMR has been demonstrated to be virtually unaffected by gross 
hemolysis [6]. 
 
2.3.2.4. Cryopreservation 
 When the total amount of blood fraction is ready, the aliquots of blood plasma or 
serum samples, if needed, should be created prior to freezing and storage so that multiple 
freezing/thawing operations are not required. 
 For lipoprotein and metabolite analysis of plasma/serum by NMR, periods of up to 
several days at 2–4 ºC are acceptable. Refrigerated plasma or serum specimens can be 
stored for up to 7 days without affecting NMR results if they are kept below 4 ºC [6]. 
Samples can generally be successfully stored at -20 ºC for moderate periods (up to 1–2 
months), but some enzymes, such as plasma esterase, may still be active at this 
temperature. Thus, for long storage periods (years) cooling at -70 ºC to -80 ºC (or even 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
 
75 
 
lower) is required [9]. 
 The only specimens for which freezing may adversely affect NMR lipoprotein results 
are postprandial samples or hypertriglyceridemic samples with fasting triglyceride values 
greater than 300 mg/dL [64]. 
 Before the cryopreserved samples are measured, they should be thawed on ice, in a 
cold-water bath or at room temperature, not by heating. Correct homogenization of 
samples after thawing is mandatory. Exposing samples to multiple freeze–thaw cycles is 
more likely to alter NMR results, so this procedure should be avoided [6]. 
 
2.3.3. 1H NMR measurement of serum/plasma 
2.3.3.1. 1H NMR sample referencing 
 One major advantage of using NMR spectroscopy to study plasma and serum is that 
measurements can often be made with minimal sample preparation (usually with only the 
addition of 5–10% D2O for locking, and a suitable standard in the sample or in an inner 
capillary for referencing or quantification purposes). Moreover, a holistic analytical profile 
can be obtained on the whole biological sample. 
 The water-soluble compound 3-(trimethylsilyl) 2,2,3,3-tetradeutero-propionic acid 
(TSP) has lately been used as the preferred reference for calibrating and quantifying 
aqueous NMR samples. Unlike 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), which has 
signals arising at 3.1 ppm (a triplet), 1.9 ppm (a pentet), and 0.8 ppm (another triplet) all of 
which correspond to methylene protons of the alkylic chain, TSP does not add any other 
signals apart from the sharp methyl resonance at 0 ppm. However, for serum or plasma, 
TSP must not be used because it interacts with proteins [65]. In the work of Kriat et al. [66] 
although formate is present in serum in small amounts, this compound is added as the 
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internal standard for referencing (at 8.47 ppm) and for the quantification of some 
metabolites in plasma [67]. However, it probably alters the pH of the sample and it has not 
been used for lipoprotein measurement in any published report. 
 One general way to use TSP as a reference substance is to introduce a co-axial inner 
capillary tube with the compound dissolved in deuterated water. This system prevents the 
TSP from interacting with the blood proteins and prevents the sample from being modified 
by deuterated solvents. The double tube system can also be used for quantification after 
the nine methylsilyl protons have been fitted around 0 ppm. 
 Because of the stability of modern NMR spectrometers, ‘Digital ERETIC’ (Digital 
Electronic REference To access In vivo Concentrations, Bruker®) is an interesting method for 
quantification in serum. It does not involve any reference substance but adds a digital signal 
at a chosen frequency to the final corrected spectrum [68]. This signal is previously 
calibrated against a reference sample and corrected taking into account the variation of the 
90º pulse length, the number of scans and the receiver gain, always after the tuning and 
matching have been automatically adjusted [69]. 
 
2.3.3.2. The Nuclear Overhauser Effect Spectroscopy (NOESY)-presaturation 
sequence 
 In our experience, and in accordance with published protocols [57,2], the best way 
to make a quick, quantitative 1H NMR measurement of plasma is to use a one-dimensional 
Nuclear Overhauser Effect Spectroscopy (NOESY)-presaturation sequence that employs the 
first increment of a 2D NOESY pulse sequence with water irradiation during the relaxation 
delay (RD) and the mixing time (τm) (Figure 2). This has the form (RD–90º–τ1–90º–τm–90º 
AQ) and in standard experiments the τm (mixing time) is around 100–150 ms, although this 
parameter is not critical. The 90º pulse length is calibrated for each sample [70]. In a 600 
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MHz Avance III spectrometer equipped with a 5 mm CPTCI cryoprobe (Bruker®), for 
example, it varies from 9 μs to 13 μs depending on whether the blood sample is plasma or 
serum. The spectral width is set to 30 ppm to facilitate phasing and baseline processing in 
an automated way, and 64–128 transients are collected into 64-128 k data points for each 
1H spectrum. 
 It should be pointed out that in spectrometers in a thermostatted room the 
application of automatic routines in all the steps of acquisition (sample temperature 
equilibration, tuning, matching, shimming, 90º pulse calibration, fixed receiver gain and 
number of scans) yields an analytical variation of less than 1% (with the digital ERETIC® 
signal) in blood plasma and serum samples [68], far less than is normally encountered in 
biological processes. 
 
2.3.3.3. NMR editing techniques 
 The single pulse spectrum of human blood plasma is very complex. The highly 
overlapped resonances from metabolites, proteins, lipids and lipoproteins in the narrow 
chemical shift range of 1–13 ppm make it very difficult to successfully identify components 
even at a high magnetic field 1H observation [1]. Therefore, throughout these studies, 
different pulse sequences were used so that results would be more accurate and reliable. 
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Figure 2. Noesy-presat 1D pulse sequence with water presaturation during recycling delay 
and mixing time. 
 
 
Figure 3. Complete 1H NMR profiling of serum which includes: a) A nuclear Overhauser 
Effect SpectroscopY (NOESY)-presaturation sequence (RD*-90–τ1–90–τm*–90 ACQ) to 
acquire a quantitative serum spectra suppressing the water peak, b) A CPMG sequence 
(spin-spin T2 relaxation filter; RD–90–[τ2–180–τ2]n–ACQ) to acquire low molecular weight 
metabolites and c) A diffusion-edited pulse sequence with bipolar gradients and the 
Longitudinal Eddy-current Delay (LED) (RD-90-GE-180-(-GE)-90-Gs-Δ-90-GD-180-(-GD)-
90-Gs-τled-90 ACQ). Legend: * Presaturation of water signal, RD Recycling Delay, 90 or 180 
radiofrequency (rf) pulse, τ1  interpulse delay, τm mixing time, τ2 half spin-echo time, GE half bipolar encoding 
gradient, Δ Diffusion time, GD half bipolar decoding gradient, Gs spoil gradient, τled longitudinal eddy-current 
delay time, ACQ acquisition. 
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 A 1D NMR profiling of a sample of serum [71] usually includes a set of 1H NMR 
spectra with a standard 1D spectrum (such as 1D-NOESY presaturation or WET pulse), a 
transversal relaxation (T2) weighted filtration sequence (such as the Carr–Purcell–
Meiboom–Gill spin-echo pulse [72,73], which removes the lipoprotein background), and a 
diffusion-edited spectrum that removes signals from low molecular weight molecules (see 
Section 2.3.4). Figure 3 shows that the application of these three NMR pulses gives three 
different spectra from a single sample of serum. 
 A wide variety of useful spectroscopic techniques can be used to edit the NMR-
detectable metabolite information in body fluids. For example, a combination of T2 editing 
and diffusion in a single experiment (DIRE) has been used by Lindon et al. as a proof of 
concept with human plasma [74]. Their experiment allowed a variable attenuation of low 
and high molecular components of plasma but has not been generally applied in a clinical 
or metabolic study. Most NMR pulses and editing techniques are based on taking proper 
account of NMR relaxation times (T1, spin-lattice or longitudinal relaxation and T2, spin–spin 
or transversal relaxation) so that they can be used to efficiently reduce the dominant 
protein background in blood plasma and serum samples [75]. They enable mobile low 
molecular weight metabolites to be detected and quantified [76], but signals from 
lipoproteins are practically removed so they do not fall within the scope of this review. On 
the other hand, a diffusion-edited NMR spectrum enhances the NMR signal of lipoproteins 
and removes the signal of small metabolites. Thus, the composition and structure of the 
constituent lipids of lipoproteins can be assigned and analyzed (Figure 4). 
 
2.3.3.4. 1H NMR in the analysis of lipoproteins 
 In the sections above, it has been clearly stated that different 1H one-dimensional 
edited spectra can provide spectroscopic data from the different components of interest of 
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a biofluid (and in general any mixture) with no previous physical or chemical separation 
[77]. In addition NMR provides invaluable information for the early diagnosis and 
assessment of health [78,79]. In general, except for T2 edited experiments, such as the 
CPMG sequence, the 1H NMR spectrum of serum strongly reflects the lipoprotein subclass 
profile of the sample. 
 
 
 
Figure 4. (A) Moieties for the principal lipids found in lipoproteins and (B) Correspondence 
between moieties and their NMR spectra signals. 
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 The most important reason for using NMR in the analysis of lipoproteins is to avoid 
their tedious physical isolation from plasma. This approach also enables direct 
measurements to be made with little sample preparation or handling. Another important 
capability of NMR is that it can directly measure the number of lipoprotein particles, a new 
CVD risk factor (see Section 2.2.2). This is why NMR has been widely used for lipoprotein 
profile analysis (see the discussion in Section 2.2.3.1). This is possible because the three 
terminal methyl moieties of triglycerides and the esterified cholesterol of lipoproteins give 
the same amount of 1H signal. Moreover, the resonance frequency is related to 
composition and size [80] of the lipoprotein which carries these lipid structures, with larger 
and smaller lipoproteins resonating at lower and higher frequencies, respectively (Figure 7). 
 The concept of using proton NMR spectroscopy to measure plasma lipoprotein 
concentrations efficiently and without reagents was introduced in the early 1990s by 
researchers from North Carolina State University [64] (see Section 2.4). Since then, 1H NMR 
spectroscopy has received wide clinical interest as a method for quantifying lipoprotein 
subclasses. This methodology was first developed in practice independently by the groups 
of Otvos et al. [81] and Ala-Korpela et al. [82,83]. Thanks to their work the number of 
clinical studies to which it has been applied over the years has increased significantly [6,79]. 
 Ala-Korpela and co-workers developed a method for the absolute quantitation of 
human lipoproteins based on 1H NMR spectroscopy and sophisticated line-shape fitting 
techniques [82]. In their earlier studies, they took NMR measurements of 66 blood EDTA-
plasma samples and 20 VLDL, IDL, LDL and HDL isolated subfractions at the stabilized 
temperature of 37 ºC using a 400 MHz spectrometer. The water signal was suppressed by a 
standard binomial 1–1 pulse sequence. A double tube system (5 mm O.D. capillary filled 
with D2O solution of TSP inside a 10 mm O.D. NMR tube) was used for purposes of 
referencing and quantification. 
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 In more recent works by the same group [84,85], NMR measurements were 
performed with a single pulse in a more sensitive 600 MHz spectrometer using a 5 mm 
double tube system (2 mm O.D. D2O capillary inside a 5 mm O.D. NMR tube) without any 
water suppression. 
 Although some lipoprotein NMR measurements have been performed below 
physiological temperature (at 298 K [26] or 303 K [86]), at these temperatures the core 
cholesterol esters of lipoprotein particles considerably diminish their NMR visibility [64]. 
Therefore, in most NMR measurements the temperature is set at physiological conditions 
[2], and even in the case of the NMR LipoProfile test® [5], plasma samples are heated to 
318 K to facilitate the deconvolution of highly overlapped lipoprotein subclass signals [6,9]. 
The resonance frequency of NMR signals of lipoprotein fractions depends on their size and 
composition, but the neighboring NMR signals of each class differ only slightly in chemical 
shift, thus limiting the reproducibility and accuracy of lipoprotein quantification in blood 
plasma by NMR line-shape fitting approaches. Therefore, to overcome the problem of 
extensive lipoprotein signal overlap in the analysis of 1H NMR spectra of plasma, another 
physical independent measurement, such as diffusivity, could be desirable in addition of 1H 
spectra. 
 There is a considerable amount of literature on NMR molecular diffusion 
measurements by pulse field gradient stimulated echo (PGSTE) [87], ranging from basic 
theory [88] to practical aspects [89,90] and applications [91]. However, the aim of this 
review is to describe lipoprotein analysis by NMR so only diffusion measurements on 
lipoproteins will be discussed. 
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2.3.4. 1H NMR diffusion spectroscopy 
2.3.4.1. Basis of NMR diffusion measurement 
 Since the initial work by Stejskal and Tanner [92], the pulse field gradient spin-echo 
(PFGSE) NMR measurement has become the most commonly used method for studying 
molecular motion properties such as diffusion. The basic sequence consists of one 90º pulse 
to generate transverse magnetization and a 180º pulse flanked by two gradient pulses to 
generate the spin-echo (Figure 5). The measurement of diffusion by NMR and its processing 
steps have led to the so-called diffusion ordered spectroscopy (DOSY) [91], an interesting 
and powerful technique for extracting the translational diffusion coefficients of the 
components of a mixture. 
 After the initial 90º pulse, the generated transverse magnetization starts to 
dephase due to chemical shift, and the evolution of hetero- and homonuclear coupling. The 
first pulsed linear field gradient adds a strong dephasing of the generated magnetization 
with a phase angle proportional to the length (δ) and the amplitude (G) of the gradient. This 
process is called gradient encoding or defocusing. Then, the intermediate 180º pulse is able 
to refocus the magnetization generating the echo. However, due to the gradient previously 
applied, the phase varies linearly along the Z-axis and only the spins within a narrow slice of 
the sample have phase angle coherence (i.e. the same phase angle). At this point the spins 
are dephased and no NMR signal can be detected from the whole sample. The second 
gradient pulse reverses the respective phase variation of the first gradient 
(decoding/refocusing) and now the spin-echo can be recorded in the usual way (Figure 5). 
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Figure 5. Basic pulse field gradient spin echo and evolution of magnetization [92]. 
 Thus, theoretically, the encoding and decoding gradients have no effect on the 
spin-echo. However, while they are being applied some of the spins move out of their slice 
as a result of Brownian motion (self-diffusion). These spins are not refocused by the second 
gradient and this leads to an attenuation of the echo amplitude, which is proportional to 
the average displacement of the molecules. Moreover, the transversal (T2) NMR relaxation 
also reduces the echo amplitude. Thus, the attenuation of the echo signal intensity (I) is 
given by: 
     
   
   
   
     
                (1) 
where τ = period that the magnetization is under the effect of the transversal relaxation 
process (component of the XY plane); T2 -= characteristic transversal relaxation time; I0 = 
initial intensity of the NMR signal; γ = gyromagnetic constant of the nucleus (commonly 1H); 
g = intensity of applied gradient (dependent on its duration, shape and strength (G)); D = 
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diffusion coefficient (related to the hydrodynamic radius of the molecule and the viscosity 
and temperature of the sample); and Δ = diffusion time, the period from encoding to 
decoding echo. 
 So that the longitudinal and transversal relaxation contributions remain constant, 
the usual way to conduct the diffusion experiment is to set the diffusion time (Δ) and vary 
the magnetic field gradient (g), usually changing the current intensity in the gradient coil. 
 If the diffusion time is constant, the relaxation terms become constant and can be 
incorporated into the initial intensity (I0), thus leading to a reduced expression: 
    
    
                 (2) 
where I'0 is the initial intensity I'0 = I0exp(-2τ/T2) reduced by relaxation. Therefore, applying 
different gradient intensities, the diffusion coefficient (D) can be calculated. 
 In order to illustrate the basis of a diffusion NMR experiment, we choose a VLDL 
fraction, rather than a serum/plasma sample, because the lipoprotein size dispersion is 
much lower. Figure 6a shows a set of attenuated spectra of a VLDL fraction and Figure 6b 
shows the calculation of the diffusion coefficient from them, using Equation 2. 
 Once the diffusion coefficient has been calculated, the Stokes–Einstein equation 
can be applied to obtain the hydrodynamic radius (rH) [91]: 
  
  
     
             (3) 
where k is the Boltzmann constant, T is the absolute temperature, g is the system viscosity 
and rH is the hydrodynamic radius. This equation assumes equilibrium of the system, infinite 
dilution conditions, a continuum solvent and spherical molecules [93]. 
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Figure 6. (A) Attenuated spectra of a VLDL fraction with increasing field strength, G. (B), 
extraction of the diffusion coefficient, fitting Equation 2.  
 
 This methodology makes it possible to use the additional dimension of diffusion 
and is called diffusion-ordered spectroscopy (DOSY) [77]. As an application, Figure 7 
illustrates a 1H schematic DOSY peak map from the methyl peak of six lipoprotein fractions 
isolated by sequential ultracentrifugation [56]. The x-axis shows the 1H spectra fractions, 
while the second dimension plots the D associated to each fraction, calculated according to 
Equation 2. It can be seen that larger fractions have higher chemical shifts. It is interesting 
to note that the resolution provided by the D dimension will play an important role in the 
analysis of lipoproteins, because it improves the separation between them. Once the Ds 
have been obtained, the application of Equation 3 will determine their associated radii. 
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Figure 7. Schematic DOSY peak map of VLDL, IDL, LDL1, LDL2, HDL2 and HDL3, showing that 
the resonance of the fractions depends on their size (the larger the lipoproteins, the higher 
the shifts in 1H-NMR spectra). The second dimension plots the diffusion coefficient D (10-7 
cm2s-1) or size (Å) [68], after Equation 3 has been applied. Spectra were acquired at 310 K 
and viscosity was measured for each sample. 
 
2.3.4.2. 1H NMR diffusion measurements 
 Lipoproteins are measured with 1D NMR methods mainly using line-shape fitting 
methods or multivariate approaches (see Section 2.4) across such specific areas of the 
spectra as the methyl and methylene peaks. However, because the signals of lipoprotein 
fractions overlap, the inherent accuracy of the method is limited, especially in medium-
sized particles such as IDL or LDL [94]. Therefore, by giving additional information on 
lipoprotein sizes DOSY and other diffusion techniques open up a new dimension in 
lipoprotein analysis. Moreover, if the gradient ranges are changed to higher values, the 
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interfering signals from smaller molecular weight metabolites in serum can be removed 
from NMR spectra with most of the signal intensity from the lipoprotein molecules being 
retained. 
 Since the work by Liu et al. [74], it has been suggested that diffusion-edited 1H NMR 
spectroscopy could be used to improve the experimental signal of lipoproteins and hence 
the resolution of the lipoprotein subclass quantification. 
 First of all, to avoid errors in the calculation of the diffusion coefficient, it is 
important that the gradient strength be properly calibrated. The most common calibration 
procedure is to use a pulse field gradient (PFG) experiment on a substance with a known 
diffusion coefficient, such as water or ethanol, at a temperature of interest [95]. 
Subsequently, other experimental settings can be applied to improve the acquired data 
[87]. 
2.3.4.2.1. Spin echo (PFGSE) replaced by stimulated echo (PFGSTE). During pulse-field 
gradient spin-echo (PFGSE), the transversal (T2) NMR relaxation reduces the echo 
amplitude. Thus, when measuring the diffusion of the large, slow-moving lipoproteins, the 
diffusion time needed to observe the attenuation is too long and the transversal relaxation 
(T2) can completely reduce the NMR signal. The gradient stimulated echo (PFGSTE) 
sequence proposed by Tanner [96] (Figure 8) is a simple improvement that is useful for 
studying compounds such as macromolecules and lipoproteins, in which T1 is much larger 
than T2. This sequence splits the 180º pulse of the spin echo into two 90º pulses: the first 
stores half of the transverse magnetization along the z-axis and, therefore, only the slower 
longitudinal relaxation (T1) is the effective relaxation path during diffusion time (D). The 
second 90º pulse restores the transverse magnetization just before the decoding gradient. 
This pulse significantly reduces the attenuation of the NMR signal in molecules with short 
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transverse relaxation (T2) (initial intensity is   
  
 
 
   
   
     instead of   
     
   
   
   
  , see 
Equations 1 and 2) and yields a better signal/noise ratio although the amplitude of the 
stimulated echo is half that of the corresponding spin echo. In conclusion, the stimulated 
echo is the pulse sequence of choice for lipoproteins that have a longer T1 than T2 values 
and slow diffusion. 
 
Figure 8. Pulse field gradient stimulated echo with z-storage that avoids T2 relaxation [96]. 
 
2.3.4.2.2. Eddy currents. During the application of a PFG experiment, the magnetic field is 
switched on and off very quickly, and the changes in the magnetic flux induce current field 
transients in the gradient coils. These currents are known as eddy currents and can 
introduce baseline, line-shape, phase and amplitude distortions and loss of coherence in 
the acquired spectra, especially when large magnetic field gradients are suddenly switched 
on and off. These distortions invalidate the information obtained from a 1D NMR spectrum 
(Figure 9). 
 
Figure 9. TSP signal of diffusion spectra with PFG affected by eddy currents (lower spectra, 
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acquired with rectangular pulse, no longitudinal eddy current delay (LED)) and without the 
effect of eddy currents (upper spectra, acquired with shine-shaped pulse and LED). 
 
 The potential error due to eddy currents is larger for unshielded probes. 
Fortunately, since the early 1990s, probes equipped with actively shielded magnetic field 
gradients have become widespread [97]. There are also three additional experimental 
strategies, which can be applied simultaneously to overcome eddy current distortion 
problems: 
 (a) A shaped gradient pulse, with slower rise and fall times, can be effective at 
reducing eddy currents [98]. Moreover, shaped gradients are more reproducible and less 
likely to produce vibrations in the sample or probe. In this way, PFGSTE experiments are 
usually performed using trapezoidal or sine-shaped pulse gradients. 
 (b) Another approach is to increase the delay time from the end of the gradient 
pulse to the start of the acquisition so that the spin-echo is recorded in a negligible eddy 
current field. This strategy is known as the ‘‘longitudinal eddy current delay’’ (LED) pulse 
sequence [99] (Figure 10a). 
 (c) One other possibility is to use preparatory gradient pulses with different 
polarities. The most common preparatory gradients are two pairs of magnetic field 
gradients with inverse polarities separated by 180º RF pulses [100]. The replacement of the 
single PFG by a pair of matched gradient pulses with inverted polarities separated by a 180º 
RF pulse has a self-compensating effect on eddy currents and a cumulative dephasing effect 
on sample magnetization encoding/decoding. This type of alternating-gradient sequence is 
called bipolar pulse pairs (BPP). It considerably reduces eddy currents and improves the 
performance of the diffusion experiment (Figure 10b) Thus, a single PFG of say, 2 ms, could 
be replaced with a BPP of 1 ms each and reduce eddy currents almost completely. 
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Figure 10. Improvements introduced to minimize eddy currents: a) longitudinal eddy-
current delay (LED) and b) bipolar-pair pulses (BPP). All gradients are represented as a 
shine-shaped PFG. 
 
2.3.4.2.3. 1D 1H NMR diffusion of serum/plasma samples. For quick acquisition and easy 
handling of the lipoprotein profile, 1D diffusion-edited 1H spectra of lipoproteins can be 
efficiently measured using a diffusion pulse sequence with bipolar gradients and the 
longitudinal eddy-current delay (LED) scheme [100] with two spoil gradients to destroy 
unwanted coherences (Figure 11). This pulse sequence (see Figure 4 for the legend) in 
equipment with a standard Z-axis gradient amplifier unit (with a maximum strength of 50 
gauss/cm) it is typically performed with a sine-shaped bipolar pulse of 2–3 ms in total (1–
1.5 ms each gradient G1) at 95% of gradient strength (which is around 33 gauss/cm for a 
sine shaped gradient). The diffusion delay (Δ), during which the molecules diffuse and their 
signal attenuates, is set from 100 to 120 ms for optimum NMR signal free of low molecular 
weight metabolites such as lactate, glucose and alanine. The 90º pulse–G2–90º pulse block, 
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during diffusion time and LED delays, stores the magnetization on the Z axis to prevent 
losses through transverse (T2) relaxation, which is usually faster than longitudinal relaxation 
(T1). No water suppression is needed in serum or plasma because the water signal is 
strongly attenuated by diffusion. This sequence has a longitudinal eddy-current delay of 5 
ms (tled) to allow these currents to decay before acquisition (ACQ). Thus, 1D 
1H NMR 
diffusion-edited acquisition has also been discussed for metabolic profiling [63] and 
lipoprotein quantification [86] but it has not been put to more general use in lipoprotein 
studies. 
 
Figure 11. Diffusion pulse sequence with bipolar gradients and the longitudinal eddy-
current delay for 1D diffusion measurements on serum/plasma. 
 
2.3.4.3. 2D 1H NMR diffusion measurements 
 As has been mentioned above, the acquisition of a set of diffusion-edited NMR 
spectra with an increasing strength in gradient enables the translational diffusion 
coefficient (D) of a certain molecule to be calculated. This parameter is a direct measure of 
self-diffusion and is related to its size in a solution. This approach has been reported to 
enhance information recovery from plasma NMR spectra [101]. 
2.3.4.3.1. Convection flows. Another problem in gradient experiments is the presence of 
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convection flows. This source of signal attenuation is easily confused with attenuation from 
true diffusion and thus distorts the diffusion coefficient (D) calculation. The convection is 
due to temperature gradients in the sample tube and can be partially reduced by improving 
temperature control. The convection attenuation makes the measured diffusion coefficient 
increase with diffusion time (Δ), and interferes with the exponential decays of intensities in 
the PFG of the experiment. This unwanted flow increases the distance traveled by the 
molecule and the attenuation shows a non-linear behavior. 
 Various experimental strategies have been recommended to avoid convection 
effects: increasing the flow of the gas heater to reduce temperature gradients [87], 
reducing sample height or using a smaller sample tube (see, for example, Shigemi [102], 
inner capillary tubes [103]) or spinning the sample to break convection flows [104]. 
 In addition, the regular and ordered nature of convection flows means that a 
modified pulse sequence can be used to compensate for their effects. This compensation is 
based on double stimulated echo (DSTE) [105] the pulse sequence of which splits the 
diffusion time (Δ) into two gradient encoding–decoding periods that refocus all constant-
velocity terms (flow and convection) (Figure 12). 
 Although the shortest and simplest PFG sequences should provide better sensitivity 
and signal-to-noise ratio, in the case of the lipoprotein diffusion measurement, the 
heterogeneity of the serum sample can cause non-uniform temperature and magnetic 
gradients. Thus, the use of a more complex DSTE pulse is recommended at the expense of 
its lower sensitivity. Also, a longitudinal eddycurrent delay (LED) and alternated bipolar pair 
pulses (BPP) should be used to avoid the deleterious effects of eddy currents (Figure 13). 
 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
94 
 
 
Figure 12. Double Stimulated Echo pulse sequence to compensate for convection in the 
sample. 
 
 
Figure 13. 2D Double-Stimulated echo experiment with bipolar gradients and the 
longitudinal eddy-current delay for diffusion measurements on serum/plasma. 
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2.3.4.3.2. 2D 1H NMR diffusion measurements of serum/plasma samples. As a rule of 
thumb, 2D diffusion-edited 1H NMR measurements can be performed with a coaxial 
double-tube system that reduces convection. The inner capillary contains a deuterated 
water solution of 3-(trimethylsilyl) 2,2,3,3-tetradeutero-propionic acid (TSP) that gives lock 
and reference signal (TSP, δ=0 ppm) without disturbing or interacting with the outer serum. 
The diffusion spectrum is recorded at 310 K (the physiological temperature) to obtain the 
full signal from melted lipids in lipoproteins and the heating air flow rate is set to the 
maximum before vibration occurs in the sample (typically 670–800 l/h). However some 
effects from convection currents still remain and can be observed if a single stimulated 
echo pulse is used. Figure 14 shows that there is a systematic error due to convection 
currents when we compare the D estimated using DSTE or STE from the same samples. 
Therefore, a double-stimulated echo pulse sequence is recommended to efficiently 
compensate for this effect. 
 
Figure 14. Diffusion coefficient calculated over the same serum sample with single 
stimulated echo (STE) and double stimulated echo (DSTE) pulse sequences. The grey line 
represents the ideal situation while the red line expresses the actual regression, which 
shows that STE pulses are affected by some convection flows. Therefore, it is recommended 
that DSTE be used for flow compensation. 
 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
96 
 
 In the spectrometer setup, a diffusion time (Δ) of 100–200 ms and a gradient pulse 
duration (δ) of 8–12 ms have to be applied to attenuate the lipoprotein signals to a 
reasonable extent with a good signal-to-noise ratio in 32–64 scans for each gradient. With 
this long gradient pulse it is important to minimize eddy currents. Thus, sine-shaped 
gradients are used, the length of the gradient pulse is divided into a bipolar pair pulse, each 
one of which is 4–6 ms, and a LED scheme of 5 ms is injected before acquisition. 
Additionally, three spoil gradients are used during the z-storage periods of the two 
stimulated echoes and the LED to shorten the phase cycle and remove unwanted 
magnetization. 
 Once the gradient pulse (δ) and diffusion time (Δ) have been optimized and fixed, 
the gradient pulse strength can be gradually increased into the linear range of the gradient 
amplifier to generate spectra in the diffusion dimension (typically, in equipment with a 
standard Z-axis gradient amplifier unit of about 55 G/cm, linearity ranges from 5% to 95%). 
Depending on the resolution needed in the diffusion dimension, 20–50 diffusion spectra 
can be measured in an exponential, squared or linear distribution of gradient values. 
 The spectra in Figure 15 were obtained from serum with the pulse sequence 
described. This type of dataset includes a huge amount of highly overlapped chemical 
information that configures a hilly and continuous mountain-shaped signal without baseline 
in the direct dimension F2 and, in the indirect dimension F1, the attenuation profiles of 
which are used to measure diffusion coefficients and calculate molecular sizes. 
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Figure 15. Detail of NMR signal attenuation of plasma lipoproteins in a 2D diffusion 
experiment. 
 
 DOSY experiments require spectra to be of high quality if they are to be processed; 
even small deviations from expected behaviour in NMR signals can cause significant 
distortions in the diffusion domain. In addition, depending on the serum or plasma sample, 
acquisition quality, signal-to-noise ratio and experimental conditions, different processing 
methods can be used [106]. Specific methods for analyzing plasma and serum lipoproteins 
by DOSY acquisitions have even been developed: for example, mathematical deconvolution 
and direct calculation of diffusion coefficient and average size (D, r) [26,103] and 
multivariate methods [86,107]. These methods for extracting useful data from the NMR 
measurement of serum, plasma or lipoprotein fractions and their usefulness for studying 
diabetes and metabolic diseases are discussed in detail in the sections below. 
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2.4. Lipoprotein analysis using NMR data 
2.4.1. Curve fitting methods for 1H NMR serum/plasma spectra 
 Since the beginning of the 1990s [108], two groups have taken huge strides in the 
analysis of NMR lipoprotein profiles. The first group, led by Otvos, created and perfected 
the LipoProfile® test, which was made commercially available in 1997 by Liposcience Inc. 
And the second group, led by Ala-Korpela, has been making in-depth studies of the 
possibilities of 1H NMR in the analysis of lipoproteins and the use of NMR spectra in the 
assessment of risk factors in population studies. In this section we shall also discuss the 
findings of Le Moyec, whose group has assessed the effects of some lipid lowering drugs by 
NMR spectroscopy. 
 Mathematical curve fitting methods go beyond the scope of this study, but a 
description can be found elsewhere [109]. For purposes of illustration, Figure 16 shows a 
methyl peak spectra fitted with nine Lorentzian functions. 
 
Figure 16. Illustration of a methyl envelope fitted with nine Lorentzian functions. 
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2.4.1.1. The method of Otvos 
 The first studies reported by Otvos appeared in the early 1990s [110,111]. They 
described a curve fitting method for quantifying the particle concentration and mean 
particle size of different lipoprotein subclasses. First, the main lipoprotein fractions 
(chylomicrons, VLDL, IDL, LDL and HDL) obtained by sequential ultracentrifugation 
[112,113] were used to obtain highly purified lipoprotein subfractions with a range of 
particle diameters that were as homogeneous as possible. Agarose gel filtration 
chromatography was used in combination with ultracentrifugation. The lipid content 
(cholesterol and triglycerides) of lipoprotein subfractions was measured by standard 
biochemistry methods and the particle size for the purified VLDL and LDL subclasses were 
assessed by Transmission Electron Microscopy (TEM). Additionally, non-denaturing gradient 
gel electrophoresis [114] was used to measure the particle sizes of the LDL [115,116] and 
HDL [117–119] subfractions. Then, 1H NMR spectra were acquired of all plasma and isolated 
lipoprotein samples on a 400 MHz NMR spectrometer equipped with a flow probe and a 
sample volume of 120 μl. All NMR measurements for lipoprotein analyses were performed 
at 47 ºC, a temperature at which the molecules in the core of the particles have an NMR-
isotropic behavior. 
 The basic principle of the method is the specific magnetic property of lipoproteins: 
i.e. that lipids in smaller lipoproteins broadcast signals at lower frequencies than lipids in 
larger ones resulting from the different compositions of the lipoproteins [80,120]. Particle 
concentrations are obtained by fitting the methyl envelope arising at around 0.8 ppm of the 
1H NMR spectra of plasma samples. The adjusted curve is calculated using a linear 
combination of 1H NMR spectra from individual lipoprotein subfractions taken from a 
reference library [6,120] in a linear least squares process [39]. Once the amplitude of each 
lipoprotein subfraction reference has been calculated, the particle concentration is 
determined (in nmol/L for VLDL and LDL, and μmol/L for HDL), using the appropriate 
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conversion factor, calculated from the lipid concentration of the core lipoprotein fraction 
and the lipoprotein’s radii [121]. This spectral library of lipoprotein subfractions, measured 
by 1H NMR, is representative of the different subfractions that can be found in human 
plasma samples of patients with either normolipidemia or dyslipidemia. It is worth 
mentioning that the area of the methyl envelope is proportional to the number of protons 
(3) for every methyl termination of the core lipids (i.e. 3 for TG and CE). This means that the 
amplitude is insensitive to compositional variability in subclasses (cholesterol ester–
triglyceride exchange mediated by cholesterol ester transport protein, CETP) [122]. 
 The mean particle sizes estimated by LipoProfile® have been compared with those 
measured by TEM (VLDL and LDL fractions) [123] and GGE (LDL and HDL fractions) [115–
119]. Agreement with GGE was excellent, although some offset differences in mass 
estimation were found between LDL sizes measured by NMR and TEM. 
 Nowadays, the LipoProfile® test is the only commercially available method that can 
quickly and accurately give information about the size and particle number of several 
lipoprotein fractions in plasma (or serum) samples [5]. It is also one of the few methods 
used in the study of lipoprotein fraction size, with the advantage that a prior separation 
process is not needed [49]. The number of fractions obtained in the LipoProfile test has 
finally been fixed at 10 (see Table 2) [6,120]. The NMR LipoProfile® test [124] has been 
available in United States hospitals since 1997 for clinical analysis. Since then, millions of 
analyses have been performed in the LipoScience laboratory in North Carolina, and more 
than 250 clinical studies have been completed. 
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Table 2. Research papers on lipoprotein characterization based on 1H-NMR spectroscopy. 
Author [Ref.] Sample set NMR Settings Feature extraction method Calculated parameters 
Otvos et al. [6] Many clinical trials 
(Comercial name: 
LipoProfile® test) 
90º One-pulse presaturation 
sequence 250 MHz-400MHz 
Temp.= 47 ºC 
Proprietary least squares 
deconvolution process on 
methyl peak 
Particle Number and size of: VLDLLarge, 
VLDLMedium, VLDLSmall, IDL, LDLLarge, LDLMedium, 
LDLSmall,   HLDLarge,  HDLMedium,  HDLSmall  
Ala-Korpela et al. [2,164] Many serum sample 
sets 
1D noesy presat 
500 MHz Temp.= 37 ºC 
Combination of different 
regression and statistical 
methods 
Concentration of total Lipids, C, PL and TG, Apo 
A-I and ApoB, particle concentration and size in 
up to 14 subfractions (CM, 5 VLDL, 1 IDL, 3 LDL 
and 4 HDL) 
Le Moyec et al. [165] 60 serum samples  90º One-pulse presaturation 
sequence 500 MHz T = 40 ºC 
Lineshape fitting of methyl 
peak 
PCA+HCA with the area of 11 deconvoluted 
Lorentzian functions  
Bathen et al. [133] 52 plasma samples 90º One pulse sequence 600 MHz 
Temp.= 44 º C 
PCA and PLS (for calibration 
models ) from the methyl and 
methylene peaks 
Plasma-TG, Plasma-CH,  VLDL-TG, VLDL-C,  IDL-
TG, IDL-C,  LDL-TG, LDL-C,  HDL TG,  HDL-C, 
Plasma- ApoA1, HDL-ApoA1, Plasma-ApoB, LDL 
ApoB 
Petersen et al. [4] 103 plasma samples 1D longitudinal eddy-current 
delay (LED) gradient 600 MHz 
Temp.=30 ºC 
PLS regression models Total-C, Plasma TG, VLDL-C, VLDL-TG, IDL-C, IDL-
TG, LDL-C,  IDL-TG, LDL1-C, LDL1-TG, LDL2-C, 
LDL2-TG, LDL3-C, LDL3-TG, HDL-C- HDL-TG, 
HDL1-C, HDL1-TG, HDL2-C, HDL2-TG, HDL3-C, 
HDL3-TG 
Kristensen et al. [134] 68 rat serum 
samples 
Composite 90º pulse sequence 
with presaturation 400 MHz 
Temp.=38 ºC 
PLS regression models Total C, VLDL-C, IDL-C, LDL-C, HDL-C 
Serrai et al. [135] 9 blood samples 90º pulse and presaturation 
500MHz Temp.=25 ºC 
Wavelet transform from FID’s Lipoprotein visible lipid quantifications and an 
estimation of non-NMR visible protein and free 
cholesterol in VLDL, IDL+LDL and HDL 
Savorani et al. [136] 18 serum samples Use ofzgcppr Bruker pulse 
sequence NMR. Temp. =  37°C on 
a 500 MHz spectrometer 
PLS regression in methylene 
peak 
TG content of CM 
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2.4.1.2. The method of Ala-Korpela 
 During the first half of the 1990s, Ala-Korpela set up a lineshape fitting model for 
deconvoluting the overlapping information in the methyl and methylene peaks of 1H NMR 
spectra of plasma samples [108,125,126], measured at the physiological temperature of 37 
ºC. In these studies, VLDL, LDL and HDL fractions were modeled by adding three Lorentzian 
components for VLDL and LDL fractions and one for HDL. The algorithm used for lineshape 
fitting analysis was FITPLAC [108,125,126], developed by Ala-Korpela himself, and the 
parameters that are mathematically optimized for every Lorentzian are half-line width, 
resonance frequency and intensity. The model also includes background resonances related 
to residual water, and albumin-bound immobile fatty acids or proteins (see Ref. [125] for 
more details). The areas of the functions are scaled using the area of an external reference 
signal [127] in a concentric coaxial tube. The highly overlapping nature of the fraction 
spectra means that, depending on the initial parameters chosen for lineshape fitting, 
numerous solutions are mathematically possible. To overcome this problem, FITPLAC was 
run many times on every spectrum, with the initial parameters being randomly chosen 
between reasonable (wide) limits. The solution selected was the one that gave the lowest 
RMS error and was physically meaningful. 
 One of his reports [125] described the use of plasma from a set of 15 volunteers 
with highly different lipid profiles and 51 plasma samples from 43 individuals (double-blind 
test). The fractions of the 15 volunteers and 5 of the 43 individuals in the double-blind test 
were sequentially ultracentrifuged to obtain their VLDL, IDL, LDL and HDL fractions. The 
lineshape fitting analysis of the methyl peak using the FITPLAC algorithm confirmed that the 
parameters of the Lorentzians for every fraction were very similar for all the individuals, so 
the half-linewidth and position of every Lorentzian was set at a constant value. This 
indicated that the main variable in the 1H NMR spectra of the lipoprotein fractions of 
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different people is the total amount (i.e. the fraction concentration). All these restrictions 
also improved the mathematical uniqueness of the solutions. The linear correlation 
between the fraction areas found by NMR and the biochemistry of the VLDL, LDL and HDL 
fractions made it possible to estimate the concentration of triglycerides, phospholipids, 
total cholesterol, free cholesterol, esterified cholesterol, total proteins, and total masses. In 
particular, correlation coefficients were found to be high (e.g. 0.98, 0.88, and 0.93) in the 
VLDL triglycerides, LDL cholesterol, and HDL cholesterol, respectively, of plasma samples. 
On the other hand, it was not possible to include the IDL fraction in the lineshape fitting 
model, since it required new free adjusting parameters to be introduced in the model. 
Moreover its contribution to the spectra was determined to be much lower than the other 
fractions. 
 Several years later, Ala-Korpela demonstrated that the inherent accuracy of 
lipoprotein subclass quantification by NMR is subclass dependent [128]. In particular, the 
classes with maximum response at the higher or lower limits of the methyl peak (VLDL and 
HDL3, respectively) have an error that is ten times lower than LDL1, the least accurate. 
Errors were 0.5% and 5%, respectively. This is consistent with the increasing overlap of the 
spectra in the center of the methyl peak. 
 
2.4.1.3. The results of Le Moyec 
 Le Moyec et al. [129] analyzed the methyl region (between 0.64 and 1.08 ppm) of 
1H NMR serum, using 11 Lorentzian functions, 6 of which represented lipids. The approach 
they used allowed them to assess the cholesterol reduction in hypercholesterolemic 
patients (n = 60) who were taking simvastatin (n=30) or atorvastatin (n=30). The integral 
areas of the 6 Lorentzian functions were used as input variables in a Principal Component 
Analysis (PCA) coupled with a Hierarchical Cluster Analysis (HCA) algorithm. The results 
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revealed that the features used from the Lorentzians could be used to cluster the patients 
before and after each treatment, although some overlapping regions were evident. They 
concluded that there is a decrease in LDL cholesterol and an increase in HDL cholesterol, 
and they assigned some function(s) to each fraction, although they could not find any 
rigorous relationship between the six functions and the lipoprotein fractions. In their report 
they do not give details about the lineshape fitting method nor the mathematical 
uniqueness of the solutions. 
 
2.4.2. Statistical correlation methods for 1H NMR spectra plasma/serum 
measurements 
 In Section 2.4.2.1 we shall review all the lipoprotein characterization methods that 
use the 1H NMR intact serum spectra envelop of the lipids peaks (i.e. with no previous 
lineshape peak deconvolution) for statistical correlation with the biochemical data obtained 
by conventional biochemistry in the lipoprotein subfractions isolated from the serum of the 
same individuals. In Section 2.4.2.2 we shall discuss the clustering of the samples according 
to their health status. 
 
2.4.2.1. Predictive methods 
 In 1995 [130,131], Ala-Korpela’s group published the results of a study of 57 
subjects with a wide range of plasma lipoprotein lipid values, including abnormalities such 
as hyperlipidemia, hypercholesterolemia and hypertriglyceridemia. VLDL triglycerides, as 
well as LDL, IDL and HDL cholesterol concentrations were available from these subjects and 
Artificial Neural Networks (ANN) were used to quantify lipid concentrations from the NMR 
spectra. 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
 
105 
 
 A total of 50% of the subjects were used for training, and the rest for validation. 
The methyl and methylene portions of the spectra (as well as the TSP region considered for 
quantification) were used as the input signals for a neuronal network with 50 hidden 
neurons and 4 neurons in the output layer. These four neurons corresponded to the four 
biochemistry values to be quantified: VLDLTG, IDL-C, LDL-C and HDL-C. The correlations 
with the validation group for each lipid value were 0.99, 0.74, 0.87 and 0.84, respectively. In 
the same study a network designed for quantifying phospholipids and their performance 
was also reported. 
 Vehtari et al. have also demonstrated the usefulness of Bayesian methods in the 
quantification of serum lipids [85]. They used the Markov Chain Monte Carlo (MCMC) 
method in a Bayesian inference algorithm to build quantitative models for lipid subclasses 
based on their 1H NMR spectra. The model, was built and trained with a set of 75 1H NMR 
spectra of serum samples representing broad lipoprotein profiles and biochemistry values 
of the main fractions (VLDL-TG, IDL-TG, IDL-C, LDL-C and HDL-C), obtained by 
ultracentrifugation. The correlations (R-values) were very good for VLDL-TG (0.985), 
acceptable for IDL-C, LDL-C and HDL-C (0.787, 0.943 and 0.933 respectively), but only poor 
for IDL-TG. 
 In 2009, Ala-Korpela’s group set up a high throughput method for serum analysis 
[2,22,23], which included the analysis of lipoproteins. The method can quantify the total 
concentration of TG and C in serum, as well as VLDL-TG, IDL-C, LDL-C and HDL-C. They also 
reported that they were able to quantify total lipid content, and particle concentrations and 
size in 14 lipoprotein subclasses, distributed in chylomicrons, 5 VLDL, 1 IDL, 3 LDL and 4 
HDL. The lipoprotein size of these subclasses was calibrated with High Performance Liquid 
Chromatography [54], although no details about the calibration process were given (Table 
2). The concentrations of Apo A-I and ApoB are also available and have been calculated 
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from the Friedewald parameters [132]. 
 This method has been applied successfully in genome-wide association studies – 
showing a high correlation between the variant rs7575840 and the ApoB-containing 
lipoproteins [24] – and in epidemiological experiments, showing associations between 
metabolic phenotypes and subclinical atherosclerosis [23]. 
 Bathen et al. [133] used PCA, partial least squares regression (PLS) predictors and 
ANN to quantify the TG and C of the main fractions, and the Apo A and Apo B 
apolipoproteins. In a study of 52 individuals (controls and subjects) with cancer and other 
diseases, the lipid and apolipoprotein values predicted when PLS models were constructed 
with the methyl and methylene peaks of a 1H NMR spectra correlated very well with the 
data obtained by standard clinical bioanalysis of the main fractions obtained by ultra-
centrifugation; the correlation coefficient for total plasma triglyceride was 0.99, for total 
plasma cholesterol 0.98, for LDL cholesterol 0.97, and for HDL cholesterol 0.88. Of the 52 
subjects, 44 were used for model calibration and the rest for validation. ANN-based 
strategies, involving either general regression or polynomial neural networks in 
combination with genetic adaptive components for parameter optimization, have been 
very effective when used for lipid and apolipoprotein quantification. 
 Petersen et al. [4] used a similar approach to Bathen et al. [133] and applied a PLS 
regression model to diffusion-edited NMR spectra in a sample set of 103 individuals. The 
model was built by applying one-dimensional longitudinal eddy current bipolar pulses and 
biochemistry data obtained from 10 lipoprotein fractions (VLDL, IDL, total LDL, LDL-1, LDL-2, 
LDL-3, total HDL, HDL-1, HDL-2, HDL3). They used the spectrum region between 5.7 and 0.2 
ppm (excluding some small areas to prevent water and the regions containing EDTA peaks 
from interfering). Full cross-validated models were built for every fraction of TG, C, total 
serum C and TG. They demonstrated that PLS models can be used to quantify lipids in 
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lipoproteins, although the resolution when multiple subclasses need to be quantified is 
rather poor, especially if the concentration is low. 
 In a recent study [134] with a sample set of 68 rat serums, PLS models were 
constructed for VLDL, IDL, LDL and HDL-C by using the information from the 1H NMR 
spectral region between 1.36 and 0.57 ppm and the cholesterol value measured after 
ultracentrifugation. It is worth noting that this is the first study to have been made of rat 
serum characterization. Unlike for human samples, there are no commercial kits for animal 
serum lipid analysis, making NMR serum characterization even more interesting. The 
correlation coefficients ranged from 0.95 (HDL C) to 0.48 (IDL-C). 
 Unlike preceding studies, Serrai et al. [135] used the FID signal instead of its Fourier 
Transform and applied a Wavelet Transform in the time domain to quantify the lipids and 
proteins in the main fractions (i.e. total and free C, TG, PL and proteins). In an experiment, 
with only nine serum samples, they correlated the biochemistry values of the main 
fractions with the Wavelet Transform coefficients extracted from the FID. The correlation 
coefficients obtained were 0.79, 0.84 and 0.92 (for LDL + IDL, VLDL and HDL, respectively) 
for visible lipids and 0.81, 0.87 and 0.88 (for VLDL, IDL + LDL and HDL, respectively) for the 
non-visible lipids (proteins and free cholesterol) (Table 2). 
 Finally, using data from the methylene peak spectra in human plasma coupled with 
multivariate calibration analysis, Savorani et al. [136] were able to predict the TG content of 
chylomicrons. The method is rapid and robust, creating new opportunities for research in 
lifestyle diseases and obesity. 
 
2.4.2.2. Clustering methods 
 For the first time in 1998 Ala-Korpela et al. [137] used Self Organizing Map (SOM) 
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networks [138,139] to represent the data derived from the methyl peak of plasma samples 
in 2D plots. The samples were placed on the surface according to their similarity, with an 
unsupervised approach and or definition of classes. The model was first trained with all the 
65 samples and then with a training set of 50 samples and a validation set of 15. In both 
cases the model successfully represented the different lipoprotein profiles: normal and 
Types IIa, IIb and IV hyperlipidemias. The map was also calibrated for different risk factors 
(i.e. TG, TC, HDL-C and LDL-C) and in all cases the samples were coherently positioned on 
the map. The SOM approach could be used to visualize the overall CHD risk, not related to 
the known individual risk factors. These results have been confirmed in a study by the same 
research group on 69 individuals, with considerable differences in lipid profiles [140]. A 
SOM representation of the choline and methyl 1H NMR regions showed a sample 
clusterization with meaningful clinical information related to CHD risk. In the same article, 
they showed the SOM analysis of simulated spectra, constructed by adding 11 subfractions 
obtained by ultracentrifugation from one individual. They defined normal spectra (N), 
metabolic syndrome spectra [141] and metabolic pathway spectra (MP), and built families 
of simulated spectra by adding different proportions of each subclass. The maps revealed a 
coherent arrangement of the simulated samples, according to the degree of metabolic 
syndrome. An interesting conclusion is that the choline region (around 3.2 ppm) is the most 
informative part of the aliphatic region (0.5–3.5 ppm). These studies by Ala-Korpela, 
together with [129], showed that the 1H NMR information that gives the lipoprotein peaks 
per se (i.e. without using subfraction lipid information) is clinically relevant. 
 Using the same samples set as in [133], Bathen et al. [142] applied Kohonen Neural 
Networks (KNN) and generative topographic mapping (GTM), two unsupervised algorithms, 
which displayed a very heterogeneous group of samples according to their lipid values. 
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2.4.3. Lipoprotein subclass surface fitting in PGSE spectroscopic 1H NMR 
signals 
 In 1993, Boerner [143] used pulse field gradient NMR to implement a diffusion 
ordered spectroscopy. He obtained a 2D spectrum consisting of a 1H NMR spectrum in the 
first dimension and the diffusion coefficient for the different molecules in the second 
dimension. For this purpose, he programmed a new algorithm called CUMULANT with 
which he obtained accurate mean diffusion coefficients; however, he could not resolve the 
lipoprotein peaks. 
 In 1996, Liu et al. [74] developed a new approach for characterizing biomolecules 
that took into account both diffusion and relaxation parameters. They demonstrated that 
the use of field gradient pulses could produce 1H–1H diffusion-edited TOCSY spectra of 
human blood plasma in which the response of low- and medium-weight components was 
filtered and only the response of macromolecules, characterized by a slow diffusion 
coefficient, remained. They proved that diffusion-edited spectra together with the 1H NMR 
relaxation times could increase the discrimination capabilities among samples in a 
metabolomic experiment with biofluids. The same group used two-dimensional diffusion-
edited total-correlation NMR spectroscopy (DETOCSY [144]) to estimate the diffusion 
coefficient of all the molecules in complex biofluids (i.e. serum), by measuring the slope of 
the metabolite area attenuation induced by the diffusion field strength. Nevertheless, they 
were unable to resolve the overlapped lipid peaks and separate the response of the 
different lipoprotein fractions. They argued that the interpretation of the derived diffusion 
coefficients could reveal changes in the aggregation or bonding circumstances of the 
molecules. They suggested that it is intrinsically not possible to resolve the lipid fraction 
peaks using higher field NMR spectrometers, because lipoprotein size is a continuum 
function in blood. In an experiment with serum rat samples [145] they demonstrated that 
control animals were better classified from those treated with a hepatotoxin model using 
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standard one-dimensional 1H NMR together with diffusion-edited spectra. The reason is 
that a better appreciation of lipid profiles is possible using diffusion-edited spectra. The 
same group developed the so-called diffusion-ordered NMR spectroscopy with statistical 
total correlation spectroscopy (STOCSY) [146]. This development displays the covariance 
intensity of the various nuclei in the same molecule across a series of spectra, including the 
diffusion coefficient calculated across the different gradient intensities. They named this 
technique statistical diffusion-ordered spectroscopy (S-DOSY). 
 Numares, a German company [147], has described a procedure for determining the 
concentration and size of lipoprotein subclass particles, and a patent application submitted 
for the invention [148]. The serum/plasma samples are measured at different temperatures 
(typically 278 K, 298 K, 308 K and 318 K). As the temperature rises, the relaxation times T1 
and T2 increase and the lineshape narrows. These measuring conditions, combined with 
three diffusionweighted 1H NMR measurements carried out with a modified STE–LED 
(stimulated echo and longitudinal eddy-current delay) pulse sequence, produce a range of 
different spectra, which depend on the attenuation of the lipoprotein fractions under each 
of the measuring conditions. Previously, the different lipoprotein classes were 
characterized individually and their characteristic parameters (chemical shift, shape of NMR 
signal intensities, signal width and line form) extracted for each temperature and gradient 
strength. Then, the simulated NMR spectrum is calculated and adjusted to the 
experimental spectrum by means of multidimensional optimization processes. The 
lipoprotein size limits of the different fractions are calculated once the particle density is 
known through their lipid contents. This method makes it possible to determine 15 
different fractions (Table 3) – including CM, VLDL, IDL, LDL, HDL fractions – and Lp(a) 
proteins. The determination of the latter is clinically very relevant because of the high 
health risk associated with this protein [45]. The method has been used to demonstrate 
that macrophage cholesterol efflux is inversely correlated with lipoprotein particle size and 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
 
111 
 
risk of CVD [149]. One study [114] investigated the heritability of the entire LDL and HDL 
subfraction profile using NMR spectrometry and found significant evidence of linkage for 
HDL size on chromosome 12 and for HDL particle concentration on chromosome 18. 
 Dyrby et al. [107] applied multi-way calibration by N-PLS and multi-way curve 
resolution using PARAFAC to 2D diffusion-edited 1H NMR spectra of human blood samples. 
The application of PARAFAC with four components extracted from the methylene peak 
revealed that these components correspond well with the four main lipoprotein groups 
(VLDL, IDL, LDL and HDL) because the diffusion coefficients (and hence their derived radii) 
that represent the extracted coefficients correspond quite well with the size characteristics 
of each fraction. However, the correlation between them and the concentration of the 
fractions is poor, probably because of the limited number of samples (n = 17). N-PLS 
calibration led to better lipoprotein lipid correlations for the four main fractions, and the 11 
subfractions considered (the correlation coefficient r had values between 0.75 and 0.98) 
(Table 3). 
 Liu et al. [26] mathematically deconvoluted the methyl and methylene peaks in the 
diffusion-edited 1H NMR spectra of one plasma sample into six Lorentzian functions, each 
one of which was characterized by amplitude, position, width and a diffusion coefficient. 
They demonstrated that the hydrodynamic radii estimated from the diffusion coefficients 
for every function has a good correlation with the radii of the conventional subfractions. 
The measurements were made at 25 ºC, a temperature at which some lipid fractions have 
reduced visibility in the NMR spectra. The experiment had no clinical implications, since 
only one plasma spectrum was processed. 
 Recently, Mallol et al. [103] used a mathematical deconvolution of the 2D diffusion-
edited spectra of plasma samples into 8 Lorentzian functions to demonstrate that the 
extracted areas and diffusion coefficients in a set of 26 plasma samples separate the 
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different lipoprotein profiles (normal, high triglycerides, low HDL/LDL ratio, and both risk 
factors) in a PCA score plot much better than the original spectra. They also showed that 
the relationship between the shift position of the Lorentzian functions and the lipoprotein 
radii calculated from the experimental diffusion coefficient agrees with results found by 
other authors [80,120], particularly in normolipidemic samples. 
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Table 3. Research methods on lipoprotein characterization based on diffusion-edited NMR spectroscopy. 
Author [Ref.] Sample set NMR settings Feature extraction method Calculated parameters 
 Smith et al. [101] Serum 
samples 
Bipolar pulse-pair and LED (BPP-
LED) pulse sequence. 400, 600 and 
800 MHz. 
Extraction of diffusion coefficient 
at each ppm spectra 
Statistical Diffusion-Ordered Spectroscopy (S-
DOSY) and Diffusion-Ordered Projection 
(DOPY) Spectroscopy 
Liu et al. [26,166] 1 plasma 
sample 
BPP-LED pulse sequence with water 
presaturation. 600 and 800 MHz 
Temp.=25 ºC 
Lineshape fitting with six 
Lorentzian functions at methyl 
and methylene peaks through the 
attenuated spectra 
Area, diffusion coefficient and hydrodynamic 
radii of every Lorentzian function.   
Dyrby et al. [167] 17 plasma 
samples 
Double stimulated echo (DSTE) 
experiment with BPP-LED 500MHz 
Temp. = 45 ºC 
Multi-way calibration by N-PLS 
and multi-way curve resolution by 
PARAFAC at methyl and methylene 
peaks 
- N-PLS Model: VLDL-TG, VLDL1-TG, VLDL2-TG, 
IDL-TG, and LDL-C, LDL1-C, LDL2-5-C, LDL6-C, 
HDL-C, HDL1-C, HDL2-C, HDL3-C 
- PARAFAC Model: VLDL-TG, IDL-TG, LDL-CH 
and HDL-C and the diffusion coefficient (and 
radii) of the main fractions 
Kremer et al. [25]  Stimulated-Echo with LED. Temp.=5 
ºC, 25 ºC, 35 ºC, 45 ºC 
Lineshape fitting with Lorentzian 
and Gaussians functions of methyl 
and methylene spectra acquired 
at different temperatures and 
diffusion gradients 
Concentration and size of : CM-C, CM-B, CM-
A, CM-Remnants, VLDL-C, VLDL-B, VLDL-A, 
IDL, LDL-C , LDL-B, LDL-A, LDL (small Dense) 
Lp(a), HDL2, HDL3  
Mallol et al. [103] 26 plasma 
samples 
DSTE-BPP-LED 
600 MHz Temp.=37 ºC 
Lineshape fitting with eight 
Lorentzian functions at methyl  
peak through the attenuated 
spectra family 
Area, position, width diffusion coefficient of 
eight Lorentzian functions. Calculation of 
associated hydrodynamic radii by the Einsten-
Stokes equation 
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2.5. NMR lipoprotein analysis in the study of diabetes and related 
diseases 
 The aim of this section is to summarize some of the main applications of NMR 
spectroscopy in the study of lipoproteins in diabetes and related metabolic diseases. Some 
articles in the literature discuss some of these studies [6,19,150]. Our aim here is to discuss 
the results of various studies that have tried to characterize diabetes using either the 
LipoProfile® Test or the platform developed by Ala-Korpela for serum analysis. This is 
expected to serve as a guide for future studies so that the outcomes can be compared and 
contrasted. 
 The main application of 1H NMR spectroscopy in the study of the metabolism of 
diabetes is the quantification of lipoprotein subclasses in T1DM and T2DM patients using 
the LipoProfile® test. This method has made it possible to relate different lipoprotein 
parameters and diabetes, and also other risk factors, in a univariate fashion. A more recent 
application led by Ala-Korpela has focused on the classification and characterization of 
diabetic states in order to highlight patho-physiological mechanisms and come to a holistic 
understanding of the disease. 
 In the first subsection, we shall discuss the results from the studies based on the 
LipoProfile® test and, in the second subsection, we shall list some of the applications of 
clustering methods for discovering the main characteristics of Diabetes Melitus. 
 
2.5.1. Quantification of lipoprotein subclasses based on the LipoProfile® 
test 
 LipoScience Inc. has carried out numerous studies on the quantification of 
lipoprotein subclasses with diabetic patients. These studies deal with a variety of issues 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
 
115 
 
such as case-control comparisons, treatment effects, or associations between lipoprotein 
subclasses, diabetes and individual risk factors (Table 4). In casecontrol studies, the 
common conclusion was that VLDL size increased and LDL size decreased in diabetic 
patients. Most of the studies agree that HDL size appears to decrease in diabetic patients, 
except in the study by Colhoun et al. [151], who found an increase in size in T1DM. On the 
other hand, there is general agreement that there is an increase in the values of total, large 
and small VLDLs, and total, medium and small LDLs. There is also general agreement that 
the values of large LDL and total HDL are lower in diabetic patients. 
 Although these were case-control studies, it should be pointed out that they 
differed not only in the type of case and controls but also in the type of diabetes. For 
instance, Colhoun et al. compared the NMR-derived lipoprotein concentrations between 
control and T1DM subjects and between men and women [151]. They also studied the 
relationship between particle sizes and coronary calcification. However, no relationship was 
found between this measure of atherosclerosis and particle size in diabetic subjects. 
 Another study on the effects of T2DM on the size and concentration of lipoprotein 
subclass particles determined by NMR [152] showed that the decrease in LDL size is the 
result of an increase in small LDL and a reduction in large LDL concentration, which 
together lead to a minimal difference in LDL cholesterol. The changes in the NMR 
lipoprotein subclass profile predictably increase the risk of cardiovascular disease and these 
were not fully apparent in the conventional lipid panel (see Section 2.2.3.1). 
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Table 4. Research methods on lipoprotein characterization in diabetic patients using 1H NMR spectroscopy 
    Size (nm) 
Particle Concentration 
VLDL (nmol/L) LDL (nmol/L) HDL (umol/L) 
Author (Year) [Ref] Type of Diabetes Experiment groups Genre VLDL LDL HDL Total Large Medium Small Total Large Medium Small Total Large Medium Small  
Colhoun H. (2002) [158] T1DM T1DM Vs Control Men   ↑ ↓  ↓       ↑  ↓ 
Women ↑ ↓ ↑   ↓   ↓  ↑  ↑  ↓ 
Garvey W. (2003) [159] T2DM T2DM Vs IS (Control) Both ↑ ↓ ↓ ↑ ↑   ↑ ↓ ↑ ↑    ↑ 
Soedamah-Muthu S.* (2003) [9] T1DM T1DM CAD Vs T1DM no-CAD Both  ↓ ↓ ↑ ↑ ↑ ↑ ↑  ↑ ↑ ↓ ↓ ↑  
Festa A. (2005) [160] T2DM Prediabetic Vs Nondiabetic Both ↑** ↓ ↓ ↑ ↑   ↑   ↑  ↓  ↑** 
Hodge A. (2009) [161] T2DM Diabetic vs Nondiabetic Both ↑ ↓ ↓*** ↑*** ↑ ↑ ↑ ↑ ↓ ↑ ↑  ↓  ↑ 
Mora S. (2010) [162] T2DM Diabetic vs Nondiabetic Women ↑ ↓ ↓ ↑ ↑  ↑ ↑ ↓ ↑ ↑ ↓ ↓  ↑ 
Soedamah-Muthu S. (2003) [173] T2DM Atorvastatin Vs Placebo Both   ↑   ↓ ↓  ↓  ↓  ↑   
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
2. State of the art 
 
117 
 
 An improvement in CAD prediction in T1DM patients has also been reported [9]. 
The particle concentrations of VLDL subclasses, small LDL, medium LDL, and medium HDL 
were found to be higher in CAD cases than in controls, while the concentration of large HDL 
particles was lower. Mean LDL and HDL particle sizes were lower in T1DM individuals. VLDL 
particle concentration was an independent predictor of CAD. While total LDL cholesterol 
was not related to CAD, LDL particle concentrations measured by NMR were strongly 
associated with CAD. This result is because small and medium LDL subclasses are the LDL 
fractions associated with CAD. Since small LDL particles contain considerably less 
cholesterol than larger LDL, they make a smaller contribution to total LDL cholesterol mass 
than to the total LDL particle number. However, LDL particle concentrations were not able 
to predict CAD independently, probably because these measures were highly correlated to 
other lipids and lipoproteins. The final conclusion was that the use of individual lipoprotein 
subclass levels might be more useful than overall mean particle sizes, as the latter did not 
improve the prediction of CAD. 
 Another study dealt with the characterization of a proatherogenic state in healthy, 
non-diabetic subjects who subsequently develop diabetes [153], and in whom increased 
small HDL particle concentration and VLDL particle size at baseline was related to incident 
diabetes at a mean follow-up of 5.2 years. Hodge et al. predicted T2DM patients [154] 
because values of NMR lipoprotein subclasses differed between subjects who developed 
diabetes and those who did not. Finally, Mora et al. characterized the proliferation of T2DM 
in women [155]. In their report, NMR lipoprotein parameters remained significantly 
different between controls and T2DM patients after adjustment for established risk factors. 
 Other studies have been made on the effects of atorvastatin on NMR-derived 
lipoprotein fraction concentrations [156], the relationships between apolipoprotein C-III 
concentrations and lipoprotein subclasses [157], the interrelations between poor glycemia 
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and lipoprotein metabolism [158], the association between retinopathy and lipoprotein 
subclasses in T1DM [159,160] and T2DM [160] diabetic patients, and the interrelations 
between diabetic nephropathy and lipoprotein metabolism [159]. It should be pointed out 
that the new associations found between retinopathy and lipoprotein subclasses were 
previously unknown and could not be detected using conventional lipid profiles. 
 
2.5.2. Characterization of metabolic features of diabetic patients using NMR 
and SOM 
 Makinen et al. used 1H NMR spectroscopy for the clinical diagnosis of diabetic 
nephropathy in T1DM patients [161]. They used two molecular windows: LIPO and LMWM. 
After a classification step, NMR was well suited to distinguish among the metabolic 
characteristics of T1DM. Finally, they showed the quantitative nature of 1H NMR for the 
determination of lipoprotein lipids, apolipoprotein components and low-molecular-weight 
metabolites. 
 Subsequently, the same workers characterized the metabolic features of Diabetic 
Kidney Disease (DKD) and the interrelations between DKD, the metabolic syndrome and 
other complications in T1DM patients [10]. They used classical biochemistry measures and 
found high triglyceride levels and low HDL levels. Recently, Valcárcel et al. used differential 
networks to characterize differences of lipoprotein metabolism-related diabetic 
dyslipidemia in prediabetic patients [162]. These differences were not shown by classical 
biochemical parameters. Finally, the addition of a third molecular window, the LIPID 
window, to the metabonomics platform led by Ala-Korpela enabled sphingomyelin and 
other lipidand lipoprotein-related parameters to be associated with kidney disease in 
patients with T1DM [163]. 
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2.6. Final conclusions 
 Each NMR spectrum from a serum/plasma sample contains a wealth of information 
about lipoproteins. NMR spectroscopy is the only technique that allows a full lipoprotein 
subfraction analysis of serum/plasma samples. On the basis of the various analysis methods 
reported in Section 2.4, we conclude that the data they provide enable the lipid 
concentration (mainly for cholesterol and triglycerides), and particle numbers and sizes for 
several subfractions (typically between 9 and 14) to be correctly measured. 
 However, there is a lack of standardization among the methods presented. One 
fundamental reason for this is that the discretization of the continuous lipoprotein sizes in 
blood is method dependent, which makes decomposing them into subfractions a rather 
arbitrary task. The traditional biochemical methods for fraction isolation (reviewed in 
Section 2.2.3.2) suggest that the number of fractions is method dependent, which makes 
direct comparison between them impossible. The calibration and validation procedures 
used to set up new NMR methods rely on the correlations made between the NMR spectra 
and the lipids (generally cholesterol and triglycerides) measured in a particular set of 
subfractions, all isolated by ultracentrifugation. In many experiments, there was a limited 
availability of a high number of serum/plasma samples representing a wide spectrum of 
dyslipidemias, which makes it very difficult to generalize the method to all sample sets. 
 The methods reviewed in Section 2.4.2 use statistical correlations for the 
quantification of cholesterol and triglycerides in several subfractions. In general, 
correlations are very good for the fractions with signals at the ends of the peak (mainly 
VLDL and HDL) and good for the fractions with signals in the middle of the peaks (i.e. IDL 
and LDL). The calculation of particle number is based on the decomposition of the methyl 
peak. Provided that the number of methyl terminations is the same in C and TG (three in 
both cases), the methyl signal amplitude remains constant, even if the cholesterol ester and 
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triglyceride composition of the lipoprotein cores varies. As has been mentioned in Section 
2.2, LDL-P is a new cardiovascular risk factor that could be accepted by the FDA 
administration as a clinical test. This parameter is calculated by the lineshape fitting of the 
methyl peak to obtain the area of the individual subfractions. Peak overlapping is intense, 
which makes it mathematically very difficult to find the individual subfractions, and the 
system is prone to finding multiple solutions, especially when the number of subfractions to 
be obtained is high. The details of the decomposition algorithms used by the groups have 
not been revealed [6], which makes it very difficult to evaluate the reported methodology 
and for other researchers to reproduce the approach. 
 The size of the lipoprotein subfractions is only given by the methods proposed by 
the groups of Otvos and Ala-Korpela. In the first case, the size of the subfractions are those 
of the proprietary library subfractions used in the decomposition process and in the second 
case, the given sizes have been calibrated using those obtained by a size-exclusion 
chromatography technique. In neither case were they measured directly. Diffusion NMR 
spectroscopy can provide a direct measure of lipoprotein radii by using the diffusion 
coefficient and applying the Einstein–Stokes equation. Nevertheless, the determination of 
the serum/plasma viscosity parameter in the formula is not straightforward. In this kind of 
experiment, the existence of a third dimension (diffusion coefficients) makes the fitting 
process more reliable, because the lipid peaks are substituted by a surface. However, at the 
present time, this approach still requires further development if it is to give reliable and 
meaningful results for clinical applications. 
 Although most of the methods reported aim to predict and quantify the lipid 
concentration, and the number or size of particles in a set of lipoprotein subfractions, some 
studies use the features extracted from the lipid peaks to find associations between them 
and different diseases and the identification of risk pathways. This approach goes beyond 
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the CVD risk factors proposed by the lipid panels and could, in the future, characterize the 
risk of CVD better and identify new phenotypes. 
 In Section 2.5 we reviewed many studies that use NMR spectroscopy to 
characterize diabetic dyslipidemias. The number and size of the particles in the lipoprotein 
fractions provided by this technique have played an essential role in obtaining insight into 
this complex metabolic disease. 
 Finally, we would like to make two points: the first is that very few methods can 
make a comprehensive analysis of lipoproteins by NMR, and it is very difficult to compare 
them because they give different parameters. That is why there are no studies comparing 
these methods among themselves or with classical methods. The techniques must be 
standardized and validated if they are to be used in the future in clinical diagnosis. If they 
are, then NMR spectrometers could be introduced into hospitals. 
 The second point concerns the lack of lipid and lipoprotein databases for use in 
NMR metabolomic studies with serum/plasma. As well as the groups whose work has been 
reviewed in this article and which specialize in lipoprotein analysis, the scientific community 
also performs qualitative lipopoprotein characterizations in the area of NMR-metabolomics. 
In other words, there is a pressing need to create measurement databases that can be 
accessed freely, as is the case for the low-weight metabolites found in serum/plasma, thus 
enabling the serum/plasma samples in research experiments to be completely profiled. 
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3.1. “Particle size measurement of lipoprotein fractions using 
diffusion-ordered NMR spectroscopy” 
3.1.1. Abstract 
 The sizes of certain types of lipoprotein particles have been associated with an 
increased risk of cardiovascular disease. However, there is currently no gold standard 
technique for the determination of this parameter. Here, we propose an analytical 
procedure to measure lipoprotein particles sizes using diffusion-ordered nuclear magnetic 
resonance spectroscopy (DOSY). The method was tested on six lipoprotein fractions, VLDL, 
IDL, LDL1, LDL2, HDL2, and HDL3, which were obtained by sequential ultracentrifugation from 
four patients. We performed a pulsed-field gradient experiment on each fraction to obtain a 
mean diffusion coefficient, and then determined the apparent hydrodynamic radius using 
the Stokes–Einstein equation. To validate the hydrodynamic radii obtained, the particle size 
distribution of these lipoprotein fractions was also measured using transmission electron 
microscopy (TEM). The standard errors of duplicate measurements of diffusion coefficient 
ranged from 0.5% to 1.3%, confirming the repeatability of the technique. The coefficient of 
determination between the hydrodynamic radii and the TEM-derived mean particle size was 
r2=0.96, and the agreement between the two techniques was 85%. Thus, DOSY experiments 
have proved to be accurate and reliable for estimating lipoprotein particle sizes. 
 
3.1.2. Introduction 
 Interest in the assessment of the size profiles of lipoprotein particles has been 
increasing due to the role of this parameter in cardiovascular disease (CVD) risk prediction 
[1]. For example, small, dense low-density lipoprotein (sdLDL) particles are removed slowly 
from the blood stream, which subjects them to oxidation processes and leads to the 
formation of atheroma [2,3]. Moreover, a predominance of sdLDL is associated with an 
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atherogenic lipoprotein phenotype that is characterized by high concentrations of plasma 
triglyceride, low concentrations of high-density lipoprotein (HDL) cholesterol and apoA-I, 
and high insulin resistance [4–7]. In contrast, HDL particles are considered to be anti-
atherogenic lipoproteins because they help reverse cholesterol transport [8,9]. In addition, 
when HDL particles are divided into large and small HDL subclasses, a decrease in the 
number of larger particles has a stronger influence on the development of CVD. The 
summary described above is based on several epidemiological studies; however, other 
studies contribute to the controversy regarding (1) whether sdLDL particle numbers may be 
considered an independent risk factor for CVD, (2) which HDL subclasses are more 
protective against CVD, and (3) whether new lipoprotein analytical methods improve risk 
assessment compared with standard lipid panels [10–13]. 
 Several methods have been developed to determine the particle sizes of different 
lipoprotein fractions. The Vertical Auto Profile-II or VAP-II test (Atherotec Inc.) fractionates 
lipoproteins on the basis of differences in density [14]. In contrast, the nuclear magnetic 
resonance (NMR) LipoProfile-II test (LipoScience Inc.) distinguishes among the different 
lipoprotein particles using the chemical shift value of the methyl NMR signal [15]. 
Lipoprotein particle sizes are then estimated based on a proprietary library containing the 
NMR signals of lipoproteins of known size. Other methods are based on gradient gel 
electrophoresis (GGE), including segmented GGE (Berkeley HeartLab), which separates 
lipoproteins based on their size, and the Quantimetrix Lipoprint LDL System, which 
estimates LDL particle sizes by comparing their electrophoretic mobility to the 
electrophoretic mobilities of particles of known size [16,17]. All of the methods described 
above are based on different physicochemical properties, which make them difficult to 
compare. In addition, they estimate lipoprotein sizes using different assumptions and 
approximations. Consequently, recent reviews have emphasized their divergence [18–22]. A 
recent study by Ensign et al. that compared the LDL particle sizes obtained using these four 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
3. Development and evaluation of a novel NMR-based advanced lipoprotein test 
149 
 
methods reported a total agreement of only up to 8% according to LDL subclass 
phenotyping (preponderance of large, intermediate, or small LDL particles) [19]. Clearly, 
there is a need for standardization [23]. Another disadvantage of the methods that are 
currently available is that information is delivered on a reduced set of lipoprotein 
subclasses. Because LDL is usually considered the most clinically relevant lipoprotein class, 
most of the studies published to date have been focused on LDL phenotyping, and other 
lipoprotein classes, such as very low-density lipoprotein (VLDL) or intermediate density 
lipoprotein (IDL), are seldom reported. Therefore, it would be beneficial to consider a 
complete profile of lipoprotein particle sizes. 
 In order to measure lipoprotein particles sizes, diffusion-ordered NMR spectroscopy 
(DOSY) might be thought as a good alternative due to its robustness and simple sample 
manipulation [24–26]. DOSY has been extensively used to measure the size distribution of 
different materials, including lipid vesicles and gold nanoparticles [27, 28]. In this study, the 
particle sizes of six lipoprotein fractions, VLDL, IDL, LDL1, LDL2, HDL2, and HDL3, were 
assessed using DOSY. To the best of our knowledge, this is the first reported work that 
attempts to assess the particle sizes of ultracentrifuged lipoprotein fractions using this 
technique. First, the attenuation of the methyl signal was used to obtain a diffusion 
coefficient for each fraction. We evaluated the diffusion coefficients that were obtained in 
terms of the signal-to-noise ratio (SNR), and we then constructed a DOSY schematic map to 
deliver a qualitative visualization plot for lipoprotein analysis. Second, the hydrodynamic 
radii of the lipoprotein fractions (RH) were derived using the Stokes–Einstein equation [24]: 
   
  
    
             (1) 
where k is the Boltzmann constant, T is the absolute temperature, and η is the solvent or 
solution viscosity. Equation 1 can be decomposed into its component pieces, i.e., the 
Einstein relationship between a thermal, stochastic property (diffusivity) and a 
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deterministic, mechanical property (mobility) [29]: 
  
 
  
              (2) 
and the Stokes relationship that relates the deterministic probe response (mobility) to the 
rheological properties of the material (viscosity): 
         
              (3) 
 While the Einstein relationship is strictly valid in this study, the Stokes relationship 
may fail since it assumes infinite dilution conditions and a continuum solvent. To enable 
some corrections to be made for obstruction effects, we therefore also measured the 
experimental viscosity. The feasibility of using Equation 1 will be explored, comparing the 
mobility and hydrodynamic radii to the mean lipoprotein sizes measured using transmission 
electron microscopy (TEM), which has been extensively used in the characterization of 
lipoprotein fractions [30]. 
 
3.1.3. Materials and methods 
3.1.3.1. Patient selection 
 Four patients attending the Lipid Clinic of Sant Joan University Hospital in Reus with 
different hyperlipoproteinemic phenotypes to cover a broad range of lipid and lipoprotein 
concentrations were recruited. Patients 1 and 3 were diabetic and suffered from lipoprotein 
lipase deficiency (Type I) and severe hypertriglyceridemia (Type V), respectively. Patients 2 
and 4 had dis-β-lipoproteinemia (Type III) and polygenic hypercholesterolemia (Type IIa), 
respectively. Blood samples were obtained after a 12-h overnight fasting period; samples 
were withdrawn into EDTA-containing tubes and centrifuged immediately for 15 min at 4 ºC 
and 1,500×g to obtain plasma. The study protocol was approved by the Ethical Committee 
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of Sant Joan University Hospital. All patients gave their written consent to participate in the 
research program. 
3.1.3.2. Lipoprotein fractionation 
 Six lipoprotein fractions were obtained from the collected plasma by sequential 
preparative ultracentrifugation in a Kontron ultracentrifuge T-1075 rotor TFT 45.6 at 4 ºC, as 
previously described [31]. The lipoproteins isolated included VLDL (0.95–1.006 g/ml), IDL 
(1.006–1.019 g/ml), LDL1 (1.019–1.044 g/ml), LDL2 (1.044–1.063 g/ml), HDL2 (1.063–1.0125 
g/ml), and HDL3 (1.125–1.210 g/ml). Sucrose was added to the samples to maintain the 
physicochemical properties of all the fractions prior to freezing, as previously described 
[32]. All lipoprotein fractions were concentrated two-fold prior to NMR analysis, with the 
exception of the LDL2 fraction of patient 2. 
 The total cholesterol and levels of triglycerides, direct LDL cholesterol, HDL 
cholesterol, and ApoB-100 in the plasma samples, as well as the lipid and apolipoprotein 
levels in the lipoprotein fractions, were measured using enzymatic and 
immunoturbidimetric assays. In Section 3.1.8, the analytical lipid and lipoprotein values are 
detailed (Table S1). 
 
3.1.3.3. Diffusion-ordered NMR spectroscopy (DOSY) 
 To prepare samples for DOSY, the lipoprotein fractions (430 μl) were transferred into 
NMR tubes (o.d. 5 mm). An internal reference tube (o.d. 2 mm, supported by a Teflon 
adapter) containing 9.9 mmol/l sodium 3-trimethylsilyl [2,2,3,3-d4]propionate (TSP) and 
0.47 mmol/l MnSO4 in 99.9% D2O was placed coaxially into the NMR sample tube. The tubes 
were maintained at 4 ºC in the sample changer until the time of analysis. 
 1H NMR spectra were recorded on a Bruker Avance III 600 spectrometer operating 
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at 600.20 MHz. Diffusion measurements were performed at 310 K to obtain a full signal 
from the melted lipids in the lipoproteins and to avoid serum degradation during 
measurement. The double-stimulated echo (DSTE) pulse program was used, with bipolar 
gradient pulses and a longitudinal eddy current delay (LED) [33]. This pulse program 
consists of a DSTE sequence followed by z-storage of the magnetization, and allows longer 
diffusion delays that are limited only by the longitudinal relaxation of the molecules. This 
requirement is compulsory if the pulse sequence is to be applied to lipoproteins, in which 
T1>>T2. A DSTE sequence efficiently compensates for flow convection currents that can 
develop in plasma samples at elevated temperatures. Additionally, three spoil gradient 
pulses were employed during the z-storage periods and during the recycle delay, to shorten 
the phase cycle and eliminate accidental refocusing of unwanted magnetization. To 
minimize the possibility of convection currents, the heating air flow rate was set to 670 l/h. 
A spectral window of 18,000 Hz was used, with an acquisition time of 1.82 s. 
 During the experiment, the relaxation delay was 2 s, the FIDs were collected into 64 
k complex data points, and 32 scans were acquired for each sample. The gradient pulse 
strength was increased from 5% to 95% of the maximum strength of 53.5 G cm−1 in 50 steps, 
in which the squared gradient pulse strength was exponentially distributed. A diffusion time 
(Δ) of 120 ms and bipolar half-sine-shaped gradient pulses (δ) of 6 ms were applied to 
obtain a reasonable amount of lipoprotein signal attenuation: 
     
                  (4) 
where                             is a gradient shape factor for the half-sine 
shape, and τ is the short delay between the pulses in a gradient pulse pair. The total 
experiment time was 1 h 45 min per sample. All spectra were Fourier transformed after 
applying an exponential function equivalent to 2 Hz Lorentzian line broadening, phase 
corrected, baseline corrected, and referenced to the TSP reference signal at 0 ppm. The SNR 
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was defined as the ratio of the methyl signal maximum in the least attenuated (lowest 
gradient) spectrum to the standard deviation of the noise height in the baseline. 
 Diffusion coefficients were obtained using a surface fitting approach, as described 
previously [34]. In this case, only one Lorentzian function was used to fit the methyl surface 
(Figure 1). The estimated diffusion coefficients and peak positions were used, together with 
their standard errors (SE), to build a schematic DOSY peak map showing the distribution of 
the different lipoprotein fractions in terms of their chemical shifts and diffusion coefficients. 
 
3.1.3.4. Viscosity measurements 
 Lipoprotein solution viscosities were measured at 37 ºC with a Cannon–Manning 
semi-micro capillary viscometer. To obtain the viscosity in millipascal seconds, the density of 
each fraction was calculated by weighing a volume of 250 μL. The kinematic viscosity was 
then measured by multiplying the efflux time of the sample between two reference lines by 
the viscometer constant provided by the manufacturer. Finally, the kinematic viscosity and 
the density were multiplied to obtain the viscosity. 
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Figure 1. Surface fitting of the attenuated methyl signal of a VLDL fraction (A) using an 
individual Lorentzian function (B). 
 
3.1.3.5. Transmission electron microscopy (TEM) 
 TEM samples were prepared by placing a drop of each lipoprotein fraction onto a 
formvar carbon film for 2 min and then blotting the excess liquid. Negative staining was 
performed with 2% phosphotungstic acid adjusted to pH 6.6; this solution was applied for 1 
min and then blotted dry. The gridded samples were examined on a JEOL JEM-1011 TEM at 
an accelerating voltage of 80 kV. The particle sizes of the lipoprotein fractions were 
calculated using the IMAQ Vision software (National Instruments Inc.). Each lipoprotein 
fraction was analyzed using a different number of micrographs. Some images were filtered 
with a Gaussian filter prior to analysis to avoid interference from noise. All images were 
then truncated to black and white, and particles at the borders were discarded. All particles 
with a circularity factor close to 1 were selected. The number of particles considered ranged 
from 100 to 800. The HDL fractions were particularly difficult to measure via TEM; only the 
HDL2 fraction from patient 2 and the HDL3 fractions of patients 2 and 3 were entered in the 
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regression analysis because these samples were the only HDL fractions that exhibited 
reasonable particle sizes. 
 
3.1.3.6. Statistical analysis 
 The diffusion coefficients among the lipoprotein subclasses were compared using 
the nonparametric Kruskal–Wallis test. The resulting P value was used to test the null 
hypothesis of all the subfractions belonging to the same subclass. P<0.05 was considered to 
be statistically significant in order to reject the null hypothesis. A simple linear regression 
analysis was used to examine the relationship between the lipoprotein mobilities and 
hydrodynamic radii obtained via NMR, and the lipoprotein particle sizes obtained via TEM. 
The parameters used to evaluate the linear regressions were the coefficient of 
determination (0≤r2≤1) and the regression lines. In order to evaluate the agreement 
between the two techniques, the root mean squared percentage error (RMSPE) of the 
differences between NMR and TEM was calculated according to the following formula: 
          
  
             
   
 
 
 
 
 
          (5) 
where NMR refers to the NMR-derived sizes, TEM to the TEM-derived sizes, and n the 
number of lipoprotein fractions. All of the analyses were performed with MATLAB Version 
7.10.0.499 R2010a (MathWorks). 
 
3.1.4. Results 
3.1.4.1. Calculation of the diffusion coefficients 
 DOSY experiments are vulnerable to some experimental limitations, such as non-
uniform field gradients, temperature gradients, and low solute concentrations [25]. The last 
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limitation is of particular concern in the analysis of lipoprotein fractions because these are 
typically diluted during several sample manipulation steps; consequently, pulsed-field 
gradient (PFG) experiments on lipoprotein fractions may yield spectra with low SNR. The 
VLDL and HDL3 fractions of patient 1 were therefore evaluated, as they represent two 
extreme cases for SNR (250:1 and 15:1, respectively). Figures 2A-B illustrate the attenuation 
of the methyl signal of these samples in a PFG experiment. While the VLDL fraction did not 
exhibit complete attenuation of the signal over the range of gradient amplitudes used, the 
HDL3 fraction was completely attenuated at high gradient strengths because of the faster 
diffusion of their particles. The HDL3 fraction also exhibited lower SNR even at low gradient 
strengths. The SNR differences between the VLDL and HDL3 fractions arose because of the 
different concentrations; the VLDL fraction of patient 1 contained 1.31 and 3.66 mmol/L of 
cholesterol and triglycerides, respectively, whereas the HDL3 fraction from the same patient 
contained 0.16 and 0.09 mmol/L, respectively (see Table S1 in Section 3.1.8). Despite the 
low concentrations found in the HDL3 fraction, the nonlinear least squares fitting of the 
experimental data to Equation 4 yielded an acceptable fitting error of ~3% (Figures 2C–F). 
The use of integral area attenuation to fit with Equation 4, instead of intensity attenuation 
as is more common in DOSY experiments, reduces the amount of uncertainty in signal 
attenuation due to noise. 
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Figure 2. SNR analysis of DOSY spectra. A-B) Signal attenuation of the VLDL and HDL3 
fractions from patient 1. C-D) Fitting of the integral area to Equation 4. E-F) Residuals of the 
fittings. 
 
 Figure 3 shows a schematic DOSY peak map of the diffusion coefficients that were 
obtained for all the fractions, details of which are also summarized in Table 1. Spectra of the 
different lipoprotein fractions from patient 3 are shown along the top as a reference. On the 
right side, projections of the diffusion coefficients are depicted. For each patient, the 
methyl signal of the neutral lipids in the lipoprotein shows faster diffusion as the lipoprotein 
densities increase. In general, larger lipoprotein subclasses yielded lower SEs. The maximum 
SE value of an estimated diffusion coefficient was ~4%, and was obtained for the LDL2 
fraction of patient 2; the estimated SE for the remaining samples was less than 1.5%. A high 
SE was observed for this particular LDL2 fraction because it was highly diluted compared 
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with the other fractions; therefore, its SNR (4:1) was around the detection level (5:1). We 
did not use the diffusion coefficient obtained for this lipoprotein fraction in further analysis. 
 
Figure 3. Schematic DOSY peak map showing the diffusion coefficients obtained by fitting 
Equation 4 to each dataset. The width along the chemical shift axis of the Gaussian curves 
represents the SE in estimating the position, while the width along the diffusion dimension 
represents the SE in estimating the diffusion coefficient. The superimposed spectra at the 
top of the figure are those acquired for the lipoprotein fractions from patient 3 and have 
been normalized for visualization purposes; the Gaussian functions at the right side 
correspond to the projection of the diffusion spectra obtained for all samples. 
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Table 1. Results from all of the measurements. D is the diffusion coefficient (% SE), M is the 
mobility,   is the viscosity expressed as mean±standard deviation, RH is the hydrodynamic 
radii, and the TEM-derived particle sizes are expressed as mean±standard deviation 
(number of particles measured); Nd = Not determined. 
Fraction Patient SNR D / (cm2 s-1) M / (cm2 s-1 J-
1
) 
 / (mPa 
s) 
RH / (Å) TEM Size / (Å) 
VLDL 1 252 0.70 (0.8) 151 0.81  402 265±113 (400) 
 2 208 1.07 (0.8) 233 0.81 261 228±110 (803) 
 3 506 1.18 (0.7) 256 1.12 171 136±49 (746) 
 4 43 1.46 (0.7) 315 0.80 195 184±44 (625) 
IDL 1 14 1.25 (1.0) 271 0.77 236 179±72 (296) 
 2 18 2.01 (0.8) 435 0.71 159 169±36 (450) 
 3 31 1.88 (0.8) 405 0.87 139 135±26 (106) 
 4 17 1.86 (1.0) 401 0.76 160 155±57 (532) 
LDL1 1 14 2.69 (0.9) 585 0.79 107 96±63 (97) 
 2 29 2.50 (0.7) 541 0.71 128 114±28 (277) 
 3 23 2.66 (0.7) 576 0.77 111 118±36 (95) 
 4 45 2.61 (0.6) 564 0.76 114 130±24 (98) 
LDL2 1 11 3.38 (1.0) 734 0.76 88 83±28 (101) 
 2 4 4.16 (3.8) 872 0.73 75 86±21 (98) 
 3 18 3.05 (0.7) 658 0.85 88 80±19 (162) 
 4 9 3.20 (1.3) 689 0.84 84 87±23 (166) 
HDL2 1 25 5.63 (0.7) 1212 0.77 52 Nd 
 2 23 5.89 (0.7) 1272 0.72 54 45±13 (18) 
 3 19 5.23 (0.8) 1130 0.73 59 Nd 
 4 19 5.53 (0.7) 1192 0.71 58 Nd 
HDL3 1 15 6.09 (1.0) 1308 0.72 52 Nd 
 2 49 6.21 (0.6) 1338 0.71 51 41±11 (122) 
 3 52 6.22 (0.7) 1341 0.74 49 39±17 (339) 
 4 41 6.51 (0.5) 1403 0.71 49 Nd 
 
 Lipoprotein subclasses could be clearly distinguished using their average diffusion 
coefficients (P=0.00073). The minimum difference in diffusion coefficient between two 
subclasses was 2.8%; the two subclasses involved were the two HDL subclasses. The SE for 
the fastest HDL2 fraction and the slowest HDL3 fraction were 0.7% and 1%, respectively, and 
these subclasses could still be statistically distinguished (P=0.021). However, there was a 
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lipoprotein fraction that exhibited an average diffusion coefficient that was out of its 
subclass range. This was the IDL fraction of patient 1, a sufferer from lipoprotein lipase 
deficiency, and exhibited an average diffusion coefficient within the range of the VLDL 
fractions. Despite the normal lipid values exhibited by this IDL fraction (see Table S1 in 
Section 3.1.8), its low diffusivity suggests that larger and more lipid-rich particles than 
expected are present. These larger particles may correspond to VLDL particles because 
complete separation of these lipoprotein fractions by ultracentrifugation cannot be 
achieved in subjects with this pathology due to the lactescent state of the plasma sample. 
 
3.1.4.2. Determination and validation of lipoprotein hydrodynamic radii 
 We obtained a mobility and hydrodynamic radius for each lipoprotein fraction using 
Equations 2 and 3, respectively (Table 1). To evaluate the validity of the Stokes relationship, 
we performed two linear regression analyses to assess the relationships between the two 
variables and the TEM-derived particle sizes. Figure 4A illustrates the regression model 
constructed using the calculated lipoprotein mobilities as a prediction variable. The two 
variables correlated satisfactorily (r2=0.78). Using the measured solution viscosity (as a 
partial correction for the effects of other solution components and of obstruction) and 
performing the linear regression analysis for hydrodynamic radius instead of mobility 
resulted in a stronger linear relationship (r2=0.90), as shown in Figure 4B. In this figure, 
dotted rectangles identify the areas in which the different lipoprotein fractions used in this 
study should be placed according to the literature (VLDL, 150–400 Å; IDL, 125–175 Å; LDL, 
90–140 Å; HDL, 25–60 Å) [35]. These rectangles represent the main lipoprotein classes since 
the size ranges that define the subsequent subclasses are study dependent. As shown in 
Figure 4B, most of the lipoprotein samples lie within their theoretical range, but all of the 
LDL2 fractions had a hydrodynamic radius slightly smaller than the minimum expected 
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value. 
 
Figure 4. Regression between NMR-derived data and TEM-derived particle sizes. A) 
Relationship between mobility (M) and TEM-derived particle sizes (y=-5.5x+1300), B) 
Relationship between hydrodynamic radii (RH) and TEM-derived particle sizes (y=1.37x-29). 
The gray line correspond to the identity line (y=1.00x+0). 
 
 Although we found a high degree of correlation between the two techniques, their 
agreement was moderate in terms of absolute values (RMSPE of 20%). This is not surprising: 
The relationship between measured diffusion coefficient and particle size is complicated by 
obstruction effects, polydispersity, shape and flexibility effects, and other limitations of the 
simple Stokes–Einstein model. Of these problems, polydispersity is expected to be one of 
the most serious. The signal measured in an NMR experiment like DOSY is proportional to 
the number of spins present, so larger particles will contribute much more strongly to the 
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NMR data than smaller, in proportion to the cube of the radius [36]. Thus, the diffusion 
coefficient obtained by NMR is expected to correspond to an “average” size larger than the 
mean of the radii obtained by TEM. 
 To assess the importance of polydispersity, we simulated an attenuating NMR 
dataset, corresponding to the parameters used for the experimental measurements, for 
each sample, using the experimental size distributions found with TEM (see Appendix in 
Section 3.1.8). These datasets were then fitted to the Stokes–Einstein equation as above 
and used to derive apparent hydrodynamic radii. For each sample, a correction factor for 
the effects of polydispersity on the NMR data was then calculated from the ratio of the 
mean TEM size listed in Table 1 to the size obtained by fitting the synthetic data. Finally, this 
correction factor was applied to the NMR data, allowing the TEM size to be compared to the 
NMR sizes corrected for the bias introduced by polydispersity. Figure 5 shows the linear 
regression between the corrected hydrodynamic radii obtained from NMR and the mean 
TEM sizes. As can be seen, this correction not only improved the correlation between the 
two techniques (r2=0.96) but also improved the agreement (RMSPE of 15%), suggesting that 
the dominant systematic factor leading to differences in apparent size was polydispersity. It 
must be stressed that this correction was aimed at evaluating the importance of 
polydispersity in the agreement between the two techniques, and that it is not expected to 
be used routinely. It should perhaps be noted that there is no reason a priori to prefer the 
bias towards small particles inherent in using average TEM radius to the bias towards larger 
particles inherent in DOSY, if a single size parameter rather than a distribution is to be used: 
it does however mean that comparisons between the two require care. 
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Figure 5. Regression between corrected NMR sizes and mean TEM sizes (y=0.99x-12). The 
gray line correspond to the identity line (y=1.00x+0). 
 
3.1.5. Discussion 
 A previous study by O’Neal et al. used light scattering (LS) methods to determine 
the hydrodynamic radii of LDL lipoproteins [37]. LS methodology also determines the 
diffusion coefficients of lipoprotein fractions and uses the Stokes–Einstein equation to 
derive their hydrodynamic radii. However, in this study, a constant viscosity was considered. 
Sakurai et al. used the same technique to obtain the hydrodynamic radii of two LDL 
subclasses that were collected by ultracentrifugation [38]. Mean particle sizes of 108 and 
102 Å for LDL1 and LDL2, respectively, were obtained. In our study, the mean particle sizes 
for the LDL1 and LDL2 subclasses were 114 and 87 Å, respectively. Thus, our approach seems 
to obtain relatively lower particle sizes for the LDL2 fraction. 
 Although the experimental viscosity measured for this study, under stress 
conditions, does not necessarily correspond to the effective viscosity experienced by 
diffusing particle, the improvement in the correlation between NMR and TEM radii when 
the experimental viscosity is used in Equation 3 suggests that this does provide an effective 
correction for the presence of solutes, including the lipoprotein. A more important reason 
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for systematic differences between radii estimated by TEM and by NMR, however, is the 
polydispersity evidenced in the TEM data (see Figures S1-S7 in Section 3.1.8). The methyl 
signal fitted to obtain the diffusion coefficient is a composite containing contributions from 
all the different lipoprotein sizes present in the sample. The diffusion coefficients obtained 
by NMR are thus the result of an averaging over all the lipoprotein present [36]. Here, we 
have demonstrated that the diffusion coefficients obtained by NMR accurately reflect the 
distribution of sizes seen in TEM data, the NMR results showing a greater contribution from 
slower (larger) particles. The method described here thus yields more reliable values than 
previous studies, in which a constant value for the viscosity was used and no corrections for 
polydispersity were attempted. 
 
3.1.6. Conclusions 
 In this study, DOSY experiments were carried out on lipoprotein fractions to assess 
their average particle sizes. The diffusion coefficients thus obtained had low estimation 
errors, demonstrating the repeatability of this technique. The hydrodynamic radii found 
when using the experimental viscosity in the Stokes–Einstein equation were highly 
correlated with the mean TEM sizes, although there was a systematic difference between 
the TEM and NMR-derived sizes. This systematic difference was shown to be explained by 
the polydisperse distributions found by TEM; once this was taken into account, a high 
degree of agreement was obtained between the two techniques. We propose that NMR is a 
potentially useful alternative to other available approaches for measuring lipoprotein 
fraction particle sizes, due to its inherent robustness and minimal sample manipulation. 
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3.1.8. Supplemental material 
 The content of this section is divided into three parts. First, a table listing the 
biochemical data of the ultracentrifuged fractions of the four patients is presented. This 
biochemical data correspond to the cholesterol, triglycerides, Apo-A and Apo-B values for 
each lipoprotein fraction. The concentration factor used to perform such analysis is 
reported as well. Second, TEM images corresponding to different fractions and patients are 
shown. Finally, the last section includes an appendix with a detailed description of the 
correction applied to the NMR-derived diffusion coefficients. 
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Table S1. Biochemical results from ultracentrifugation. 
Fraction Patient Conc. Factor Chol. 
(mmol/L) 
Trig. 
(mmol/L) 
ApoA-I 
(mg/dl) 
ApoB-100 
(mg/dl) 
VLDL 1 1 1,31 3,66 - - 
 2 1 2,27 2,86 - 14 
 3 2 3,03 5,40 - 38 
 4 2 0,35 0,72 - 3 
IDL 1 1 0,21 0,25 - - 
 2 1 0,61 0,18 - 3 
 3 2 0,55 0,30 - 2 
 4 2 0,37 0,18 - 3 
LDL1 1 2 0,26 0,15 - 3 
 2 2 1,08 0,18 - 16 
 3 2 0,79 0,2 - 19 
 4 2 2,95 0,29 - 72 
LDL2 1 2 0,22 0,11 - 4 
 2 1 0,15 0,05 - 1 
 3 2 0,98 0,14 - 21 
 4 2 0,5 0,08 - 7 
HDL2 1 2 0,23 0,17 26 - 
 2 2 0,36 0,10 32 - 
 3 2 0,30 0,08 19 - 
 4 2 0,56 0,08 31 - 
HDL3 1 2 0,16 0,09 28 - 
 2 2 0,72 0,17 109 - 
 3 2 0,47 0,14 84 - 
 4 2 0,75 0,09 97 - 
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Figure S1. TEM images of VLDL particles for patients A) 1 (magnification of 50k), B) 2 
(magnification of 40k), C) 3 (magnification of 200k), and D) 4 (magnification of 120k). 
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Figure S2. TEM images of IDL particles for patients A) 1 (magnification of 150k), B) 2 
(magnification of 80k), C) 3 (magnification of 100k), and D) 4 (magnification of 250k). 
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Figure S3. TEM images of LDL1 particles for patients A) 1 (magnification of 200k), B) 2 
(magnification of 200k), C) 3 (magnification of 120k), and D) 4 (magnification of 200k). 
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Figure S4. TEM images of LDL2 particles for patients A) 1 (magnification of 150k), B) 2 
(magnification of 100k), C) 3 (magnification of 250k), and D) 4 (magnification of 250k). 
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Figure S5. TEM images of HDL2 particles for patients A) 1 (magnification of 400k), B) 2 
(magnification of 150k), C) 3 (magnification of 150k), and D) 4 (magnification of 100k). 
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Figure S6. TEM images of HDL3 particles for patients A) 1 (magnification of 200k), B) 2 
(magnification of 250k), C) 3 (magnification of 80k), and D) 4 (magnification of 120k). 
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Figure S7. Lipoprotein particle size distributions. 
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Appendix 
 For each lipoprotein fraction, we obtained a weighed distribution of lipoprotein 
particles sizes using the experimental distributions N(RTEM) found by TEM: 
 
 
 

0
TEMTEM
TEMTEM
TEM
dRRN
dRRN
=RF
           (1) 
where RTEM are the lipoprotein sizes. Moreover, we obtained a diffusion coefficient for each 
lipoprotein particle: 
 
TEM
TEM
R
kT
RD
6

            (2)
 
 Then, we simulated the signal attenuation for each lipoprotein particle assuming 
that the NMR signal is proportional to the volume of a given lipoprotein particle and using 
the diffusion coefficient obtained previously: 
   TEMRDGTEMTEM eRRGI
'2223
,
            (3) 
where α is a proportionallity factor. Finally, integrating the signal attenuation of all 
lipoprotein particles within a given fraction taking into account its weighed size distribution 
we can obtain a simulated average signal attenuation: 
     


0
3 '222
, TEM
RDG
TEMTEMTEMav dReRRFRGI
TEM
       (4)
 
 Fitting this simulated average attenuation to Eq. 5 we obtained a corrected diffusion 
coefficient for each lipoprotein fraction. 
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3.2. “Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data 
for the characterization of human plasma lipoproteins” 
3.2.1. Abstract 
 Determining the concentration and size of lipoprotein complexes is very important 
due to their role in cardiovascular diseases and metabolic disorders. However, standard 
methods for lipoprotein fractionation are manual and time consuming and cannot be used 
as standard diagnostic tools. Because different subclasses of lipoproteins have different 
radii and, hence, different diffusion velocities, we propose a fast and reliable method that 
uses 2D diffusion-edited 1H NMR spectroscopy to acquire a set of 2D spectra of plasma 
samples, followed by a surface fitting algorithm based on Lorentzian functions to estimate 
the sizes and the relative proportions of different lipoprotein subclasses. We were able to 
demonstrate that the derived sizes and positions related to the Lorentzian functions follow 
an exponential relationship for normolipidaemic and dislipaemic samples with coefficients 
of determination (r2) of 0.85 and 0.81, respectively. Moreover, we found a linear 
relationship between the width and size of the Lorentzian functions for normolipidaemic 
samples (r2=0.88) while for dislipaemic samples this relation was nonlinear (r2=0.62). 
Dividing our samples set into four different lipoprotein profiles (normal lipid values, low 
HDL/LDL ratio, high triglycerides values and both risk factors) and using principal 
component analysis (PCA) followed by multivariate analysis of variance (MANOVA), our 
method was able to statistically discriminate between those groups, with p-values of 
0.0016, 0.0006, <1e-4 and 0.0035, respectively. These parameters are characteristic and 
indicative of different lipoprotein profiles and can be used to distinguish between 
normolipidaemic, hypercholesterolaemic, hypertriglyceridaemic and chylomicronaemic 
profiles. 
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3.2.2. Introduction 
 Cholesterol esters and triglycerides are packed within the liver into round 
macromolecules surrounded by a monolayer of phospholipids, free cholesterol and 
proteins that give rise to lipoprotein complexes. Lipoproteins are divided into five main 
classes depending on their size and density: chylomicrons (Q; radii 400–2500 Å), very low 
density lipoproteins (VLDL; radii 150–400 Å), intermediate density lipoproteins (IDL; radii 
125–175 Å), low density lipoproteins (LDL; radii 90–140 Å) and high density lipoproteins 
(HDL; radii 25–60 Å) [1]. Furthermore, these main classes can be divided into different 
subclasses to obtain a more detailed lipoprotein profile [2]. 
 The concentration of blood plasma lipids transported by lipoproteins is a widely 
used metric for cardiovascular disease (CVD) risk assessment [3-5]. In addition, recent 
studies have shown that CVD risk is also related to the size distribution of lipoprotein 
molecules [6, 7]. For instance, LDL particles are known as bad cholesterol, but small and 
dense LDL particles are considered more atherogenic than larger ones. Among HDL 
particles, the most buoyant are more protective than the smallest and most dense HDL 
particles. Chylomicrons are not usually taken into account in medical screening because 
they are not found in fasting samples and because the manipulation of chylomicron-rich 
samples is more difficult and their biochemical analysis is less reliable. However, it has been 
suggested that postprandial triglyceride concentrations are better at predicting the risk of 
CVD [8]. Thus, it is important to develop a fast and reliable method for measuring a 
complete lipoprotein profile, including lipid and lipoprotein concentrations and the size 
distributions of different lipoprotein subclasses, from both fasting and non-fasting subjects. 
 The main classes and subclasses of lipoproteins are usually characterised by density 
gradient ultracentrifugation [9], gel electrophoresis [10, 11] or precipitation [10]. These 
techniques are manual and time consuming and cannot be used as standard analyses for 
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clinical purposes. Their use has been summarised by the NIH in the USA [12-14]. In routine 
clinical analysis, where ultracentrifugation is impractical, the level of LDL cholesterol is 
estimated from HDL cholesterol measurements (measured after a precipitation process). 
The total cholesterol and triglycerides are estimated with the Friedewald formula [15]. This 
method may only be used when the total triglyceride concentration is less than 4.5 mmol/l. 
Recently, new techniques have been developed to allow the direct measurement of LDL 
cholesterol from plasma; however, these procedures are neither widely used nor clinically 
validated [16, 17]. 
 Alternatively, plasma lipoproteins can be measured by 1H NMR spectroscopy [18]. 
This methodology has been used for disease risk assessment and diagnostics [19]. The NMR 
spectra contain many peaks originating from both medium and low molecular weight 
metabolites, as well as broad signals coming mainly from cholesterol and triglycerides 
associated with lipoproteins [20]. The intense signals arising at 0.8 and 1.3 ppm correspond 
to the terminal methyl and methylene groups, respectively. These signals are frequently 
used for lipoprotein characterisation. Jeyarajah et al. used the methyl lipid signal for 
lipoprotein subclass quantification [21]. Currently, they can obtain the concentration and 
size of up to nine lipoprotein subclasses [22]. Their method involves the spectral 
deconvolution of the methyl signal, where a leastsquares curve-fitting algorithm is used to 
extract the individual lipoprotein signal amplitudes. This test has been commercialised by 
Liposcience Inc. (North Carolina, NC, USA) and distributed since 1997 under the commercial 
name of NMR Lipoprofile. To date, more than two million analyses have been performed 
using Liposcience technology. 
 Other studies have used statistical correlations between 1H NMR spectra and 
biochemical data by means of PLS regression models to quantify blood plasma lipids [23, 
24]. Suna et al. quantified eleven lipoprotein subclasses and used self-organising maps 
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(SOM) to classify lipoprotein profiles according to different clinical situations [25]. In 
addition, researchers have also used Bayesian methods to build robust models that 
correlate NMR spectra with cholesterol and triglycerides of the main lipoprotein classes 
[26]. 
 However, none of the aforementioned methods is capable of directly estimating 
lipoprotein size distributions. For this purpose, there has been increasing interest in 2D 
diffusion-edited 1H NMR spectroscopy for the analysis of plasma samples [27, 28]. Briefly, 
by applying a gradient strength iteratively, different NMR spectra are acquired while their 
intensities are attenuated. Changes in the NMR intensity of a given peak depend not only 
on the strength of the gradient applied, but also on the diffusion coefficient of the 
metabolite from which such resonance originates. Thus, using diffusion NMR experiments it 
is possible to obtain estimated diffusion coefficients of the lipoproteins within a plasma 
sample. Once the diffusion coefficients have been derived, they can be entered into the 
Stokes–Einstein equation to assess the hydrodynamic radius. 
 Several prior works have used diffusion experiments. Liu et al. measured one serum 
sample at 298 K to obtain six Lorentzian functions from the deconvolution of the methyl 
and methylene peaks [29]. Each function was associated with an average diffusion 
coefficient (or a mean lipoprotein size). The same group has shown that the use of 
diffusion-edited experiments improved their assessments of hepatotoxicity in rat blood 
serum compared to assessments derived from traditional 1H NMR spectra [30]. Dyrby et al. 
performed a diffusion-edited experiment on plasma samples at 318 K and applied three-
way chemometrics algorithms such as N-PLS and PARAFAC models to quantify lipoprotein 
subclasses in human plasma samples [31]. Additionally, Numares (Regensburg, Germany) 
described a method to quantify lipoprotein subclasses based on the line-shape fitting of the 
methyl and methylene peaks of 1H NMR spectra measured at different gradient strengths 
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and temperatures [32]. 
 In this study, a method for the deconvolution of the methyl peaks of plasma 
samples with different dislipaemias is presented. The areas and averaged diffusion 
coefficients from the deconvoluted functions obtained from our method are then used as 
input parameters for a multivariate comparison of the different lipoprotein profiles under 
study. Compared with 1H-NMR line-shape fitting methods [23-26], this approach is much 
more robust because the function parameters are adjusted using the spectra of n gradients 
[29, 31, 32]. Although Liu et al. proposed a similar approach to the one applied in this work, 
only one serum sample was used, and the potential benefits of the method were neither 
demonstrated nor exploited [29]. 
 
3.2.3. Materials and methods 
3.2.3.1. Plasma sample handling and analytical methods 
 In our study, we used two sample sets. 
 
3.2.3.1.1. Sample set No. 1 
 Blood samples (n=8) were obtained from patients attending the Lipid Unit of HUSJ 
(Hospital Universitari Sant Joan de Reus, Spain) because of lipid metabolism disturbances: 
normolipidaemia (n=3), hypercholesterolaemia (n=1), hypertriglyceridaemia (n=1) and 
hyperchylomicronaemia (n=3). Written informed consent was obtained from the 
volunteers. Table S1 in Section 3.2.7 details the analytical lipoprotein profile values 
obtained from patients in sample set No. 1. Samples were obtained after a 12-h overnight 
fasting period. Venous blood (20 ml) was withdrawn into EDTA tubes and centrifuged 
immediately for 15 min at 4 ºC and 1500xg to obtain plasma. From the plasma, total 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
3. Development and evaluation of a novel NMR-based advanced lipoprotein test 
184 
 
cholesterol, triglycerides, direct LDL and HDL cholesterol, Apo A1 and Apo B100 were 
determined by standard enzymatic and immunoturbidimetric assays adapted for the Cobas-
Mira-Plus autoanalyzer (SPINREACT S.A.U, Spain). 
 Seven lipoprotein fractions were isolated from the plasma by sequential 
preparative ultracentrifugation using density ranges of <0.95 g/ml for Q, 0.95–1.006 g/ml 
for VLDL, 1.006–1.019 g/ml for IDL, 1.019–1.044 g/ml for LDL1, 1.044–1.063 g/ml for LDL2, 
1.063–1.0125 g/ml for HDL2 and 1.125–1.210 g/ml for HDL3. The samples were 
ultracentrifuged in a Kontron ultracentrifuge T-1075 rotor TFT 45.6 at 4 ºC for 30 min at 
17,000 rpm to obtain Q; for 20 h at 40,000 rpm to obtain VLDL, IDL, LDL1 and LDL2 
sequentially; and 40 h at 40,000 rpm to isolate HDL2 and HDL3 [33]. The fractions were 
retrieved by aspiration and dialysed against PBS for 24 h to remove NaCl and NaBr excess. 
 The lipids and apolipoprotein contents in the lipoprotein fractions were also 
measured using enzymatic and immunoturbidimetric assays adapted for the Cobas-Mira-
Plus autoanalyzer (SPINREACT S.A.U, Spain). 
 
3.2.3.1.2. Sample set No. 2 
 Human blood (n=18) was obtained from healthy and mild-to-moderate 
hypercholesterolaemic volunteers, and the plasma was prepared as described above. 
Samples were kept at -80 ºC until NMR spectroscopic analysis was performed. 
 Total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), ApoA1, and 
ApoB100 were quantified using standard methods on an autoanalyzer (Beckman Coulter-
Synchron, Galway, Ireland). LDL cholesterol (LDL-C) was calculated using the Friedewald 
formula. 
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3.2.3.2. 2D diffusion-edited 1H NMR measurements 
 For the NMR measurement, 430 μl of serum or buffered isolated subclass was 
transferred to a 5-mm NMR tube. A double tube system was used. The external reference 
tube (O.D. 2 mm, supported by a Teflon adapter) containing the reference substance (9.9 
mmol/l sodium 3-trimethylsilyl[2,2,3,3-d4]propionate (TSP) and 0.47 mmol/l MnSO4 in 
99.9% D2O) was placed coaxially into the NMR sample tube (O.D. 5 mm). This double tube 
system was kept at 4 ºC in the sample changer until the moment of analysis. 
 1H NMR spectra were recorded at 310 K on a Bruker Avance III 600 spectrometer 
operating at a proton frequency of 600.20 MHz (14.1 T) equipped with a 10 A GREAT 1/10 
gradient amplifier unit (Bruker®) using a 5-mm CPTCI triple resonance (1H, 13C, 31P) pulse 
field gradient cryoprobe. Diffusion measurements were performed at 310 K to obtain a full 
signal from the melted lipids in the lipoproteins and to avoid serum degradation during the 
measurement. 
 One-dimensional reference 1H pulse experiments were carried out using the 
nuclear Overhauser effect spectroscopy (NOESY)-presaturation sequence (RD-90º-τ1-90º-
τm-90º ACQ) to suppress the residual water peak. The time τ1 was set to 4 μs, and the time 
τm (mixing time) was 100 ms. The 90º pulse length was calibrated for each sample and 
varied from 10.5 to 13.1 μs [34]. The result of the 90º pulse calibration of each sample was 
then used for the diffusion experiment. The spectral width was 30 ppm (18,000 Hz), and a 
total of 64 transients were collected into 64,000 data points for each spectrum. 
 The double stimulated echo (DSTE) pulse program (Figure 1), including bipolar 
gradient pulses and a longitudinal eddy current delay (LED), was used [35]. This pulse 
program is composed of a stimulated echo sequence with z-storage of the magnetisation, 
allowing for longer diffusion delays limited only by the longitudinal relaxation of the 
molecules. This requirement is compulsory if the pulse sequence is to be applied to 
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lipoproteins, where T1 >> T2. A double stimulated echo sequence efficiently compensates 
for flow convection currents that typically develop at elevated temperatures. Additionally, 
three orthogonal homospoil gradients are employed during the z-storage periods and 
during the repetition delay to shorten the phase cycle and eliminate accidental refocusing 
or unwanted magnetisation. 
 
Figure 1. 2D double stimulated echo experiment with bipolar gradients and longitudinal 
eddy-current delay. 
 
 To further minimise the occurrence of convection currents, the heating air flow rate 
was set to 670 l/h. A spectral window of 18,000 Hz was accumulated in an acquisition time 
of 1.82 s to compare the attenuation with the one-dimensional NOESY. 
 The relaxation delay was 2 s, the FIDs were collected into 64,000 complex data 
points, and 64 scans were acquired on each sample. The gradient pulse strength was 
increased from 5 to 95% of the maximum strength of 53.5 G cm-1 (0.535 T m-1) in 50 steps, 
where the squared gradient pulse strength was exponentially distributed. This distribution 
yields a concentration of experimental points around low-intensity gradients, where all 
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subclasses contribute to the spectra, and scattered measures in high intensity gradients, 
where the signals of small subclasses are attenuated [27]. A diffusion time of 104 ms and 
bipolar sine shaped gradient pulses of length 12 ms were applied to obtain a reasonable 
amount of diffusion of the lipoprotein signals in the raw serum. The total experiment time 
was 1 h 45 min per sample. 
 
3.2.3.3. Surface fitting 
 When a DSTE pulse sequence is applied, the NMR signal obtained can be described 
using the following equation according to the applied gradient G [27]: 
        
   
 
 
    
 
    
  
 
 
  
 
 
           (1) 
where γ is the 1H magnetogyric ratio, δ (6 ms) is the length of the gradient pulse, G is the 
gradient strength (Gauss cm-1), D is the diffusion coefficient (cm2 s-1), Δ (120 ms) is the 
effective diffusion time, τ (100 μs) is a short delay, 2/π is a gradient shape factor for the 
sine-bell-shaped gradient, and I and I0 are the NMR signal intensities in the presence and 
absence of the gradient pulses, respectively. 
 For fully resolved resonances, the calculated diffusion coefficient in a given 
chemical shift is directly related to a single molecule. However, the methyl envelope is a 
broad region in which the responses of the different lipoprotein subclasses overlap. In our 
model, we decomposed the methyl envelope peak by a sum of a series of Lorentzian 
functions: 
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where S0 is the methyl envelope intensity,     
 
 
   
 
   
  
 
 
  
 
 , n is the number of 
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Lorentzian functions used to fit the envelope, hi, si and σi are the height, shift and width of a 
Lorentzian function, respectively, and Di is the diffusion coefficient related to the ith 
Lorentzian function. Once the diffusion coefficients have been estimated, the Stokes–
Einstein equation can be applied to derive the radius associated with each function 
according to the following relationship: 
  
  
     
             (3) 
where k (J K-1) is the Boltzmann constant, T (K) is the temperature, η (Pa s) is the plasma 
viscosity and RH (Å) is the hydrodynamic radius. We have used a constant value of 1.1 mPa s 
as it has been reported that normal viscosity values in control individuals range from 1.10 
to 1.30 mPa s at 37 ºC [36]. 
 Eight Lorentzian functions (F1–F8) were chosen to fit the NMR spectra of blood 
plasma. Function F1 was used to fit the background within the region 0.7–1 ppm. Functions 
F2–F8 were used to fit the methyl region within the range 0.8–0.9 ppm. We chose to run 
the algorithm using a constrained approach in order to avoid obtaining multiple solutions 
across different runs. Thus, the lower and upper bounds for the function heights were set 
to 0 and to the maximum of the methyl signal of the corresponding sample, respectively. 
The lower and upper bounds for the widths were set between 25 and 50 Hz for function F1 
and between 3 and 10 Hz for functions F2–F8. The lower and upper bounds of the positions 
were set between 0.9 and 1 ppm for function F1. The region between 0.8 and 0.9 ppm was 
divided into seven intervals of equal width, and the limits of each interval were used as 
constraints to estimate the positions of functions F2–F8, placing each function in a different 
interval. Finally, the lower and upper bounds for the diffusion coefficients were set to 0 and 
to 15 cm2 s-1, respectively. The initial parameters taken for each surface fitting were 
randomly chosen between the constraints considered above, and spectra acquired at a 
gradient strength less than 13% of the maximum strength were discarded to avoid 
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interferences from low molecular weight metabolites. 
 To measure the goodness of the fit, we used the normalized root mean squared 
error (NRMSE) expressed as a percentage: 
         
              
  
 
 
 
   
                   
             (4) 
where Sexp and Sest are the experimental and estimated surfaces, respectively, n is the 
number of points considered in the interval length (0.7–1 ppm), and m is the number of 
gradients used. In our experiment, n and m have the same values for each sample and 
those are 300 data points and 34 gradients, respectively. 
 
3.2.3.4. Statistical analysis 
 Principal component analysis (PCA) was carried out to determine the relationships 
between the NMR-derived areas. In addition, we performed MANOVA between pairs to 
test the discriminatory power of the resulting PCA model, obtaining the statistical 
significance (p-value) of the clustering. All statistical analyses were computed in MATLAB, 
Ver. 7.9.0.529 (The MathWorks) using the PLS-Toolbox, Ver. 5.2.2 (Eigenvector Research). 
 
3.2.4. Results and discussion 
 The methyl region of a 2D diffusion-edited 1H NMR spectrum from Sample 7 is 
shown in Figure 2a. The optimal Lorentzian functions for the same sample are shown in 
Figure 2b, and the logarithm of the attenuation of the intensity of each function is plotted 
against the squared gradient strength in Figure 2c. From Equation 1 it can be derived that 
the slope of the logarithm of attenuation is related to the diffusion coefficient for a given 
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chemical shift. Table 1 lists the means and standard deviations of the intensities, widths, 
chemical shifts, diffusion coefficients and sizes of the eight plasma samples of sample set 
No. 1. The estimated sizes clearly fall within the lipoprotein size ranges found in the 
literature [18, 37]. The NRMSEs for each sample were: 0.71, 1.04, 0.74, 1.19, 1.08, 1.22, 
0.59 and 0.80%, respectively. Higher errors correspond to samples containing higher 
concentrations of either cholesterol or triglycerides. Function F1, which is associated with 
background lipoprotein responses, was excluded from further analysis. 
 An important issue was the number of functions used for the surface fitting. We 
have found that the minimum number that allows a good fitting for all the samples is eight, 
where the first one (F1) is used to fit the broad contributions from proteins (mainly albumin 
and albuminrelated compounds). If the number of functions is increased, the convergence 
time also increases, and more than one good solution appears. However, most of the 
additional solutions have no biophysical meaning (i.e., the sizes for components F2–F8 are 
not sorted). 
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Figure 2. a) Example of 2D diffusion-edited 1H NMR spectra (sample 7); b) optimal functions 
used to fit the surface; and c) representation of the logarithm of the intensity of each 
function against the square gradient strength (Gauss2 cm-2). 
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Table 1. Average and standard deviation values of position (ppm), width (Hz), intensity (x105 
a.u.), diff. coeff. (cm2 s-1), radius (Å) and rel. area (%) for functions F2 to F8. 
Function Position 
(ppm) 
Width 
(Hz) 
Intensity 
(a.u.) 
Diff. Coeff. 
(10-7 cm2 s-1) 
Radiusa 
(Å) 
Rel. Area 
(a.u.) 
F2 0.875 ± 0.002 12.5 ± 
0.2 
1.64 ± 1.59 0.8 ± 0.2 271 ± 64 43.7 ± 25.9 
F3 0.862 ± 0.001 8.6 ± 2.0 0.61 ± 0.29 1.2 ± 0.3 176 ± 44 14.6 ± 4.5 
F4 0.853 ± 0.002 8.1 ± 1.8 0.39 ± 0.13 1.9 ± 0.5 118 ± 32 10.5 ± 6.5 
F5 0.841 ± 0.002 9.3 ± 0.4 0.39 ± 0.14 3.7 ± 1.1 60 ± 18 11.7 ± 7.0 
F6 0.832 ± 0.001 8.3 ± 1.0 0.38 ± 0.12 4.4 ± 0.6 48 ± 6 9.6 ± 4.3 
F7 0.823 ± 0.002 7.2 ± 1.0 0.31 ± 0.07 5.1 ± 0.5 41 ± 4 7.3 ± 4.0 
F8 0.814 ± 0.002 5.8 ± 1.2 0.14 ± 0.03 6.8 ± 0.8 31 ± 4 2.7 ± 1.6 
aA viscosity value of η=1.10 mPa s was used to derive the estimated sizes related to each 
Lorentzian function according to the Einstein-Stokes equation. 
 
 Another important concern is related to the application of the Stokes–Einstein 
equation to plasma samples, which is used to derive the radius of the lipoproteins. The 
viscosity of the sample is needed to determine the radius value. Though normal values in 
control individuals range from 1.10 to 1.30 mPa s at 37 ºC, patients with chylomicrons, 
hypertriglyceridaemia or mixed hyperlipidaemia have been found to have mean plasma 
viscosities significantly higher than those of controls [38, 39]; thus, the actual radius 
depends on the specific sample and should be measured for every sample. On the other 
hand, the Stokes–Einstein equation is strictly valid for a spherical particle with a radius, RH, 
in a continuum solvent. It is often used to estimate the sizes of molecules in solution under 
dilute conditions [28]. These conditions are not satisfied in the case of plasma samples, and 
therefore, the calculated radius could require a further correction taking into account all 
these factors. Indeed, the viscosity parameter does not directly determine the diffusion 
coefficient in concentrated systems, where obstruction effects are important. All these 
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aspects have not been discussed in previous works related to diffusion NMR experiments 
and plasma [29, 31, 32]. For all the above reasons, the calculated radius values of 
lipoprotein subfractions should be taken as estimates. 
 In Figures 3A-B, we plot the dependence between the chemical shifts of functions 
F2–F8 and their derived sizes for normolipidaemic and dislipaemic samples, respectively. 
Our model shows that there is a decrease in particle size along the chemical shift axis for all 
the samples. This tendency can be modelled by the following equation: 
                      (5) 
where a=1.2 x 10-16 Å and b=-48.5 seg for normolipidaemic samples, a=6.3 x 10-17 Å and b = 
-49.4 seg for dislipaemic samples, and s represents a given chemical shift. The coefficient of 
determination for normolipidaemic and dislipidaemic samples is r2=0.85 and r2=0.81, 
respectively. In addition, there is evidence that functions with maxima at the same 
chemical shift can have different sizes, depending on the sample, suggesting that the size of 
an individual subclass depends not only on the position of the maximum but also on its 
width. Indeed, when analysing the relationship between the chemical shift and the width of 
a given function (Figures 3C-D), there is an almost linear dependence for normolipidaemic 
samples (r2=0.88), whereas for pathological samples, this relationship is non-linear 
(r2=0.62). 
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Figure 3. Radius (Å) and width (Hz) plotted against the chemical shift (ppm) related to the 
fitting functions (F2-F8) for sample set No. 1: a-c samples with normal lipid values and b-d 
samples with a dislipaemic status. 
 
 From our experimental data, we have shown that the radius associated with the 
Lorentzian functions decreases exponentially along the chemical shift axis. It is worth noting 
that the diffusion coefficients and the positions of the functions are not fixed before the 
fitting. This means that our method is able to find this relationship in an unsupervised way. 
These results are in good agreement with those of [21, 40, 41]. However, we have observed 
that functions related to dislipidaemic samples presented associated radii that were 
significantly different from the theoretical values. This is especially evident in the 
chylomicron-rich samples, where some functions have higher associated radii, which makes 
sense from a biological point of view. This finding reveals that the slower diffusion 
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coefficients associated with functions F2–F4 are indicative of the presence of chylomicrons 
in the sample. 
 On the other hand, we have observed that there is an almost linear increase in the 
widths of functions coming from normolipidaemic samples, whereas for dislipaemic 
samples this linear relationship no longer holds. This has been already investigated by other 
authors and they found that the averaged methyl lineshape is significantly narrower in 
cancer patients than in control patients [42, 43]. However, our method reveals that this 
behaviour is mostly due to the functions arising at higher chemical shifts (i.e. functions with 
larger associated radii). For chylomicron-rich samples, the widths of functions F2 and F3 are 
much lower than those of normolipidaemic samples. Thus, we have demonstrated that the 
chemical shifts of the functions are related not only to the average size of lipoproteins but 
also their widths. 
 In Figure 4, we present the relative contributions (%) of the areas associated with 
the functions for each sample of Sample set No. 1. Note the high differences between the 
different lipoprotein profiles (chylomicron-rich, hypertriglyceridaemic, 
hypercholesterolaemic and normolipidaemic samples). For instance, the radii associated 
with function F2 in samples 5 and 6 are indicative of the presence of chylomicrons, because 
of their very high values (>350 Å), which fit perfectly with large lipoproteins. 
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Figure 4. Relative areas (%) of functions F2-F8 for sample set No. 1. Samples are coloured 
according to their lipidaemic status. 
 
 Finally, we performed the same surface fitting procedure on sample set No. 2, and 
PCA of all 26 samples (sample sets Nos. 1 and 2), was carried out using the relative areas of 
functions F2–F8. Figure 5A shows the scores of PC1 versus PC2, representing 88% of the 
total variance. The samples were colour-coded according to the NCEP guidelines for CVD 
risk assessment for biochemistry values for every sample (Table 1), resulting in four 
different groups: normolipidaemia, low HDL/LDL ratio, high triglycerides and samples 
displaying both risk factors. Along PC1, which represents 71% of the total variation, samples 
tend to cluster according their triglyceride content. Thus, all triglyceride-rich samples 
present negative values for PC1, whereas normolipidaemia samples hold positive PC1 
values. PC2, explaining 17% of the variance, explains differences in the HDL/LDL ratios 
among the groups considered. The statistical reliability of the lipoprotein combination 
subset determined was established by MANOVA testing in a pair-wise comparison. The 
results are shown in Figure 5A as a network connecting the centroids of each cluster and 
the statistical significance of the discriminatory power of each pair of groups. Figures 5B-C 
show the loading plots for PC1 and PC2, respectively. From this figure it is clear that the 
separation along PC1 is mainly due to the relative area of function F2 (mean radii of 362 Å) 
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and functions F4–F8 (mean radius from 133 to 32 Å, respectively), which seem to be 
inversely correlated. On the other hand, the variable that contributes most to the 
separation along PC2 is the relative area of F3 (mean radius of 166 Å). Furthermore, 
functions F7 and F8 also contribute to that separation and are inversely correlated to F3. 
This result would suggest that the ratio HDL/LDL is mainly represented by large LDL 
particles and small HDL particles. Moreover, function F4 (mean radius of 133 Å) does not 
contribute to the discrimination of samples in terms of their HDL/LDL ratio. 
 
Figure 5. PCA of samples from sample sets No. 1 and No. 2 (n=26) plotted against with the 
areas of functions F2-F8. a) Score diagram showing the distribution of lipoprotein profiles; 
and b) loading diagram of PC1 and PC2, showing the most relevant variables involved in the 
above distribution. 
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 Using an unsupervised algorithm such as PCA fitted on the area under the curve of 
each of the seven functions considered, we observed that samples belonging to different 
classes of dislipaemias, and thus presenting different lipoprotein profiles, tend to cluster 
according to their dislipaemia group. For instance, we confirm the results of Kumpula et al. 
who used SOM analysis with complete lipid profiles to show that large LDL particles are 
associated with relatively high LDL cholesterol and that small dense LDL particles are 
related to low plasma LDL cholesterol concentrations [41, 44]. In addition, the fact that 
function F2 (mean radius of 362 Å) and functions F4–F8 (mean radius from 133 to 32 Å, 
respectively) are inversely correlated agree with what we know of the metabolic pathways 
of lipoprotein particles, as it is known that higher triglyceride concentrations are inversely 
correlated with HDL cholesterol [40]. In order to test the need for a feature extraction 
method based on the surface fitting of the methyl signal with a collection of Lorentzian 
functions, we performed a PCA using only one gradient increment where attenuation of 
low molecular weight metabolites has been achieved (Figure S1). In this case, the clustering 
is not as strong as before. From these results, it can be determined that the area of each of 
the functions fitted with the methodology presented might be further used in fingerprinting 
strategies as a complementary tool to diagnose dislipaemias. 
 One important issue addressed by our method was fixing the measurement 
temperature. Some authors reported a temperature of 298 K, where the core cholesterol 
ester of LDL particles is not completely fluidised, but the temperature convection effects 
produced by the gradients are minimised [29]. Nevertheless, we have chosen to measure 
the plasma at 310 K for two main reasons. First, this is the physiological temperature, and 
all the lipids in the lipoproteins are melted, resulting in a stronger signal [18, 19]. A second 
consideration was that there is some consensus using this measuring temperature as the 
standard for serum [19]. Jeyarajah et al. and Dyrby et al. used 318 K, well above the phase-
transition temperature, but we were concerned that some protein degradation processes 
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in the serum samples may be initiated at this temperature [21, 45]. We used a DSTE 
experiment to avoid convection currents that could arise at 310 K [31]. 
 In our approach, we fitted the surface of the methyl peaks of plasma samples of 2D 
diffusion-edited 1H NMR spectra using eight Lorentzian functions; each was characterised 
by an amplitude, width, chemical shift and diffusion coefficient (i.e., size). NMR-derived 
areas are associated with a lipoprotein fraction, with a concentration value given by the 
area of the function (related to the width and amplitude) and an average lipoprotein size, 
which is inversely related to the extracted diffusion coefficient through the Stokes–Einstein 
equation (Equation 3). 
 
3.2.5. Conclusions 
 In this study, we used 2D diffusion-edited 1H NMR experiments on plasma samples 
to characterise plasma profiles. A total of eight Lorentzian functions were used to fit the 
methyl peak at different gradient strengths. We demonstrate that the derived areas are 
useful in differentiating lipoprotein profiles. In agreement with previous studies [36], we 
have experimentally demonstrated that when the lipoprotein plasma profiles are 
normolipidaemic, there is a perfect exponential relationship between the radii of the 
lipoproteins derived from the diffusion coefficient of the function and the shift positions of 
the maxima of the Lorentzian functions used to fit the surface. For non-normolipidaemic 
plasma profiles, this relationship deviates from the ideal exponential behaviour. In contrast 
with the previous line-fitting approaches, our diffusion-based method is able to overcome 
the non-ideal behaviour of non-normolipidaemic samples and to give results in accordance 
with classical biochemical analysis. 
 Thus, the surface fitting of 2D diffusion-edited 1H NMR experiments provides a 
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robust way in which to characterise lipoproteins in plasma samples, yielding discrete size 
distributions for an arbitrary number of NMR-derived lipoprotein subclasses. 
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3.2.7. Supplemental material 
Table S1. Analytical values of patients from sample set No. 1. 
  Sample 
  1 2 3 4 5 6 7 8 
Cholesterol (mmol/l) Total 4.52 5.17 5.80 5.14 4.79 8.95 4.85 6.79 
 VLDL 0.31 0.95 0.15 2.14 1.48 2.86 0.15 0.39 
 IDL 0.19 0.19 0.13 0.60 0.21 0.65 0.16 0.21 
 LDL1 1.10 0.72 2.30 0.50 0.49 0.84 1.93 3.40 
 LDL2 0.51 1.77 0.49 0.14 0.89 1.54 0.36 1.17 
 HDL2 0.72 0.20 0.97 0.12 0.10 0.41 0.64 0.12 
 HDL3 0.76 0.58 0.45 0.99 0.44 0.57 0.64 0.67 
Triglycerides 
(mmol/l) 
Total 1.24 2.66 0.82 3.64 6.3 8.37 0.8 1.45 
 VLDL 0.60 1.94 0.31 2.30 3.46 4.76 0.30 0.81 
 IDL 0.06 0.14 0.08 0.15 0.18 0.26 0.06 0.08 
 LDL1 0.09 0.06 0.22 0.06 0.09 0.18 0.19 0.32 
 LDL2 0.01 0.06 0.02 0.00 0.05 0.15 0.01 0.04 
 HDL2 0.05 0.00 0.06 0.02 0.01 0.06 0.03 0.03 
 HDL3 0.08 0.07 0.13 0.07 0.12 0.16 0.06 0.07 
Apo B (mg/dl) LDL1 81 54 146 32 39 73 124 192 
 LDL2 58 167 50 8 106 186 36 118 
Apo A (mg/dl) HDL2 147 7 152 40 18 30 127 18 
 HDL3 186 176 163 194 162 182 170 180 
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Figure S1. PCA of the methyl signal using only a gradient strength where low molecular 
metabolites have been completely attenuated. 
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3.3. "Liposcale: a novel advanced lipoprotein test based on 2D 
diffusion-ordered 1H NMR spectroscopy" 
3.3.1. Abstract 
 Determination of lipoprotein particle size and particle number using advanced 
lipoprotein analyses is of particular interest since the LDL particle number has been shown 
to improve cardiovascular disease risk prediction. Advanced lipoprotein tests (ALT), 
however, are not yet routinely introduced in clinical practice partly due to the lack of 
standardization. Here we present the Liposcale test, a novel ALT based on 2D diffusion-
ordered 1H NMR spectroscopy. Our method uses diffusion coefficients to provide a direct 
measure of the mean particle sizes and particle numbers of the main lipoprotein classes and 
nine subclasses, namely large, medium and small VLDL, LDL and HDL. Using 177 plasma 
samples from healthy individuals and the concentration of apolipoprotein B and A from 
isolated lipoprotein fractions (as surrogates of particle numbers), we compared the 
accuracy of our NMR test to the Lipoprofile test commercialized by Liposcience. Our test 
showed a stronger correlation between the NMR-derived lipoprotein particle numbers and 
VLDL-ApoB, LDL-ApoB, and HDL-ApoA concentrations (r=0.87, r=0.91, and r=0.68, 
respectively) than the Lipoprofile test (r=0.78, r=0.75, and r=0.60, respectively). We also 
converted LDL particle numbers to ApoB equivalents (mg/dL) to allow a direct comparison 
with an established biochemical parameter. Our test yielded more accurate values of LDL-
ApoB than the Lipoprofile test (absolute mean bias of 1.7 and 7.4 mg/dL, respectively). 
Finally, a second cohort of 322 subjects, including type 2 diabetic patients with and without 
atherogenic dyslipidemia (AD) was characterized using the Liposcale test. Principal 
component analysis distinguished between both phenotypes (AUC=0.87) and showed 
concordant relationships between variables explaining AD. Altogether, our method provides 
reproducible and reliable characterization of lipoprotein classes and subclasses and it is 
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applicable to pathological states such as AD. 
 
3.3.2. Introduction 
 Abnormal levels of blood lipids such as high concentrations of LDL cholesterol (LDL-
C) and low concentrations of HDL cholesterol (HDL-C) increase the risk of cardiovascular 
disease (CVD), the first cause of death in developed countries [1]. Accordingly, the European 
Atherosclerosis and Cardiology Societies, and The National Cholesterol Education Program 
(NCEP) through their third report of the Adult Treatment Panel (ATP), established LDL-C and 
non-HDL-C as the primary and secondary target, respectively, of cholesterol-lowering 
therapy to reduce cardiovascular risk [2]. LDL-C lowering therapy has been shown to reduce 
the rate of cardiovascular events in patients with or without cardiometabolic risk (CMR) [3, 
4]. However, a large proportion of patients under treatment, as well as undiagnosed 
individuals, may suffer cardiovascular events despite showing normal LDL-C levels. 
Cardiovascular events are more likely to occur in patients with diabetes and metabolic 
syndrome. These pathologies share a common phenotype characterized by high content of 
triglycerides, a preponderance of small, -dense LDL particles, and low HDL levels. In 
individuals with this particular phenotype, LDL-C has been shown to be a poor predictor of 
cardiovascular risk, so standard lipid panels that measure the cholesterol or triglyceride 
content of lipoproteins seem to be insufficient to predict risk of CVD. To fill this gap, 
advanced lipoprotein tests (ALT) [5] that allow for an extensive characterization of 
lipoprotein particles through a range of additional parameters such as size and particle 
number have been proposed for improving assessment of risk of CVD and for guiding lipid-
lowering therapies [6]. 
 NMR spectroscopy is a technique that enables analysis of lipoprotein particles [5]. 
Briefly, depending on the size of the particle, the methyl moieties of the lipids in lipoprotein 
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particles resonate at slightly different frequencies, the smaller particles resonating at lower 
frequencies. Therefore lipoproteins can be quantified either by decomposing the methyl 
signal of the core lipids into individual signals [7, 8] or using statistical methods on the 
entire methyl envelope to estimate lipid concentrations [9]. Currently three methodologies 
use NMR to characterize lipoprotein particles. The method described by Jeyarajah et al. 
provides the size and particle number of the main lipoprotein classes (i.e., VLDL, LDL, and 
HDL) and the particle number of nine lipoprotein subclasses [7]. This method is built on a 
library of 1D NMR spectra from previously isolated lipoprotein fractions and on an 
algorithm that fits their NMR methyl signal with those of lipoproteins from serum or plasma 
samples. The particle sizes of the isolated lipoprotein fractions were determined by 
transmission electron microscopy and gradient gel electrophoresis. A second method 
described by Kaess et al. characterizes fifteen lipoprotein subclasses measuring the samples 
by magnetic field gradient intensities and temperatures [8]. The latter NMR methodology 
was reported by Ala-Korpela and colleagues [9], and it estimates lipid content, size and 
particle numbers of the main lipoprotein classes, as well as the particle number of fourteen 
lipoprotein subclasses based on regression models calibrated using the lipid content and 
size obtained by high performance liquid chromatography. 
 NMR-based ALTs have demonstrated that LDL and HDL particle numbers (LDL-P and 
HDL-P) are more powerful than classical cholesterol markers as indices of cardiovascular risk 
[10]. For instance, LDL-P better indicated atherosclerotic risk than LDL-C in individuals with 
discordant LDL-P and LDL-C levels [11]. This discordance is usually explained based on the 
large variability in the amount of cholesterol per LDL particle and to differences in LDL 
particle size. In another study, HDL-P, but not HDL-C, was inversely associated with carotid 
intima-media thickness after adjusting for covariates [12]. Moreover, the use of NMR-
derived lipoprotein subclasses improved risk stratification for subclinical atherosclerosis in 
comparison to conventional lipids [13]. Altogether, these and other evidences have 
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precipitated two significant events: 1) the 510(k) clearance from the U.S. Food and Drug 
Administration to market the Vantera(R) Clinical Analyzer commercialized by Liposcience, 
the first NMR-based diagnostic platform that determines LDL-P, and 2) the recommendation 
from the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices 
to include LDL-P in the guidelines used to manage CMR based on the evidences collected 
from twenty-five clinical studies [14]. 
 Despite these advances, there is still some controversy about the introduction of 
NMR-based ALTs into clinical practice partly due to the fact that current methods do not 
provide a direct measure of lipoprotein sizes. As an alternative to current NMR methods, 
here we present the Liposcale test, a novel method for characterizing lipoprotein particles 
based on 2D diffusion-ordered 1H NMR spectroscopy (DOSY). DOSY allows measuring the 
diffusion coefficients and directly calculating lipoprotein sizes through the Stokes-Einstein 
equation [15]. Noteworthy, a direct measure of lipoprotein sizes is of particular importance 
since they are used to compute lipoprotein particle numbers by dividing the spatial volume 
of the total lipid molecules by the mean volume (i.e. size) of the lipoprotein particles. Our 
rationale is that using DOSY to directly calculate lipoprotein sizes should yield more accurate 
measurements of lipoprotein particle numbers than current NMR-based ALT methods. To 
develop our new DOSY-based ALT we used a cohort of 177 healthy individuals and then we 
compared the lipoprotein particle numbers obtained using the Liposcale test with those 
obtained using the FDA-cleared ALT commercialized by Liposcience. Finally, we applied the 
Liposcale test to characterize a second cohort of 322 type 2 diabetic patients with and 
without atherogenic dyslipidemia. Our results demonstrate that our methodology can be 
applied to study samples with aberrant lipid and lipoprotein concentrations and can add 
insight into the understanding of metabolic diseases. 
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3.3.3. Materials and methods 
3.3.3.1. Study subjects 
 We used samples from the VITAGE project to develop the Liposcale test [16]. Briefly, 
177 healthy non-smoking men (0 cigarettes/day for >6 months) were enrolled in Clermont-
Ferrand (France) and Reus (Spain). Exclusion criteria were familial hypercholesterolemia, 
chronic diseases (including diabetes, cancer, cardiac insufficiency, inflammatory diseases, 
and unstable hypertension), or alcohol abuse. Mean age was 45.8 ± 15.5 years, including a 
minimum age of 19 years and a maximum age of 75 years. Fasting venous blood samples 
were collected in EDTA tubes and centrifuged immediately for 15 min at 4ºC at 1500 x g. 
Plasma samples were then kept at -80ºC until further analysis. The ethics committee of the 
two recruiting centers approved the study protocol, and written informed consent was 
obtained from all volunteers. 
 We used a second cohort to validate the results provided by the Liposcale test. 
Eligible participants were 322 type 2 diabetic men and women, ranging 30-80 years of age, 
with (n=100) or without (n=222) atherogenic dyslipidemia (AD). AD was defined as having 
triglyceride levels over 150 mg/dL and HDL-C levels under 40 mg/dL (men) or 50 mg/dL 
(women). Exclusion criteria were the presence of cardiovascular disease, chronic hepatic or 
renal alterations. Patients under lipid-lowering medication entered a wash-out period of 4 
weeks. Samples were kept at -80ºC until NMR analysis. The study protocol was also 
approved by the ethics committee of the participating institution. 
 
3.3.3.2. Lipid and lipoprotein measurements 
 Lipoproteins were separated by sequential preparative ultracentrifugation, using a 
Kontron 45.6 fixed-angle rotor in a Centrikon 75 (Kontron Instruments, Italy). The 
lipoprotein fractions isolated were VLDL (d<1.006 g/ml), IDL (d=1.006-1.019 g/ml), LDL 
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(d=1.019-1.063 g/ml), and HDL (d=1.063-1.21 g/ml). Their cholesterol and triglyceride 
content was quantified using standard enzymatic assays adapted to the Cobas-Mira-Plus 
autoanalyzer (SPINREACT S.A.U., Spain) [17]. The concentration of ApoB100 and ApoA1 in 
the ultra-centrifuged fractions were also quantified using an immunoturbidimetric assay 
adapted to the Cobas-Mira-Plus auto-analyzer (SPINREACT S.A.U., Spain). The assay and the 
value of the calibrator concentration were standardized against the Certified Reference 
Material ApoA1 WHO/IFCC SP1-01 and ApoB100 WHO/IFCC SP3-07. Plasma samples were 
also analyzed by Liposcience (Raleigh, USA) to obtain reference values of VLDL, LDL, and 
HDL sizes and particle numbers [7]. 
 
3.3.3.3. Advanced lipoprotein testing using DOSY 
 2D diffusion-ordered 1H NMR spectroscopy (DOSY): Plasma samples were analyzed 
by NMR spectroscopy using a modified existing protocol [18]. Briefly, 1H NMR spectra were 
recorded on a BrukerAvance III 600 spectrometer, operating at a proton frequency of 600.20 
MHz (14.1 T), at 310 K. We used the double stimulated echo (DSTE) pulse program with 
bipolar gradient pulses and a longitudinal eddy current delay (LED). The relaxation delay 
was 2 seconds, the finite impulse decays (FIDs) were collected into 64K complex data points 
and 32 scans were acquired on each sample. The gradient pulse strength was increased 
from 5 to 95% of the maximum strength of 53.5 Gauss cm-1 in 32 steps. The squared 
gradient pulse strength was linearly distributed. 
 Surface fitting: The methyl signal was surface fitted using a previously reported 
procedure [18]. The number of functions was increased to account for the nine lipoprotein 
subclasses. The uniqueness of the solutions was studied by fitting each sample ten times 
with randomly chosen initial values of the signal intensities. As a result, we obtained unique 
solutions for all samples after 10 runs. Normalized root mean squared errors (NRMSE) of 
the fittings were calculated as previously described [18]. The initial values of the signal 
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intensities were taken to be the mean solution values of all samples. 
 Prediction of lipid concentration: PLS regression models were calibrated to predict 
the cholesterol and triglyceride concentration of the main lipoprotein fractions (VLDL, LDL, 
and HDL). For the VLDL fraction, only the concentration of triglycerides was determined 
because cholesterol concentrations of VLDL particles were very low compared with the 
concentrations of triglycerides. Validation performance of the PLS models were assessed by 
venetian blinds cross-validation splitting the data 10 times. Coefficients of determination 
between the predicted and reference concentrations ranged from 0.79 to 0.98 in the 
calibration step. The coefficients of determination of the validation step ranged from 0.81 to 
0.98 and are in the range of other reported studies [19]. 
 Lipoprotein sizing and particle number determination: The NMR functions were 
associated with a given lipoprotein class (VLDL, LDL or HDL) according to their associated 
NMR size. The main lipoprotein fractions were defined as VLDL (38.6-81.9 nm), LDL (14.7-
26.6 nm) and HDL (6.0-10.9 nm). The mean particle size of every main fraction (VLDL, LDL, 
and HDL) was derived by averaging the NMR area of each fraction by its associated size. To 
obtain particle-weighted lipoprotein sizes, each NMR area was divided by their associated 
volume. Then a mean particle size was obtained for each lipoprotein class by multiplying 
the NMR lipoprotein particle sizes by their fractional particle concentration relative to the 
total particle concentration of a given class: 
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where Ai and    are the area (au) and radius (Å) of a given lipoprotein particle i. The particle 
numbers of each lipoprotein main fraction were calculated by dividing the lipid volume by 
the particle volume of a given class. The lipid volumes were determined by using common 
conversion factors to convert concentration units obtained from the PLS models into 
volume units [7]. The relative areas of the lipoprotein components used to decompose the 
2D spectra were used to derive the particle numbers of the nine lipoprotein subclasses. 
 
3.3.3.4. Spiking experiments 
 We performed spiking experiments to validate the grouping of the NMR functions. 
Serum samples were obtained from three volunteers. Lipoprotein fractions (VLDL, LDL and 
HDL) were obtained by sequential ultra-centrifugation as described above. Then, serum 
samples were spiked with the lipoprotein fractions from the same subjects one by one. A 
serum sample made up with buffer to equal volumes as the spiked samples was also 
analyzed. 
 
3.3.3.5. Analytical performance 
 The analytical performance of the Liposcale test involved blood samples from two 
volunteers. Briefly, fasting venous blood samples were collected in EDTA tubes and 
centrifuged immediately for 15 min at 4ºC at 1500 x g. Then, 5 aliquots were obtained for 
each subject and kept at -80ºC until the NMR analysis. The repeatability of the method was 
studied based on the analyses of the 5 aliquots of the two subjects in the same day, while 
the reproducibility was based on the analyses of the 5 aliquots of the two subjects through 
3 consecutive days. 
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3.3.3.6. Statistical analyses 
 The Bland-Altman plot was used to measure the agreement between both NMR 
techniques in assessing particle sizes and numbers [20]. This plot uses the differences 
between observations made by the two methods on the same subjects and it analyses the 
agreement between two methods in terms of bias and precision. When there is a 
relationship between difference and magnitude, the standard Bland-Altman analysis can be 
extended either with a logarithmic transformation approach or a more general regression 
approach. As a measure of agreement we calculated the percentage error (PE) between 
both techniques, as described previously [21]: 
         
       
                (2) 
We also defined a maximum PE by using the CV of the old method twice in Equation 2. 
 Spearman analysis was used to assess the relationship between continuous 
variables. All the analyses were performed with MATLAB version 7.10.0.499 R2010a 
(MathWorks). PLS and PCA models were built using PLS Toolbox (Eigenvector Research). 
 
3.3.4. Results 
3.3.4.1. Assignment of DOSY NMR functions to the main lipoprotein classes 
 The Liposcale test provides lipid concentrations (i.e., triglycerides and cholesterol), 
sizes and particle numbers for VLDL, LDL and HDL classes, as well as the particle numbers of 
nine subclasses, namely large, medium and small VLDL, LDL and HDL, respectively. Figure 1 
provides an overview of the Liposcale test showing the most important processes on which 
the characterization of lipoprotein classes is based. The use of the diffusion dimension 
represents the main difference between our approach and the NMR-based platform 
commercialized by Liposcience. The Liposcale test uses 2D spectra from DOSY experiments 
(Figure 1A) to decompose the lipoprotein peak from (CH3) proton resonances into nine 
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Lorentzian functions (i.e., F1 to F9) (Figure 1B). This approach largely prevents multiple 
solutions and, consequently, enhances robustness of the measurements. Indeed, we 
obtained an average NRMSE for the surface fittings of less than 1.5% (see Materials and 
Methods section for details), which indicates that our deconvolution is highly reproducible. 
According to the Einstein-Stokes equation, the larger the diffusion coefficient the smaller 
the size of a given lipoprotein particle it will be. Thus, we associated the nine NMR functions 
with the three main lipoprotein classes based on their described size ranges (Figure 1C) 
[22]: F1 to F3 (38.6-81.8 nm) were associated with the VLDL particles, functions F4 to F6 
(15.2-27.6 nm) with the LDL particles, and functions F7 to F9 (5.6-11.6 nm) with the HDL 
particles. These associations were validated using spike-in experiments. We isolated VLDL, 
LDL and HDL particles from serum samples of three volunteers by ultracentrifugation (see 
Materials and Methods section for details), and each isolated lipoprotein fraction was mixed 
one by one with the serum sample of the same individual. Figure 2 shows the average 
relative change of every lipoprotein class in serum, represented as the total NMR area 
corresponding to VLDL (i.e., F1 to F3), LDL (F4 to F6) and HDL (F7 to F9) particles by applying 
our surface-fitting algorithm. Our results indicate that only the area of the lipoprotein 
fraction that has been spiked-in shows a substantial increment, demonstrating that our 
NMR functions are correctly assigned to VLDL, LDL and HDL particles. 
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Figure 1. Overview of the Liposcale test. A) Experimental DOSY spectra. Seven gradients out 
of thirty-two total are shown for visualization purposes. The first gradient has been filled in 
black to show the NMR regions of the spectra that are used to calibrate and predict 
cholesterol and triglyceride concentrations using PLS regression. In red we show the 
attenuation of the methyl NMR signal along the gradient axis to show the region used to 
characterize the different lipoprotein subclasses. B) Surface fitting process for a given 
sample. The experimental attenuation of the methyl NMR signal (left) and the nine NMR 
functions used to fit the experimental surface (right). C) Using this methodology we can 
elucidate nine lipoprotein subclasses, namely large, medium, and small VLDL, LDL and HDL. 
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Figure 2. Spike-in experiments with isolated VLDL, LDL and HDL particles in serum samples. 
Mean relative changes in the total area under the NMR functions for each lipoprotein class 
(VLDL=F1+F2+F3, LDL=F4+F5+F6, and HDL=F7+F8+F9). Each color represents spiked serum 
samples either with isoalted VLDL, LDL, or HDL fractions. 
 
3.3.4.2. Correlation between lipoprotein particle numbers and apolipoprotein 
concentrations 
 Next, we explored the degree of correlation between the VLDL, LDL and HDL 
particle numbers calculated using the Liposcale and the LipoProfile tests, and the 
apoliproprotein content of each lipoprotein class, since the apolipoprotein concentrations in 
each class can serve as a surrogate of the number of particles. Figure 3A shows a strong 
positive linear relationship between the concentration of VLDL-ApoB determined using 
biochemical methods and the VLDL-P values determined using the Liposcale test (r=0.91) 
and the LipoProfile test (r=0.75). Similarly, the correlation coefficients between LDL-P 
determined via the Liposcale and LipoProfile tests and its respective apolipoprotein 
concentration were 0.86 and 0.78, respectively (Figure 3B). Finally, the correlation 
coefficients between HDL-P and HDL-ApoA were 0.68 for the Liposcale test and 0.60 for the 
LipoProfile test (Figure 3C). Thus, the Liposcale test showed a stronger correlation 
between lipoprotein particle number and apolipoprotein concentration than the FDA-
cleared NMR method that we took as the benchmark for the measurement of the number 
of particles in each lipoprotein class. 
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Figure 3. Regression analyses that examine the relationship among lipoprotein particle 
numbers using the Liposcale and LipoProfile tests, and the apolipoprotein concentrations 
of A) VLDL, B) LDL, and C) HDL particles. 
 
3.3.4.3. LDL particle size and number agreement between the Liposcale and the 
LipoProfile NMR tests 
 LDL-P is the most validated and clinically useful parameter that advanced 
lipoprotein tests can determine. In this regard, three consensus reports [3, 23, 24] have all 
recommended that apoB and/or measurements of LDL-P shall be incorporated into existing 
consensus guidelines for advanced cardiometabolic risk management. Thus, here we 
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measured the agreement between our 2D-NMR test (i.e., Liposcale) and the 1D-NMR test 
(i.e., LipoProfile) (see Figures 4A-B). From the VITAGE cohort, the mean LDL-size and LDL-P 
were 17.5 nm and 967.1 nmol/L using Liposcale, and 21.3 nm and 1133.1 nmol/L using 
LipoProfile, respectively. This results in an average LDL-size and LDL-P difference (i.e., bias) 
between both methods of 3.7 nm and 166 nmol/L, respectively. We further analyzed the 
agreement between both methods using the Bland-Altman plot. The plot is characterized by 
a proportional bias in the form of a negative linear relationship between the two methods 
resulting from fewer number of small LDL particles using the Liposcale test in comparison 
with the LipoProfile test. The logarithmic transformation of data did not correct this 
proportional error. Thus, to narrow down the limits of agreement the difference between 
the methods was regressed on the average of the two methods (Figure 4B). 
 The coefficient of variation (CV) of LDL size and LDL-P was 3.6% and 22.5% using the 
Liposcale test, and 3.4% and 32.3%, respectively, using the LipoProfile test. The percentage 
error (PE) obtained between both methods was 4.8% for LDL size, and 39.4% for LDL-P. In 
short, we consider that the agreement between both NMR tests is acceptable based on a PE 
below 5% for LDL-Size and 50% for LDL-P. 
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Figure 4. Bland-Altman analyses to measure the agreement between both NMR tests in 
assessing particle sizes and numbers. Comparison of A) LDL-size and B) LDL-P as assessed by 
the Liposcale and the LipoProfile tests. Comparison of LDL-ApoB concentrations measured 
from isolated LDL fractions using a classical biochemical method and the same 
concentration estimated using C) the Liposcale test and D) the LipoProfile test. 
 
 The concentration of ApoB-100 serves as a reference value of LDL particle number 
due to the fact that each LDL particle contains only one molecule of ApoB-100. In this 
regard, some authors have suggested that LDL particle numbers (nmol/L) should be 
converted to apolipoprotein B (ApoB) equivalents (mg/dL) to allow a direct comparison with 
an established biochemical parameter [14]. Thus, to investigate which NMR test yielded 
more accurate LDL-P values, we converted LDL particle concentration (nmol/L) into ApoB 
concentration (mg/dL) on the basis of a molecular weight for ApoB-100 of 550 kDa [14]. 
Once again, we assessed the agreement between the LDL-ApoB concentrations estimated 
by the Liposcale and LipoProfile tests, and the same concentration assayed biochemically 
from LDL fractions isolated by ultracentrifugation (see Materials and Methods for details) 
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using the Bland-Altman plot. The Bland-Altman analysis revealed a mean difference 
between the LDL-ApoB concentration estimated using the LipoProfile test and biochemical 
methods of 7.4 mg/dL, while for Liposcale this mean difference was -1.7 mg/dL (Figures 4C-
D). The CV of LDL-ApoB concentration biochemically assayed was 26.5%, yielding a 
maximum PE of 40%. LDL-ApoB concentration obtained using the Liposcale and the 
LipoProfile tests yielded a CV of 22.5% and 32.3%, respectively. Thus, the PE between the 
biochemical assay and Liposcale was 34.8%, and 41.8% when comparing with LipoProfile. 
 
3.3.4.4. Analytical Performance of the Liposcale test 
 Next we assessed the precision of the Liposcale test understood as the ability of the 
assay to consistently reproduce the same result when different sample aliquots are taken 
from the same specimen. The repeatability of the method, calculated from the analysis of 
five different aliquots from two different subjects within the same day (i.e., n=10), on the 
determination of cholesterol and triglyceride concentrations, and particle numbers for the 
LDL class and its small, medium and large subclasses, was ≤ 7%. The reproducibility on the 
same parameters, calculated from the same five aliquots ran on three consecutive days, was 
≤ 10% (see Tables S1-S2 in Section 3.3.7). Similarly, the repeatability and reproducibility for 
cholesterol and triglycerides concentration, and VLDL and HDL particle number, were ≤ 6%. 
Finally, both repeatability and reproducibility for the mean particle size for every lipoprotein 
class were ≤ 1%. Overall, the precision values of our 2D-NMR method are within the range 
of those reported by Liposcience Inc. for the LipoProfile test [7]. 
 
3.3.4.5. Characterization of atherogenic dyslipidemia in an independent cohort of 
diabetic patients 
 To demonstrate that the Liposcale test can be used to characterize and discriminate 
individuals with aberrant lipid and lipoprotein values, we implemented our 2D-NMR 
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method on a cohort study of 322 subjects that includes type 2 diabetic patients (T2DM) 
with (n=100) and without (n=222) atherogenic dyslipidemia (AD). A principal component 
analysis (PCA) using the input variables cholesterol and triglycerides concentrations, mean 
sizes and mean particle numbers of VLDL, LDL and HDL classes, and particle numbers of 
nine subclasses of lipoproteins, shows two separate clusters along PC1 (41.42% of the 
variance) corresponding to the two patient groups, that is, T2DM and T2DM with AD (Figure 
5A). In order to evaluate which are the main variables responsible for the separation of the 
T2DM patients with and without AD, the resulting loadings were visualized in a variables-
loading plot (Figure 5B). The plot reveals that the triad of AD, namely increased blood 
concentrations of small, dense LDL particles, decreased HDL particles, and increased 
triglycerides concentration, contributes to the separation of the two patient groups. 
Importantly, the loadings plot also shows that T2DM patients with AD have a smaller 
number of large and medium LDL and HDL particles relative to T2DM patients without AD. 
Moreover, patients with T2DM and AD have a greater number of total LDL and, in particular, 
of small LDL particles. Patients with AD also have greater number of small HDL particles but, 
on the contrary, it does not lead to an increase in total HDL particle numbers. 
 Considering the first principal component as the output of a putative classifier, we 
calculated the receiver-operating curve (ROC) in order to evaluate the classificatory power 
of our PCA model. As can be observed in the ROC curve depicted in Figure 6, our approach 
showed an area under the curve (AUC) of 0.87, showing an excellent classification 
performance to discriminate between T2DM patients with and without AD. All together, 
these results demonstrate that the Liposcale test is clinically useful to classify individuals 
showing an abnormal lipid and lipoprotein pattern that is typical of AD, which has emerged 
as an important risk factor for myocardial infarction and cardiovascular disease. 
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Figure 5. A) Scores plot and B) loadings plot for a PCA model built to discriminate between 
T2DM with and without AD. 
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Figure 6. ROC curve evaluating the discriminatory power of the PCA model. 
 
3.3.5. Discussion 
 The methyl moieties of the lipids in lipoprotein particles resonate at slightly 
different frequencies depending on the size of the particle, the smaller particles resonating 
at lower frequencies [25]. Though different lipoprotein subclasses may in theory be 
deconvoluted within the 1D-NMR spectrum according to their chemical shift positions, it 
has proven to be complicated in practice due to significant spectral overlap as different 
lipoprotein subclasses contribute to NMR resonance at the same frequency [18]. This is of 
great importance for LDL subclasses, which are particularly difficult to characterize due to 
the effect of neighboring lipoprotein classes (i.e., VLDL and HDL) [26, 27]. Provided that LDL-
P has been validated as a better CVD predictor than LDL-C when these measures are 
discordant, the addition of a second dimension in the NMR spectrum by means of a 
diffusion experiment (i.e., DOSY) helps to better characterize this lipoprotein class. DOSY 
allows the separation of the lipoprotein subclasses according to their diffusion coefficient, 
and with the use of the Stokes-Einstein equation, DOSY NMR yields an objective separation 
of lipoprotein subclasses based on their size and favors the uniqueness of mathematical 
solutions compared to 1D-NMR. 
 In this study we present a novel advanced lipoprotein test based on DOSY NMR 
spectroscopy called Liposcale, which has been compared to the established NMR method 
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developed and commercialized by Otvos et al. and Liposcience (i.e., LipoProfile) [7], 
respectively, which has become the only FDA-cleared blood test that directly quantifies LDL 
particles. Our study constitutes the first attempt to compare two 1H NMR methodologies, 
which is particularly important within the framework of standardized advanced lipoprotein 
tests [14, 28] if LDL particle number is intended to be used in cardiovascular risk 
management. 
 The agreement between the 2D-NMR (Liposcale) and 1D-NMR (LipoProfile) 
methods for measuring LDL-P revealed a linear dependency between the difference and the 
magnitude of the measurements. However, the LDL-ApoB values obtained using our 2D-
NMR method were more in conformity with biochemical values than those obtained using 
the FDA-cleared test. This disagreement between the two NMR methodologies may come 
partly from the small bias between the lipoprotein sizes determined by the two methods, 
through which our 2D-NMR method estimates smaller LDL particle sizes in comparison with 
the 1D-NMR method. This might be a consequence of the method used to derive the 
particle concentrations. While the LipoProfile test computes mass-weighted particle 
numbers, our method computes particle-weighted particle numbers. From our point of 
view, the particle-weighted approach is more realistic since the concentration of small 
particles exceed the concentration of larger ones. A previous study also reported a linear 
dependence between the difference and magnitude of LDL-size measured by Liposcience 
and gradient gel electrophoresis (GGE) [29]. On the other hand, no method-comparison 
study has evaluated different LDL-P assays. As well as the Liposcience test, ion mobility (IM) 
analysis has been shown to be an alternative method for directly measuring LDL-P [30]. 
However, concerns have been raised about its lack of accuracy [31]. 
 Concerning HDL particles, our 2D-NMR method showed a better correlation 
between HDL-P and HDL-ApoAI concentration relative to the LipoProfile test. Even so, 
regardless of which NMR method is used, the correlation between HDL-P and HDL-ApoAI is 
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not as good as when correlating LDL-P and the ApoB content. This could be partially 
explained by the lack of a direct relationship between HDL particles and ApoAI molecules. 
Unlike in LDL where each particle contains one molecule of ApoB, HDL particles contain 
between 2 and 4 molecules of ApoAI. A recent study has shown that the values of HDL-P 
estimated using an updated version of the Shen model, that relates the HDL-size and the 
ratio of HDL-C to ApoA-I concentration, are approximately 50%-60% lower than the HDL-P 
measurements obtained using the established NMR technique commercialized by 
Liposcience [32]. As can be seen in Figure 3C, the Liposcale test estimated HDL-P values that 
are lower than the ones estimated by the LipoProfile test and consequently are more 
concordant with the number of HDL particles estimated by the modified Shen model [32]. 
 
3.3.6. Conclusions 
 We evaluated a new methodology for quantifying lipoprotein subclasses based on 
2D diffusion-ordered 1H NMR spectroscopy (DOSY), which directly measures the sizes of 
lipoprotein particles. This methodology can provide the lipid concentration, lipoprotein size 
and lipoprotein particle numbers of the main fractions and subclasses. We found very 
similar correlations between our test and a reference NMR technique, although our derived 
particle numbers measured yielded higher correlations with external validations such as the 
concentration of VLDL-ApoB, LDL-ApoB, and HDL-ApoA. Moreover, the characterization of 
AD on type 2 diabetic patients further demonstrated the applicability of our methodology in 
a population with pathological states. 
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3.3.7. Supplemental material 
Table S1. Intra-assay precision. 
  Subject 1 Subject 2 
  Mean SD CV (%) Mean SD CV (%) 
Lipids (mg/dL) VLDL-TG 23,7 0,7 3,0 18,1 0,5 3,0 
 LDL-C 52,1 3,4 6,5 72,5 5,2 7,1 
 LDL-TG 15,0 0,5 3,1 11,4 0,1 0,9 
 HDL-C 67,8 1,2 1,8 49,3 0,8 1,7 
 HDL-TG 10,8 0,2 1,6 6,3 0,1 1,1 
Particle Number* VLDL-P 17,6 0,6 3,4 13,3 0,5 3,4 
 Large VLDL-P 0,3 0,0 10,0 0,2 0,0 10,6 
 Medium VLDL-P 1,5 0,1 4,3 1,4 0,1 6,0 
 Small VLDL-P 15,8 0,6 3,9 11,7 0,5 3,9 
 LDL-P 539,6 29,3 5,4 669,4 41,9 6,3 
 Large LDL-P 40,6 2,4 5,9 59,5 4,4 7,3 
 Medium LDL-P 147,5 7,6 5,2 179,6 8,9 4,9 
 Small LDL-P 351,4 22,2 6,3 430,4 29,8 6,9 
 HDL-P 32,6 0,7 2,3 27,9 0,7 2,5 
 Large HDL-P 2,6 0,1 2,9 1,1 0,1 9,1 
 Medium HDL-P 12,1 0,3 2,6 6,2 0,5 8,0 
 Small HDL-P 18,0 0,9 4,8 20,6 1,2 5,9 
Size (nm) VLDL 39,0 0,1 0,3 39,1 0,1 0,3 
 LDL 19,8 0,0 0,1 19,8 0,0 0,1 
 HDL 8,2 0,0 0,3 8,0 0,0 0,4 
*VLDL/LDL: nmol/L; HDL: µmol/L 
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Table S2. Day-to-day precision based on the analyses of 5 aliquots of two different subjects 
for 3 days. 
  Subject 1 Subject 2 
  Mean SD CV (%) Mean SD CV (%) 
Lipids (mg/dL) VLDL-TG 24,2 1,3 5,5 18,2 0,7 3,7 
 LDL-C 53,8 4,2 7,7 70,3 8,2 11,6 
 LDL-TG 15,0 0,5 3,6 11,4 0,5 4,3 
 HDL-C 67,8 1,1 1,7 49,5 0,9 1,9 
 HDL-TG 10,8 0,2 1,5 6,4 0,1 1,5 
Particle Number* VLDL-P 17,9 0,7 4,2 13,4 0,5 3,6 
 Large VLDL-P 0,3 0,0 8,9 0,2 0,0 23,4 
 Medium VLDL-P 1,5 0,3 16,9 1,4 0,2 11,7 
 Small VLDL-P 16,0 0,5 3,4 11,9 0,5 4,4 
 LDL-P 552,3 35,0 6,3 654,0 67,2 10,3 
 Large LDL-P 42,2 4,6 11,0 57,3 7,7 13,4 
 Medium LDL-P 152,0 11,4 7,5 169,7 20,2 11,9 
 Small LDL-P 358,2 26,0 7,3 426,9 43,1 10,1 
 HDL-P 31,8 1,7 5,3 28,2 1,3 4,7 
 Large HDL-P 2,7 0,2 7,3 1,1 0,1 10,8 
 Medium HDL-P 12,4 0,8 6,4 6,1 0,7 11,1 
 Small HDL-P 16,8 2,5 15,1 20,9 2,1 9,8 
Size (nm) VLDL 39,0 0,2 0,5 39,0 0,3 0,7 
 LDL 19,8 0,0 0,2 19,8 0,0 0,2 
 HDL 8,3 0,1 0,9 8,0 0,1 0,7 
*VLDL/LDL: nmol/L; HDL: µmol/L 
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4.1. NMR measurements of serum/plasma samples to characterize 
lipoprotein particles 
 Nuclear magnetic resonance (NMR) spectroscopy enables us to obtain a 
comprehensive analytical profile including the most abundant chemical components such 
as lipoproteins, aminoacids, organic acids, carbohydrates and albumin found in biological 
samples [1, 2]. In this thesis, we focused on the analysis of lipoprotein particles either in 
serum or plasma since detailed characterization of these macromolecular complexes can be 
obtained quickly without the need to apply complex sample preparation procedures. In 
fact, the most important reason for the use of NMR in the analysis of lipoproteins is to 
avoid the tedious physical isolation of the different lipoprotein fractions and subfractions 
from serum or plasma. In addition, another important advantage of using NMR 
spectroscopy to study plasma and serum is that measurements can often be made with 
minimal sample preparation, usually with only the addition of 5–10% D2O for locking and a 
suitable standard in the sample or in an inner capillary for referencing or quantification 
purposes. Finally, measurements between different labs are comparable. Indeed, the 
coefficient of variation associated with inter- and intra-laboratory NMR experiments is 
typically very low and biological differences between individuals are far greater than the 
variations induced by experimental factors [3]. 
 Nevertheless, the results obtained when analyzing lipoprotein particles by NMR will 
be rendered worthless if samples are not collected, stored, and prepared correctly. For this 
reason, protocols for handling biofluids, such as plasma and serum, have recently been 
proposed [4]. In this regard, Section 2.3.2 offers an overview of the different handling and 
conservation aspects that must be taken into account when dealing with serum or plasma 
samples for the analysis of lipoprotein particles by NMR. Whenever possible, the analyst 
UNIVERSITAT ROVIRA I VIRGILI 
DEVELOPMENT AND EVALUATION OF A NOVEL ADVANCED LIPOPROTEIN TEST  BASED ON 2D DIFFUSION-ORDERED 1H NMR SPECTROSCOPY 
Roger Mallol Parera 
Dipòsit Legal: T 975-2015 
4. Discussion 
238 
 
should be involved throughout the design and decision-taking-process of all protocols, from 
the experimental design and sample collection to final data results. This involvement is 
becoming more and more important in serum and plasma analysis, since it can lead to good 
inter-laboratory reproducibility. 
 Once serum or plasma samples are ready to be analyzed, the choice of the NMR 
pulse sequence to be used in order to obtain the desired information is decisive. Thus, 
Sections 2.3.3 and 2.3.4 describe a series of NMR pulses that can be applied to serum and 
plasma samples depending on the sort of molecules under investigation. Because our 
interest is the study of lipoprotein particles, this thesis is focused on the use of pulsed field 
gradient experiments. In fact, the single pulse spectrum of human serum or plasma samples 
is very complex. The highly overlapped resonances from metabolites, proteins, lipids and 
lipoproteins in the narrow chemical shift range of 1–13 ppm make it very difficult to 
successfully identify components even at a high magnetic fields [1]. Briefly, the resonance 
frequency of NMR signals of lipoprotein particles depends on their size and composition, 
but the neighbouring NMR signals of each class differ only slightly in chemical shift, thus 
limiting the reproducibility and accuracy of lipoprotein quantification in blood plasma by 
NMR line-shape fitting approaches. Therefore, to overcome the problem of extensive 
lipoprotein signal overlap in the analysis of NMR spectra of serum or plasma, another 
physical and independent measurement, such as diffusivity, could be desirable in addition 
to the chemical shift information. In this regard, different pulse sequences can be used so 
that results can be more accurate and reliable. A wide variety of useful spectroscopic 
techniques can be used to edit the NMR-detectable metabolite information in body fluids. 
In the case of lipoprotein particles, a diffusion-edited NMR spectrum enhances the NMR 
signal of lipoproteins and removes the signal of small metabolites. 
 Once the proper NMR pulse sequence has been selected, one have to configure a 
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set of acquisition parameters to obtain high quality raw data. The most crucial parameters 
to bear in when using diffusion experiments are the number of gradients used, their spatial 
distribution, the number of scans, and the temperature acquisition. In order to let the low 
molecular weight metabolites diffuse so only the signals from lipoprotein particles remain, 
one have to select a minimum gradient strength at which all the signals from low molecular 
weight metabolites are suppressed. Liu et al. used gradient values of 30% to 95% of the 
maximum gradient strength [5]. In the case of Dyrby et al., they used gradient strength 
values of 5% to 95% of the maximum strength, although they discarded the first gradients in 
further analyses since signals from low molecular weight metabolites are still visible at 
percentage of gradient strength below 25% [6]. Regarding the number of gradients and 
scans used, in the first case they used 64 gradients and 64 scans, while in the second case 
they used 24 gradients an 256 scans. 
 Another important issue addressed by our method was fixing the measurement 
temperature. Some authors reported NMR measurements below physiological temperature 
(298 K [5] or 303 K [7]), where the core cholesterol ester of LDL particles is not completely 
fluidised, minimizing its NMR visibility [8] but the temperature convection effects produced 
by the gradients are minimised. On the other hand, Jeyarajah et al. [9] and Dyrby et al. [6] 
used 318 K, well above the phase-transition temperature. In the case of the NMR 
LipoProfile® test, plasma samples are heated to 318 K to facilitate the deconvolution of 
highly overlapped lipoprotein subclass signals [9, 10]. However, we were concerned that 
some protein degradation processes in the serum samples may be initiated at this 
temperature. The method described by Kaess et al. characterizes fifteen lipoprotein 
subclasses [11]. The serum/plasma samples are measured at different temperatures 
(typically 278 K, 298 K, 308 K and 318 K). As the temperature rises, the relaxation times T1 
and T2 increase and the lineshape narrows. These measuring conditions, combined with 
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three diffusion weighted NMR measurements carried out with a modified STE–LED 
(stimulated echo and longitudinal eddy-current delay) pulse sequence, produce a range of 
different spectra, which depend on the attenuation of the lipoprotein fractions under each 
of the measuring conditions. In our case, we have chosen to measure the plasma at 310 K 
for two main reasons. First, this is the physiological temperature, and all the lipids in the 
lipoproteins are melted, resulting in a stronger signal [12, 13]. A second consideration was 
that there is some consensus using this measuring temperature as the standard for serum 
[13]. The use of the DSTE experiment avoids convection currents that could arise at 310 K 
[6]. 
 
4.2. Data processing and analysis of raw NMR spectra 
 After the acquisition of the NMR spectra, they have to be processed in a manner 
that important biological and clinical information is obtained. For this purpose, we have 
developed the Liposcale test composed by a set of mathematical and computational steps 
that yield a comprehensive profile of lipoprotein particles. These computational steps 
involve using the NMR spectra in different ways so different characteristics of the 
lipoprotein particles are obtained in one shot. Section 2.4 describes the most important 
methods to process NMR data to characterize lipoprotein particles. In general, NMR-derived 
lipoprotein information can be obtained either by decomposing the methyl signal of the 
core lipids into individual signals [5, 9, 11, 14] or using statistical methods on the entire 
methyl envelope to estimate lipid concentrations [2, 7, 15]. Moreover, the mathematical 
and computational treatment of the raw NMR data will depend on its dimensionality nature 
(1D or 2D) [5, 6, 9, 11, 16]. Finally, the resulting NMR-derived information will vary 
depending on the calibration data used and the degree of data processing that is 
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performed. Briefly, the different NMR methodologies yield very different profiles, which can 
be composed by lipid parameters, particle size, particle numbers and/or raw NMR areas. 
Overall, NMR has proven to be a straightforward and useful technique for the qualitative 
and quantitative measurement of lipoproteins, giving the cholesterol and triglyceride 
concentration [7], as well as the particle number of different subclasses and their size [9]. 
This is a great achievement because even though the behaviour of the different lipoprotein 
subclasses is modulated by their size, the overlap between them in the spectra is severe, 
and sophisticated deconvolution algorithms are required for data analysis [9]. 
 Section 3.2 describes the first attempt to characterize lipoprotein particles directly 
from plasma using DOSY. Briefly, we applied a mathematical deconvolution algorithm to 
decompose the DOSY spectra of 26 plasma samples into eight Lorentzian functions. We 
further used the obtained NMR areas to demonstrate that the extracted areas could 
separate the different lipoprotein profiles (normal, high triglycerides, low HDL/LDL ratio, 
and both risk factors) in a principal component analysis (PCA) score plot much better than 
the original spectra [17]. The results of this study also showed that the relationship 
between the shift position of the Lorentzian functions and the lipoprotein radii calculated 
from the experimental diffusion coefficient agrees with results found by other authors [18], 
particularly in normolipidemic samples. An important issue in this first attempt was fixing 
the number of functions used for the surface fitting. We have found that the minimum 
number that allows a good fitting for all the samples is eight, where the first one (F1) is 
used to fit the broad contributions from proteins (mainly albumin and albumin related 
compounds). If the number of functions is increased, the convergence time also increases, 
and more than one good solution appears. However, most of the additional solutions have 
no biophysical meaning (e.g., the sizes for components F2–F8 are not sorted). 
 Then, Section 3.3 describes the Liposcale test, the second version of our algorithm 
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to characterize lipoprotein particles directly from either serum or plasma samples. The 
Liposcale test provides lipid concentrations (i.e., triglycerides and cholesterol), sizes and 
particle numbers for VLDL, LDL and HDL classes, as well as the particle numbers of nine 
subclasses, namely large, medium and small VLDL, LDL and HDL, respectively. The number 
of particles in each lipoprotein class (VLDL, LDL, and HDL) were calculated by dividing the 
volume occupied by cholesterol and triglycerides (after a conversion of concentration units 
into volume units), by the volume of the mean particle size obtained by NMR for every class 
(see Materials and Methods for details). The concentration of cholesterol and triglycerides 
in VLDL, LDL, and HDL classes were obtained by calibrating a partial least squares (PLS) 
regression model. The rationale for calibrating the PLS models was to use them to further 
predict the cholesterol and triglycerides concentrations on the second cohort. The mean 
particle sizes were derived by averaging the NMR area of each fraction by its associated size. 
In this version, we used nine Lorentzian functions to decompose the lipoprotein peak from 
(CH3) proton resonances of the DOSY experiments (i.e., F1 to F9). We assigned a fixed 
diffusion coefficient value, and a fixed amplitude and chemical shift to each function on the 
basis of their mean values obtained from a previous deconvolution step with all the 
parameters free, avoiding multiple solutions and, consequently, enhancing robustness of 
the measurements. 
 We then compared the Liposcale test with the LipoProfile®, the established NMR 
method developed and commercialized by Otvos et al. and Liposcience (i.e., LipoProfile®) 
[9], respectively. The LipoPorfile test has become the only FDA-cleared blood test that 
directly quantifies LDL particles. Our study constitutes the first attempt to compare two 
NMR methodologies, which is particularly important within the framework of standardized 
advanced lipoprotein tests [19, 20] if LDL particle number is intended to be used in 
cardiovascular risk management. In fact, the reliable application of risk cutpoints and 
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treatment goals, which are based on data derived from epidemiologic trials, requires 
precise and accurate analytical measurements to be medically useful. The accuracy and 
precision of a method is established by standardization, a process involving a reference 
system of primary and secondary measurement procedures and reference materials, which 
assures that reported results for an analyte will agree with other laboratories over time, 
independent of methodology. At this time, no performance goals have been established by 
the NCEP or any other expert panel for LDL-P. However, standardization is not a prerequisite 
for the establishment of an association of a biomarker with a clinical outcome within any 
single laboratory and study, but it is critical for comparison between laboratories and 
studies or if data from several laboratories will be pooled for the establishment of disease 
risk assessments or treatment cutpoints. In this regard, LDL-P could conceivably conformed 
to the apo B Lipid Standardization Program (LSP) by adding the VLDL particle number to the 
LDL-P and converting nanomoles per liter (nmol/L) to mass units (mg/dL) based on the 
molecular weight of apo B (550.000 Da). 
The agreement between the 2D-NMR (Liposcale) and 1D-NMR (LipoProfile®) 
methods for measuring the two LDL-P revealed a linear dependency between the difference 
and the magnitude of the measurements. However, the LDL-ApoB values obtained using our 
2D-NMR method were more in conformity with biochemical values than those obtained 
using the LipoProfile test. This disagreement between the two NMR methodologies may 
come partly from the small bias between the lipoprotein sizes determined by the two 
methods, through which our 2D-NMR method estimates larger and smaller LDL particle 
sizes in comparison with the 1D-NMR method. This is a consequence of the wider dynamic 
range of lipoprotein sizes that allows DOSY spectra and the surface-fitting algorithm of the 
Liposcale test. Similarly, our 2D-NMR method showed a better correlation between HDL-P 
and HDL-ApoAI concentration relative to the LipoProfile test. Even so, regardless of which 
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NMR method is used, the correlation between HDL-P and HDL-ApoAI is not as good as when 
correlating other lipoprotein classes and the ApoB content. This could be largely due to the 
lack of a direct relationship between HDL particles and ApoAI molecules, unlike LDL 
particles and ApoB. In this case, each HDL particle contains between 2 and 4 molecules of 
ApoAI. Finally, the precision values of our 2D-NMR method are within the range of those 
reported by Liposcience Inc. for the LipoProfile test. 
 An important concern is related to the application of the Stokes–Einstein equation 
to serum or plasma samples, which is used to derive the radius of the lipoproteins. The 
viscosity of the sample is needed to determine the radii of the lipoprotein particles. Though 
normal values in control individuals range from 1.10 to 1.30 mPa s at 37ºC, patients with 
chylomicrons, hypertriglyceridaemia or mixed hyperlipidaemia have been found to have 
mean plasma viscosities significantly higher than those of controls [21, 22]. Thus, the radius 
depends on the specific sample and should be measured for every sample. On the other 
hand, the Stokes–Einstein equation is strictly valid for a spherical particle with a radius, RH, 
in a continuum solvent (infinite dilution conditions). It is often used to estimate the sizes of 
molecules in solution under dilute conditions [23]. These conditions are not satisfied in the 
case of serum or plasma samples, and therefore, the calculated radius could require a 
further correction taking into account all these factors. Indeed, the viscosity parameter 
does not directly determine the diffusion coefficient in concentrated systems, where 
obstruction effects are important. Section 3.1 describes a method for measuring 
lipoprotein sizes from isolated lipoprotein fractions. In this case, the viscosity values for 
each fraction were measured experimentally. Although the experimental viscosity 
measured for this study, under stress conditions, did not necessarily correspond to the 
effective viscosity experienced by diffusing particle, the improvement in the correlation 
between NMR and TEM radii when the experimental viscosity was used suggested that this 
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does provide an effective correction for the presence of solutes, including the lipoproteins. 
Another correction would imply the dilution of the samples being analyzed. However, 
because the inherent limitation of NMR is its low sensitivity, the dilution of the samples to 
avoid the obstruction effects commented above would lead to a decrease in signal to noise 
ratio and thus to noisier and poorer spectra. To compensate for this effect, one could 
increase the number of scans in each acquisition, but the acquisition time would become 
compromised. 
 
4.3. Clinical utility of NMR-based advanced lipoprotein tests 
 Finally, the main application of NMR spectroscopy in the study of the metabolism of 
diabetes is the quantification of lipoprotein subclasses. This analytical technique has made 
it possible to relate different lipoprotein parameters and diabetes, and also other risk 
factors, in a univariate fashion (see Section 2.5). In case-control studies, the common 
conclusion was that VLDL size increased and LDL size decreased in diabetic patients. Most 
of the studies agree that HDL size appears to decrease in diabetic patients. On the other 
hand, there is general agreement that there is an increase in the values of total, large and 
small VLDLs, and total, medium and small LDLs. There is also general agreement that the 
values of large LDL and total HDL are lower in diabetic patients. A more recent application 
has focused on the classification and characterization of diabetic states in order to highlight 
patho-physiological mechanisms and come to a holistic understanding of the disease. 
 In this thesis, we have combined both approaches by developing a novel NMR-
based advanced lipoprotein test to characterize lipoprotein subclasses and then we have 
applied clustering methods to distinguish between different pathological states. Section 
3.3.4.5 demonstrates that the Liposcale test can be used to characterize and discriminate 
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individuals with aberrant lipid and lipoprotein values. For this purpose, we implemented our 
2D-NMR method on a cohort study of 322 subjects that includes type 2 diabetic patients 
(T2DM) with and without atherogenic dyslipidemia (AD). A PCA using the input variables 
cholesterol and triglycerides concentrations, mean sizes and mean particle numbers of 
VLDL, LDL and HDL classes, and particle numbers of nine subclasses of lipoproteins, showed 
two separate clusters corresponding to the two patient groups, that is, T2DM and T2DM 
with AD. In order to evaluate which were the main variables responsible for the separation 
of the T2DM patients with and without AD, the resulting loadings were visualized in a 
variables-loading plot. The plot revealed that the triad of AD, namely increased blood 
concentrations of small, dense LDL particles, decreased HDL particles, and increased 
triglycerides concentration, contributed to the separation of the two patient groups. 
Importantly, the loadings plot also showed that T2DM patients with AD had a smaller 
number of large and medium LDL and HDL particles relative to T2DM patients without AD. 
Moreover, patients with T2DM and AD had a greater number of total LDL and, in particular, 
of small LDL particles. Patients with AD also had greater number of small HDL particle but, 
on the contrary, it did not lead to an increase in total HDL particle numbers. Considering the 
first principal component as the output of a putative classifier, we calculated the receiver-
operating curve (ROC) in order to evaluate the classificatory power of our PCA model. Our 
approach showed an excellent classification performance to discriminate between T2DM 
patients with and without AD. All together, these results demonstrate that the Liposcale test 
is clinically useful to classify individuals showing an abnormal lipid and lipoprotein pattern 
that is typical of AD, which has emerged as an important risk factor for myocardial infarction 
and cardiovascular disease. 
 NMR-based ALTs have demonstrated that LDL and HDL particle numbers are more 
powerful than classical cholesterol markers as indices of cardiovascular risk [16, 24-26]. 
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These and other evidences have stressed the importance of adding other parameters when 
analyzing lipoproteins such as the Apo B concentration or the number of lipoprotein 
particles and their size. In this regard, the National Lipid Association Expert Panel has 
recently advised testing of LDL-P to assess and manage cardiovascular risk [27] and the 
AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices 
recommended to include LDL-P in the guidelines used to manage CMR based on the 
evidences collected from twenty-five clinical studies [20]. 
 At the same time, there is some controversy about whether the LDL and HDL 
subclass parameters improve cardiovascular risk prediction in comparison with the 
standard lipid panel guidelines. It has been reported that the relationship between LDL 
particle size and cardiovascular risk is not inherent to this parameter but related to the fact 
that smaller particles lead to an increase in the particle number of this type of LDL [27]. 
Moreover, many of these tests are of limited accessibility and because of their high cost 
they cannot be applied to the general population. In addition, it may be difficult to identify 
the groups that might benefit from them. But in the context of personalized medicine, they 
could be used in selected groups of patients who have been identified as having some risk 
factors. As has been mentioned above, diabetic individuals characterized by a 
preponderance of small-dense LDL particles, high triglyceride levels and low HDL-C levels 
are a target group that is well-suited for an LDL-P measurement. 
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 In this thesis it has been demonstrated that 2D diffusion-ordered 1H NMR 
spectroscopy (DOSY) is a suitable technique for the characterization of lipoprotein particles. 
We have tested this hypothesis within different contexts and approximations, from the 
analysis of lipoprotein fractions previously isolated using ultracentrifugation to the analysis 
of serum/plasma samples without the need for separation protocols and with minimal 
sample manipulation. Regarding the data processing approaches after acquisition of the 
NMR spectra, we used a surface fitting algorithm to characterize the 2D signal attenuation 
from DOSY experiments to obtain the average particle sizes in the case of the lipoprotein 
fractions and a discrete number of NMR areas in the case of the plasma samples. 
 The diffusion coefficients obtained in the first study presented in Section 3.1 had 
low estimation errors, demonstrating the repeatability of this technique. The hydrodynamic 
radii found when using the experimental viscosity in the Stokes–Einstein equation were 
highly correlated with the mean TEM sizes, although there was a systematic difference 
between the TEM and NMR-derived sizes. This systematic difference was shown to be 
explained by the polydisperse distributions found by TEM; once this was taken into account, 
a high degree of agreement was obtained between the two techniques. 
 In the study presented in Section 3.2 we demonstrated that the derived areas are 
useful in differentiating lipoprotein profiles. In fact, we demonstrated experimentally that 
when the lipoprotein plasma profiles are normolipidaemic, there is a perfect exponential 
relationship between the radii of the lipoproteins derived from the diffusion coefficient of 
the function and the shift positions of the maxima of the Lorentzian functions used to fit 
the surface. For non-normolipidaemic plasma profiles, this relationship deviates from the 
ideal exponential behaviour. In contrast with the previous line-fitting approaches, our 
diffusion-based method is able to overcome the non-ideal behaviour of non-
normolipidaemic samples and to give results in accordance with classical biochemical 
analysis. 
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 Finally, in Section 3.3 we presented the final version of the Liposcale test, the NMR-
based advanced lipoprotein test developed within the context of this thesis. The Liposcale 
test also uses a surface fitting algorithm to characterize the 2D signal attenuation of 
serum/plasma samples. In this case, the algorithm was extended to provide average particle 
sizes of the main lipoprotein classes (VLDL, LDL and HDL) directly from serum/plasma 
samples and the particle numbers of nine subclasses (namely large, medium and small 
VLDL, LDL and HDL). We found very similar correlations between our test and a reference 
NMR technique, although our derived particle numbers measured yielded higher 
correlations with external validations such as the concentration of VLDL-ApoB, LDL-ApoB, 
and HDL-ApoA. Moreover, the characterization of AD on type 2 diabetic patients further 
demonstrated the applicability of our methodology in a population with pathological states. 
 Importantly, the main difference between our 2D NMR approach and current 1D 
NMR methods is that the addition of a second dimension in the NMR spectrum by means of 
a diffusion experiment allows the separation of the lipoprotein subclasses according to their 
diffusion coefficient, and with the use of the Stokes-Einstein equation, DOSY NMR yields an 
objective separation of lipoprotein subclasses based on their size and favors the uniqueness 
of mathematical solutions compared to 1D NMR. 
 Altogether, 2D diffusion-ordered 1H NMR spectroscopy provides a robust way in 
which to characterise lipoproteins either in lipoprotein fractions or in serum/plasma 
samples. Indeed, we propose that DOSY is a potentially useful alternative to other available 
approaches for measuring lipoprotein fraction particle sizes or discrete size distributions for 
an arbitrary number of NMR-derived lipoprotein subclasses due to its inherent robustness 
and minimal sample manipulation. 
 In the clinical setting, although advanced lipoprotein testing is not yet ready for 
routine clinical use, there is a need to account for a complete lipoprotein subclass 
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composition, size and functionality analysis to determine whether (i) progressive changes in 
lipoproteins are useful as therapeutic targets and (ii) certain subgroups of individuals can 
benefit from these analyses. These methods may also be important for advancing research 
and understanding the pathophysiology of CVD. 
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